

=> fil hcaplus
 FILE 'HCAPLUS' ENTERED AT 09:05:47 ON 21 APR 2005
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 21 Apr 2005 VOL 142 ISS 17
 FILE LAST UPDATED: 20 Apr 2005 (20050420/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=>
 =>

=> d stat que
 L1 1 SEA FILE=REGISTRY ABB=ON PLU=ON "4-FLUORO-N-(INDAN-2-YL) BENZAMIDE"/CN
 L2 SEL PLU=ON L1 1- CHEM : 2 TERMS
 L3 3 SEA FILE=HCAPLUS ABB=ON PLU=ON L2


=>
 =>

=> d ibib abs hitstr l3 1-3


L3 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 2002:637636 HCAPLUS Full-text
 DOCUMENT NUMBER: 137:185515
 TITLE: Preparation of acylated indanyl amines and their use as remedies in upregulation of endothelial nitric oxide synthase
 INVENTOR(S): Strobel, Hartmut; Wohlfart, Paulus; Safarova, Alena; Walser, Armin; Suzuki, Teri; Dharanipragada, Ramalinga M.
 PATENT ASSIGNEE(S): Aventis Pharma Deutschland GmbH, Germany
 SOURCE: PCT Int. Appl., 137 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----

WO 2002064545	A1	20020822	WO 2002-EP1444	20020212
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2437944	AA	20020822	CA 2002-2437944	20020212
EE 200300369	A	20031015	EE 2003-369	20020212
EP 1373191	A1	20040102	EP 2002-722067	20020212
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
BR 2002007211	A	20040127	BR 2002-7211	20020212
JP 2004518719	T2	20040624	JP 2002-564478	20020212
US 2003055093	A1	20030320	US 2002-73160	20020213
ZA 2003005413	A	20040428	ZA 2003-5413	20030714
NO 2003003565	A	20031013	NO 2003-3565	20030812
PRIORITY APPLN. INFO.:			EP 2001-102850	A 20010213
			WO 2002-EP1444	W 20020212
OTHER SOURCE(S):	MARPAT 137:185515			
GI				



I



II

AB Title compds. [I; R1-R4 =; A = CH₂, CHOH, CH(C1-C3-alkyl); B = CH₂, CH(C1-C3-alkyl); R5 = aryl, heteroaryl] are prepared and are useful in the upregulation of endothelial nitric oxide synthase (eNOS). Title compds. I may therefore be useful for the manufacture of medicaments for the treatment of cardiovascular diseases, stable or unstable angina pectoris, coronary heart disease, Prinzmetal angina, acute coronary syndrome, heart failure, myocardial infarction, stroke, thrombosis, peripheral artery occlusive disease, endothelial dysfunction, atherosclerosis, restenosis, endothelial damage after PTCA (percutaneous trans-luminal coronary angioplasty), hypertension, essential hypertension, pulmonary hypertension, secondary hypertension, renovascular hypertension, chronic glomerulonephritis, erectile dysfunction, ventricular arrhythmia, diabetes or diabetes complications, nephropathy or retinopathy, angiogenesis, asthma bronchial, chronic renal failure, cirrhosis of the liver, osteoporosis, restricted memory performance, a restricted ability to learn, or for the lowering of cardiovascular risk of postmenopausal

women or after intake of contraceptives. Thus, the title compound II was prepared from 2-amino-4-methylindane and 4-fluorobenzoyl chloride, purified by HPLC and was in vitro tested on human umbilical vein cord endothelial cells for activation effect of eNOS transcription with EC-50(μM) = 6.0 and TIR(max) = 2.80.


IT 291756-32-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation method of acylated indanyl amines and use as remedies in upregulation of endothelial nitric oxide synthase)

RN 291756-32-6 HCAPLUS

CN Benzamide, N-(2,3-dihydro-1H-inden-2-yl)-4-fluoro- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2002:637530 HCAPLUS Full-text

DOCUMENT NUMBER: 137:163839

TITLE: **4-Fluoro-N-indan-2-yl benzamide** and its use as pharmaceutical

INVENTOR(S): Wohlfart, Paulus; Suzuki, Teri; Dharanipragada, Ramalinga M.; Safarova, Alena; Walser, Armin; Strobels, Hartmut

PATENT ASSIGNEE(S): Aventis Pharma Deutschland GmbH, Germany

SOURCE: PCT Int. Appl., 17 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002064146	A1	20020822	WO 2002-EP1443	20020212
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2437966	AA	20020822	CA 2002-2437966	20020212
EE 200300368	A	20031015	EE 2003-368	20020212
EP 1361882	A1	20031119	EP 2002-722066	20020212
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			

10/653,977

BR 2002007178	A	20040330	BR 2002-7178	20020212
JP 2004518713	T2	20040624	JP 2002-563939	20020212
US 2003022939	A1	20030130	US 2002-73330	20020213
US 6617359	B2	20030909		
ZA 2003005412	A	20040902	ZA 2003-5412	20030714
BG 107994	A	20040831	BG 2003-107994	20030715
US 2004019114	A1	20040129	US 2003-623775	20030722
US 6812253	B2	20041102		
NO 2003003546	A	20030924	NO 2003-3546	20030811
US 2005054729	A1	20050310	US 2004-920395	20040818
PRIORITY APPLN. INFO.:			EP 2001-102852	A 20010213
			WO 2002-EP1443	W 20020212
			US 2002-73330	A1 20020213
			US 2003-623775	A1 20030722

AB The present invention relates to **4-fluoro-N- indan-2-yl benzamide** according to the formula (I), and its use as pharmaceutical for stimulating expression of endothelial NO synthase. The compound (I) can be used for the therapy and prophylaxis of cardiovascular diseases like stable and unstable angina pectoris, Prinzmetal angina (spasm), acute coronary syndrome, heart failure, myocardial infarction, stroke, thrombosis, peripheral artery occlusive disease PAOD, atherosclerosis, restenosis, endothel damage after PTCA, essential hypertension, pulmonary hypertension, secondary hypertension, renovascular chronic glomerulonephritis, erectile dysfunction, ventricular arrhythmia, and the lowering of cardiovascular risk of postmenopausal women or after intake of contraceptive, the therapy and propylaxis of diabetes and diabetes complications (nephropathy, retinopathy), angiogenesis, asthma bronchiale, chronic renal failure, cirrhosis of the liver, restricted memory performance or a restricted ability to learn.


IT **291756-32-6P, 4-Fluoro-N-indan-2-yl benzamide**

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(benzamide compound for stimulating expression of endothelial NO synthase for treatment of diseases)

RN 291756-32-6 HCAPLUS

CN Benzamide, N-(2,3-dihydro-1H-inden-2-yl)-4-fluoro- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2000:628105 HCAPLUS Full-text

DOCUMENT NUMBER: 133:222452

TITLE: Aryl and heteroaryl amide compounds for the potentiation of cholinergic activity

INVENTOR(S): Yamada, Akira; Aoki, Satoshi

PATENT ASSIGNEE(S): Fujisawa Pharmaceutical Co., Ltd., Japan

SOURCE: PCT Int. Appl., 37 pp.

CODEN: PIXXD2


DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000051970	A1	20000908	WO 2000-JP601	20000203
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2371827	AA	20000908	CA 2000-2371827	20000203
AU 2000023257	A5	20000921	AU 2000-23257	20000203
AU 766655	B2	20031023		
EP 1159258	A1	20011205	EP 2000-902080	20000203
EP 1159258	B1	20041110		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
TR 200102494	T2	20020121	TR 2001-200102494	20000203
BR 2000010225	A	20020122	BR 2000-10225	20000203
JP 2002538132	T2	20021112	JP 2000-602198	20000203
RU 2211215	C2	20030827	RU 2001-126120	20000203
AT 282022	E	20041115	AT 2000-902080	20000203
US 2003096847	A1	20030522	US 2002-285526	20021101
US 6664293	B2	20031216		
US 2004048904	A1	20040311	US 2003-653977	20030904
PRIORITY APPLN. INFO.:			AU 1999-8912	A 19990226
			WO 2000-JP601	W 20000203
			US 2001-926058	B3 20010822
			US 2002-285526	A3 20021101
OTHER SOURCE(S):		MARPAT 133:222452		
		GI		



AB Amide compds. (R1)(R2)X-Y-Q-R3 (I) and their salts are disclosed [wherein: R1, R2 = aryl or ar(lower)alkyl, or are taken together to form lower alkylene or lower alkenylene, each of which may be substituted with aryl or may be condensed with a cyclic hydrocarbon optionally substituted with lower alkyl, lower alkoxy, aryl, aryloxy or halogen; R3 = lower alkyl, lower alkoxy, aryl, arylamino or aryloxy (each of which may be substituted with lower alkoxy or halogen), pyridyl, or pyridylamino; X = CH or N; Y = bond or NH; Q = CO; with provisos]. I are potentiators of cholinergic activity, and are useful as anti-amnesia or anti-dementia agents. I are thus useful for treating a

10/653,977


variety of central nervous system conditions, e.g., Alzheimer's dementia. For instance, reaction of 1,2,3,6-tetrahydropyridine with 4-fluorophenyl isocyanate in THF at room temperature gave title compound II. Selected compds. I were active in a rat penile erection assay at doses of 0.1-0.32 mg/kg i.p.

IT 291756-32-6P, 4-Fluoro-N-(indan-2-yl)benzamide

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of aryl and heteroaryl amide compds. as cholinergic agonists)

RN 291756-32-6 HCAPLUS

CN Benzamide, N-(2,3-dihydro-1H-inden-2-yl)-4-fluoro- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> _

=> d stat que

L1 STR



NODE ATTRIBUTES:

DEFAULT MLEVEL IS ATOM

GGCAT IS PCY AT 9

DEFAULT ECLEVEL IS LIMITED


GRAPH ATTRIBUTES:

RSPEC 1

NUMBER OF NODES IS 11

STEREO ATTRIBUTES: NONE


L2 STR



NODE ATTRIBUTES:
 DEFAULT MLEVEL IS ATOM
 GGCAT IS PCY AT 9
 DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
 RSPEC 1
 NUMBER OF NODES IS 11


STEREO ATTRIBUTES: NONE
 L3 STR



NODE ATTRIBUTES:
 DEFAULT MLEVEL IS ATOM
 GGCAT IS PCY AT 9
 DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
 RSPEC 1
 NUMBER OF NODES IS 11

STEREO ATTRIBUTES: NONE
 L4 STR



X @11

VPA 11-3/4/5 U

NODE ATTRIBUTES:

NSPEC IS R AT 9

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:


RSPEC 1

NUMBER OF NODES IS 11

STEREO ATTRIBUTES: NONE

L5 23903 SEA FILE=REGISTRY SSS FUL (L1 OR L2 OR L3) AND L4

L8 STR



REP G1=(1-10) C

NODE ATTRIBUTES:

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED


GRAPH ATTRIBUTES:

RSPEC 1

NUMBER OF NODES IS 12

STEREO ATTRIBUTES: NONE

L14 STR



NODE ATTRIBUTES:

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RSPEC 1

NUMBER OF NODES IS 10

STEREO ATTRIBUTES: NONE

L15 817 SEA FILE=REGISTRY SUB=L5 SSS FUL L8 AND L14

L16 101 SEA FILE=HCAPLUS ABB=ON PLU=ON L15

L17 55 SEA FILE=HCAPLUS ABB=ON PLU=ON L16 AND PD=<FEBRUARY 26, 1999

=>

=>

=> d ibib abs hitstr l17 1-55

L17 ANSWER 1 OF 55 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1999:709819 HCAPLUS Full-text

DOCUMENT NUMBER: 132:50133

TITLE: Absolute configuration of marine diterpenoid kalihinol A

AUTHOR(S): Shimomura, Masako; Miyaoka, Hiroaki; Yamada, Yasuji
CORPORATE SOURCE: School of Pharmacy, Tokyo University of Pharmacy and Life Science, Tokyo, 192-0392, Japan
SOURCE: Tetrahedron Letters (1999), 40(45), 8015-8017


CODEN: TELEAY; ISSN: 0040-4039

PUBLISHER: Elsevier Science Ltd.

DOCUMENT TYPE: Journal

LANGUAGE: English

GI



I

AB The absolute configuration of marine diterpenoid kalihinol A was determined by applying the CD exciton chirality method to bis-p-bromobenzamide I, which was converted from kalihinol A. This is the first determination of the absolute configuration of a kalihinane-type diterpenoid.


IT 252962-67-7P

RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
(CD spectrum of bis-p-bromobenzamide converted from kalihinol A)

RN 252962-67-7 HCAPLUS


CN Benzamide, N,N'-[(1S,4S,4aS,5R,6R,8aS)-4-[(2R,5S)-5-chlorotetrahydro-2,6,6-trimethyl-2H-pyran-2-yl]decahydro-6-hydroxy-1,6-dimethyl-1,5-naphthalenediyl]bis[4-bromo- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



REFERENCE COUNT: 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 2 OF 55 HCAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 1999:663081 HCAPLUS Full-text
 DOCUMENT NUMBER: 132:49597
 TITLE: Enantioselective Palladium-Catalyzed Allylic Alkylation Using E- and Z-Vinylogous Sulfonates
 AUTHOR(S): Evans, P. Andrew; Brandt, Thomas A.
 CORPORATE SOURCE: Brown Laboratory Department of Chemistry and Biochemistry, University of Delaware, Newark, DE, 19716, USA
 SOURCE: Organic Letters (1999), 1(10), 1563-1565
 CODEN: ORLEF7; ISSN: 1523-7060
 PUBLISHER: American Chemical Society
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 132:49597
 GI



AB The E- and Z-vinylogous sulfonates of β -phenylcinnamyl alc. derivs., e.g. I, undergo rapid and enantioselective palladium-catalyzed allylic alkylation ($\geq 90\%$ ee) with the palladium complex of the phosphino-1,3-oxazine 3 and sodium salt of di-Me malonate.

IT **252942-69-1P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(stereoselective prepn of phenylalkylpropenylmalonate via allylic alkylation of E- and Z-vinylogous sulfonates catalyzed by chiral phosphinooxazine palladium complexes)

RN 252942-69-1 HCAPLUS

10/653,977

CN Benzamide, 2-fluoro-N-[(1S,2R,3S,5R)-2-(hydroxymethyl)-6,6-dimethylbicyclo[3.1.1]hept-3-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



REFERENCE COUNT: 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 3 OF 55 HCAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 1999:96236 HCAPLUS Full-text
 DOCUMENT NUMBER: 130:139174
 TITLE: Preparation of 1,2,3,4-tetrahydronaphthalenes as h5-HT1B antagonists
 INVENTOR(S): Berg, Stefan; Linderberg, Mats; Ross, Svante; Thorberg, Seth-Olov; Ulff, Bengt
 PATENT ASSIGNEE(S): Astra Aktiebolag (Publ), Swed.
 SOURCE: PCT Int. Appl., 118 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9905134	A1	19990204	WO 1998-SE1390	19980715 <--
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
TW 438781	B	20010607	TW 1998-87111330	19980713
CA 2296518	AA	19990204	CA 1998-2296518	19980715 <--
AU 9883703	A1	19990216	AU 1998-83703	19980715 <--
AU 739569	B2	20011018		
EP 1000048	A1	20000517	EP 1998-934104	19980715
EP 1000048	B1	20021127		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
TR 200000229	T2	20000621	TR 2000-200000229	19980715
BR 9811042	A	20000815	BR 1998-11042	19980715
EE 200000041	A	20001016	EE 2000-200000041	19980715
EE 4238	B1	20040216		
NZ 502384	A	20010525	NZ 1998-502384	19980715
JP 2001510837	T2	20010807	JP 2000-504131	19980715
AT 228510	E	20021215	AT 1998-934104	19980715

10/653,977


RU 2194696	C2	20021220	RU 2000-104802	19980715
PT 1000048	T	20030331	PT 1998-934104	19980715
ES 2187983	T3	20030616	ES 1998-934104	19980715
SK 283918	B6	20040504	SK 1999-1883	19980715
ZA 9806588	A	19990125	ZA 1998-6588	19980723 <--
HR 980404	B1	20021031	HR 1998-980404	19980723
US 6313118	B1	20011106	US 1998-171577	19981021
NO 2000000356	A	20000327	NO 2000-356	20000124
NO 315609	B1	20030929		
US 6228857	B1	20010508	US 2000-621387	20000721
HK 1025963	A1	20030523	HK 2000-105178	20000817
US 2001051626	A1	20011213	US 2001-902000	20010710
US 6410532	B2	20020625		
US 2001051623	A1	20011213	US 2001-902123	20010710
US 6534652	B2	20030318		

PRIORITY APPLN. INFO.:

SE 1997-2799	A	19970725
WO 1998-SE1390	W	19980715
US 1998-171577	A2	19981021
SE 1999-190	A	19990122
WO 2000-SE79	A1	20000114

OTHER SOURCE(S): MARPAT 130:139174

GI



AB Title compds. [I; X = N, CH; Y = NHCH₂, CH₂NH, NHCO, CONH, NHSO₂, etc.; R = OCF₃, OCHF₂, OCH₂F, CN, OH, SO₃Me, SO₃CF₃, F, Cl, Br, heterocyclic ring, etc.; R₁ = H, alkyl, cycloalkyl; R₂ = alkyl, cycloalkyl, aryl, arylmethyl, heterocyclic ring, etc.] as (R)-enantiomers, (S)-enantiomers or racemates in the form of a free base or pharmaceutically acceptable salts thereof, and pharmaceutical compns. containing title compds. are prepared via acylation, alkylation, halogenation, as h5-HT_{1B} antagonists for use in the treatment of 5-hydroxytryptamine mediated disorders, disorders in the central nervous system. Thus, I, (X = N; R₁ = 5-CH₃; Y = CONH; R₂ = 4-morpholinophenyl) was prepared and chromatog. separated via Chiral AGP semi-preparative column.

IT **220051-93-4P**


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(preparation of tetrahydronaphthalenes as h5-HT_{1B} antagonists)

RN 220051-93-4 HCAPLUS

CN Benzamide, 4-chloro-N-[(2R)-1,2,3,4-tetrahydro-5-methyl-8-(4-methyl-1-piperazinyl)-2-naphthalenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 4 OF 55 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1999:96109 HCAPLUS Full-text

DOCUMENT NUMBER: 130:172992

TITLE: Indan muscarinic agonists

INVENTOR(S): Hollinshead, Sean Patrick; Huff, Bret Eugene; Hughes, Philip Floyd; Mendoza, Jose Serafin; Mitch, Charles Howard; Staszak, Michael Alexander; Ward, John Stanley; Wilson, Joseph Wendell

PATENT ASSIGNEE(S): Eli Lilly and Company, USA

SOURCE: PCT Int. Appl., 96 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9904778	A1	19990204	WO 1998-US15475	19980721 <--
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2297906	AA	19990204	CA 1998-2297906	19980721 <--
AU 9885918	A1	19990216	AU 1998-85918	19980721 <--
EP 1003495	A1	20000531	EP 1998-937136	19980721
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI, RO				
JP 2001510797	T2	20010807	JP 2000-503835	19980721
US 2001012848	A1	20010809	US 2000-740380	20001219
US 6395735	B2	20020528		

PRIORITY APPLN. INFO.:

US 1997-53404P P 19970722
US 1998-116408 B3 19980716
WO 1998-US15475 W 19980721

OTHER SOURCE(S): MARPAT 130:172992

GI



AB The present invention provides novel indan-like compds. which can be useful for treating psychosis and other conditions associated with the modulation of a muscarinic receptor. Examples are given for formulations of the compds. Among a large number of compds. prepared was I. Muscarinic receptor binding data are also given.

IT **194028-98-3P**


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(acetylation of; indan muscarinic agonist pharmaceuticals)

RN 194028-98-3 HCAPLUS

CN Benzamide, 3,4-dichloro-N-[(1R,2R)-1,2,3,4-tetrahydro-2-hydroxy-7-nitro-1-naphthalenyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



IT **194029-01-1P**


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(condensation of; indan muscarinic agonist pharmaceuticals)

RN 194029-01-1 HCAPLUS

CN Benzamide, N-[(1R,2R)-2-(acetyloxy)-7-amino-1,2,3,4-tetrahydro-1-naphthalenyl]-3,4-dichloro-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



IT 194029-00-0P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(hydrolysis of; indan muscarinic agonist pharmaceuticals)

RN 194029-00-0 HCAPLUS

CN Benzamide, N-[(1R,2R)-2-(acetyloxy)-1,2,3,4-tetrahydro-7-[(1-pyrrolidinylmethylene)amino]-1-naphthalenyl]-3,4-dichloro-, rel- (9CI)
(CA INDEX NAME)

Relative stereochemistry.

Double bond geometry unknown.



IT 194027-99-1P 194028-05-2P 194028-08-5P
194028-09-6P 194028-14-3P 194028-15-4P
194028-16-5P 194028-18-7P 194028-24-5P
194028-25-6P 194028-29-0P 194028-31-4P
194028-32-5P 194028-34-7P 194028-35-8P
194028-36-9P 194028-37-0P 194028-40-5P
194028-41-6P 194028-43-8P 194028-49-4P
194028-50-7P 194028-61-0P 194028-62-1P
194028-64-3P 194028-65-4P 194028-69-8P
194028-70-1P 194028-73-4P 194028-74-5P
194028-77-8P 194028-82-5P 194028-83-6P
194028-84-7P 194028-87-0P 210832-07-8P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(indan muscarinic agonist pharmaceuticals)

RN 194027-99-1 HCAPLUS


CN Benzamide, 3,5-dichloro-N-[(1R,2R)-2,3-dihydro-2-hydroxy-6-[(1-

10/653,977

pyrrolidinylmethylene)amino]-1H-inden-1-yl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry unknown.




RN 194028-05-2 HCAPLUS

CN Benzamide, 2-chloro-N-[(1R,2R)-2,3-dihydro-2-hydroxy-6-[(1-pyrrolidinylmethylene)amino]-1H-inden-1-yl]-4-nitro-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry unknown.




RN 194028-08-5 HCAPLUS

CN Benzamide, N-[(1R,2R)-2,3-dihydro-2-hydroxy-6-[(1-pyrrolidinylmethylene)amino]-1H-inden-1-yl]-3,5-difluoro-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.

Double bond geometry unknown.




RN 194028-09-6 HCAPLUS
 CN Benzamide, N-[(1R,2R)-2,3-dihydro-2-hydroxy-6-[(1-pyrrolidinylmethylene)amino]-1H-inden-1-yl]-2,3-difluoro-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
 Double bond geometry unknown.




RN 194028-14-3 HCAPLUS
 CN Benzamide, N-[(1R,2R)-2,3-dihydro-2-hydroxy-6-[(1-pyrrolidinylmethylene)amino]-1H-inden-1-yl]-2,3,6-trifluoro-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
 Double bond geometry unknown.



RN 194028-15-4 HCAPLUS
 CN Benzamide, N-[(1R,2R)-2,3-dihydro-2-hydroxy-6-[(1-pyrrolidinylmethylene)amino]-1H-inden-1-yl]-3-fluoro-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.
 Double bond geometry unknown.



RN 194028-16-5 HCAPLUS

CN Benzamide, 2,3-dichloro-N-[(1R,2R)-2,3-dihydro-2-hydroxy-6-[(1-pyrrolidinylmethylene)amino]-1H-inden-1-yl]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry unknown.



RN 194028-18-7 HCAPLUS

CN Benzamide, N-[(1R,2R)-2,3-dihydro-2-hydroxy-6-[(1-pyrrolidinylmethylene)amino]-1H-inden-1-yl]-2,3,4-trifluoro-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.




RN 194028-24-5 HCAPLUS

CN Benzamide, N-[(1R,2R)-2,3-dihydro-2-hydroxy-6-[(1-pyrrolidinylmethylene)amino]-1H-inden-1-yl]-3,4,5-trifluoro-, rel- (9CI) (CA INDEX NAME)


10/653,977

Relative stereochemistry.
Double bond geometry unknown.




RN 194028-25-6 HCAPLUS
CN Benzamide, N-[(1R,2R)-2,3-dihydro-2-hydroxy-6-[(1-pyrrolidinylmethylene)amino]-1H-inden-1-yl]-2,3,4,5-tetrafluoro-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.



RN 194028-29-0 HCAPLUS
CN Benzamide, 2-chloro-N-[(1R,2R)-2,3-dihydro-2-hydroxy-6-[(1-pyrrolidinylmethylene)amino]-1H-inden-1-yl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.




10/653,977

RN 194028-31-4 HCAPLUS

CN Benzamide, 2,6-dichloro-N-[(1R,2R)-2,3-dihydro-2-hydroxy-6-[(1-pyrrolidinylmethylene)amino]-1H-inden-1-yl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry unknown.




RN 194028-32-5 HCAPLUS

CN Benzamide, 2,4,6-trichloro-N-[(1R,2R)-2,3-dihydro-2-hydroxy-6-[(1-pyrrolidinylmethylene)amino]-1H-inden-1-yl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry unknown.




RN 194028-34-7 HCAPLUS

CN Benzamide, N-[(1R,2R)-2,3-dihydro-2-hydroxy-6-[(1-pyrrolidinylmethylene)amino]-1H-inden-1-yl]-2,4,5-trifluoro-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.


Double bond geometry unknown.



RN 194028-35-8 HCAPLUS

CN Benzamide, N-[(1R,2R)-2,3-dihydro-2-hydroxy-6-[(1-pyrrolidinylmethylene)amino]-1H-inden-1-yl]-2,6-difluoro-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry unknown.



RN 194028-36-9 HCAPLUS

CN Benzamide, N-[(1R,2R)-2,3-dihydro-2-hydroxy-6-[(1-pyrrolidinylmethylene)amino]-1H-inden-1-yl]-2-iodo-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry unknown.



RN 194028-37-0 HCAPLUS


CN Benzamide, N-[(1R,2R)-2,3-dihydro-2-hydroxy-6-[(1-pyrrolidinylmethylene)amino]-1H-inden-1-yl]-2,4-difluoro-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.




RN 194028-40-5 HCAPLUS
CN Benzamide, N-[(1R,2R)-2,3-dihydro-2-hydroxy-6-[(1-pyrrolidinylmethylene)amino]-1H-inden-1-yl]-3-fluoro-4-(trifluoromethyl)-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.



RN 194028-41-6 HCAPLUS
CN Benzamide, N-[(1R,2R)-2,3-dihydro-2-hydroxy-6-[(1-pyrrolidinylmethylene)amino]-1H-inden-1-yl]-2-fluoro-6-(trifluoromethyl)-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.




RN 194028-43-8 HCAPLUS

CN Benzamide, 3,5-dichloro-N-[(1R,2R)-6-[[(dimethylamino)methylene]amino]-2,3-dihydro-2-hydroxy-1H-inden-1-yl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry unknown.




RN 194028-49-4 HCAPLUS

CN Benzamide, N-[(1R,2R)-6-[[(dimethylamino)methylene]amino]-2,3-dihydro-2-hydroxy-1H-inden-1-yl]-3-fluoro-5-(trifluoromethyl)-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry unknown.




RN 194028-50-7 HCAPLUS

CN Benzamide, N-[(1R,2R)-6-[[(dimethylamino)methylene]amino]-2,3-dihydro-2-hydroxy-1H-inden-1-yl]-3,4,5-trifluoro-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry unknown.




RN 194028-61-0 HCAPLUS

CN Benzamide, 3,4-dichloro-N-[(1R,2R)-6-[[1-(dimethylamino)ethylidene]amino]-2,3-dihydro-2-hydroxy-1H-inden-1-yl]-, rel- (9CI) (CA INDEX NAME)


10/653,977

Relative stereochemistry.
Double bond geometry unknown.




RN 194028-62-1 HCAPLUS
CN Benzamide, 3,4-dichloro-N-[(1R,2R)-2,3-dihydro-2-hydroxy-6-[(1-piperidinylmethylene)amino]-1H-inden-1-yl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.



RN 194028-64-3 HCAPLUS
CN Benzamide, N-[(1R,2R)-2,3-dihydro-2-hydroxy-6-[(1-piperidinylmethylene)amino]-1H-inden-1-yl]-3-fluoro-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry unknown.



RN 194028-65-4 HCAPLUS
CN Benzamide, 3-chloro-N-[(1R,2R)-2,3-dihydro-2-hydroxy-6-[(1-piperidinylmethylene)amino]-1H-inden-1-yl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.


10/653,977



RN 194028-69-8 HCAPLUS

CN Benzamide, 2,4-dichloro-N-[(1R,2R)-2,3-dihydro-2-hydroxy-6-[(1-piperidinylmethylene)amino]-1H-inden-1-yl]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry unknown.



RN 194028-70-1 HCAPLUS

CN Benzamide, 2-chloro-N-[(1R,2R)-2,3-dihydro-2-hydroxy-6-[(1-piperidinylmethylene)amino]-1H-inden-1-yl]-4-nitro-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry unknown.



RN 194028-73-4 HCAPLUS

CN Benzamide, 2,3-dichloro-N-[(1R,2R)-2,3-dihydro-2-hydroxy-6-[(1-piperidinylmethylene)amino]-1H-inden-1-yl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.




RN 194028-74-5 HCAPLUS

CN Benzamide, N-[(1R,2R)-2,3-dihydro-2-hydroxy-6-[(1-

10/653,977


piperidinylmethylene)amino]-1H-inden-1-yl]-3,4,5-trifluoro-, rel- (9CI)
(CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.




RN 194028-77-8 HCAPLUS
CN Benzamide, N-[(1R,2R)-2,3-dihydro-2-hydroxy-6-[(1-piperidinylmethylene)amino]-1H-inden-1-yl]-3,4-difluoro-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.




RN 194028-82-5 HCAPLUS
CN Benzamide, 3,5-dichloro-N-[(1R,2R)-2,3-dihydro-2-hydroxy-6-[(1-piperidinylmethylene)amino]-1H-inden-1-yl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.



RN 194028-83-6 HCAPLUS
CN Benzamide, N-[(1R,2R)-2,3-dihydro-2-hydroxy-6-[(1-piperidinylmethylene)amino]-1H-inden-1-yl]-3,5-difluoro-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry unknown.



RN 194028-84-7 HCAPLUS

CN Benzamide, 3-bromo-N-[(1R,2R)-2,3-dihydro-2-hydroxy-6-[(1-piperidinylmethylene)amino]-1H-inden-1-yl]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry unknown.



RN 194028-87-0 HCAPLUS

CN Benzamide, N-[(1R,2R)-2,3-dihydro-2-hydroxy-6-[(1-piperidinylmethylene)amino]-1H-inden-1-yl]-2-iodo-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry unknown.



RN 210832-07-8 HCAPLUS

CN Benzamide, N-[(1R,2R)-2,3-dihydro-2-hydroxy-6-[(1-pyrrolidinylmethylene)amino]-1H-inden-1-yl]-2,5-difluoro-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.




IT 194028-92-7P 220383-96-0P 220383-99-3P
 220384-00-9P 220384-05-4P 220384-06-5P
 220384-07-6P 220384-08-7P 220384-09-8P
 220384-10-1P 220385-31-9P

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (indan muscarinic agonist pharmaceuticals)

RN 194028-92-7 HCAPLUS

CN Benzamide, 3,4-dichloro-N-[(1R,2R)-1,2,3,4-tetrahydro-2-hydroxy-7-[(1-pyrrolidinylmethylene)amino]-1-naphthalenyl]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.
 Double bond geometry unknown.



RN 220383-96-0 HCAPLUS

CN Benzamide, 4-chloro-N-[(1R,2R)-6-[[[(dimethylamino)methylene]amino]-2,3-dihydro-2-hydroxy-1H-inden-1-yl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
 Double bond geometry unknown.



RN 220383-99-3 HCAPLUS


CN Benzamide, 3,4-dichloro-N-[(1R,2R)-2,3-dihydro-2-hydroxy-6-[(1-

10/653,977

pyrrolidinylmethylene)amino]-1H-inden-1-yl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry unknown.




RN 220384-00-9 HCAPLUS

CN Benzamide, 4-chloro-N-[(1R,2R)-2,3-dihydro-2-hydroxy-6-[(1-pyrrolidinylmethylene)amino]-1H-inden-1-yl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry unknown.




RN 220384-05-4 HCAPLUS

CN Benzamide, 3,4-dichloro-N-[(1R,2R)-6-[[[(dimethylamino)methylene]amino]-2,3-dihydro-2-hydroxy-1H-inden-1-yl]-, monohydrochloride, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry unknown.

10/653,977




● HCl

RN 220384-06-5 HCAPLUS

CN Benzamide, 4-bromo-N-[(1R,2R)-2,3-dihydro-2-hydroxy-6-[(1-pyrrolidinylmethylene)amino]-1H-inden-1-yl]-3-methyl-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry unknown.



RN 220384-07-6 HCAPLUS

CN Benzamide, N-[(1R,2R)-2,3-dihydro-2-hydroxy-6-[(1-pyrrolidinylmethylene)amino]-1H-inden-1-yl]-3-iodo-4-methyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.




RN 220384-08-7 HCAPLUS

10/653,977


CN Benzamide, 3-bromo-N-[(1R,2R)-2,3-dihydro-2-hydroxy-6-[(1-pyrrolidinylmethylene)amino]-1H-inden-1-yl]-4-fluoro-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.




RN 220384-09-8 HCAPLUS
CN Benzamide, 3-bromo-N-[(1R,2R)-2,3-dihydro-2-hydroxy-6-[(1-pyrrolidinylmethylene)amino]-1H-inden-1-yl]-4-methyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.



RN 220384-10-1 HCAPLUS
CN Benzamide, 3-chloro-N-[(1R,2R)-2,3-dihydro-2-hydroxy-6-[(1-pyrrolidinylmethylene)amino]-1H-inden-1-yl]-4-fluoro-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry unknown.



RN 220385-31-9 HCAPLUS

CN Benzamide, 3,4-dichloro-N-[(1S,2S)-6-[[1-(dimethylamino)ethylidene]amino]-2,3-dihydro-2-hydroxy-1H-inden-1-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




IT 194028-99-4P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(reduction of; indan muscarinic agonist pharmaceuticals)

RN 194028-99-4 HCAPLUS

CN Benzamide, N-[(1R,2R)-2-(acetyloxy)-1,2,3,4-tetrahydro-7-nitro-1-naphthalenyl]-3,4-dichloro-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



REFERENCE COUNT:

1

THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 5 OF 55 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1998:757076 HCAPLUS Full-text

DOCUMENT NUMBER: 130:91655

TITLE: Synthesis of physiologically active substances. 19.
Synthesis and pesticidal activity of ureas and amides
with bicyclic monoterpenyl derivatives (mites)AUTHOR(S): Nomura, Masato; Kasemura, Kazuo; Obana, Mitsuhiko;
Sakurano, Masaru; Fujihara, YoshihitoCORPORATE SOURCE: Faculty of Engineering, Kinki University,
Higashihiroshima-shi, Takaya, Umenobe, 739-2116, JapanSOURCE: Nihon Yukagakkaishi (1998), 47(11),
1241-1249

CODEN: NIYUFC; ISSN: 1341-8327

PUBLISHER: Nihon Yukagaku Gakkai

DOCUMENT TYPE: Journal

LANGUAGE: Japanese

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB 2-Carene, 3-carene, thujone and d-menthol were converted to secondary amines by hydroboration, Jones oxidation, oximation (N,N- dimethylhydrazonation, methylation and elimination reaction) or reduction with LiAlH₄. The secondary amine derivs. were condensed with six chlorides to obtain urea and amide compds. Twenty-four monoterpene derivs. obtained were tested for acaricidal activity toward Tyrophagus putrescentiae and Dermatophagoides farinae. On filter paper, compds. I-VI from 2-carene and 3-carene showed higher pesticidal activity than N,N-diethyl-m-toluamide (DEET) for D. farinae. In air dusting for D. farinae, I and IV-VI at 0.2 g/m² had exterminative effects for a long time, and were more active than DEET.

IT 219572-53-9P 219572-55-1P 219572-58-4P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BUU (Biological use, unclassified); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation, phys. and spectral properties, and acaricidal activity of)

RN 219572-53-9 HCAPLUS

CN Benzamide, 2-chloro-N-[(1S,6R)-3,7,7-trimethylbicyclo[4.1.0]hept-2-yl]-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 219572-55-1 HCAPLUS

CN Benzamide, 2-chloro-N-[(1R,6S)-4,7,7-trimethylbicyclo[4.1.0]hept-3-yl]-

(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 219572-58-4 HCAPLUS

CN Benzamide, 2-chloro-N-[(1R,4S,5S)-4-methyl-1-(1-methylethyl)bicyclo[3.1.0]hex-3-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L17 ANSWER 6 OF 55 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1998:708084 HCAPLUS Full-text

DOCUMENT NUMBER: 130:61207

TITLE: Identifying the cholesterol binding domain in the
nicotinic acetylcholine receptor with
[125I]azido-cholesterol

AUTHOR(S): Corbin, John; Wang, Howard H.; Blanton, Michael P.

CORPORATE SOURCE: Department of Biology, University of California, Santa Cruz, CA, 95064, USA

SOURCE: Biochimica et Biophysica Acta (1998),
1414(1-2), 65-74

CODEN: BBACAQ; ISSN: 0006-3002

PUBLISHER: Elsevier Science B.V.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB A novel photoreactive analog of cholesterol, 3 α -(4-azido-3-[125I]iodosalicylic)-cholest-5-ene ([125I]azido-cholesterol), was used to label both native acetylcholine receptor (AChR)-rich membranes from *Torpedo californica* and affinity-purified *Torpedo* AChRs reconstituted into lipid vesicles. In both cases all four AChR subunits incorporated [125I]azido-cholesterol on an equal molar basis and neither the pattern nor the extent of labeling was affected by the presence of the agonist carbamylcholine. Labeled regions in each of the AChR subunits were initially mapped by *Staphylococcus aureus* V8 protease digestion to large fragments which contain the AChR transmembrane segments. Sites of [125I]azido-cholesterol incorporation were further mapped by exhaustive tryptic digestion of the V8 protease subunit fragments α V8-20 (α Ser-173-Glu-338), α V8-10 (α Asn-339-Gly-439), and γ V8-14 (γ Leu-373-Pro-489). The digests were separated by reverse-phase high-performance liquid chromatog. and labeled peptides identified by amino-terminal sequence anal. [125I]Azido-cholesterol labeling was localized to peptides that contain almost exclusively the α -M4, α -M1 and γ -M4 membrane

spanning segments. These results establish that the binding domain for cholesterol is at the lipid-protein interface of the AChR.


IT 218288-79-0

RL: ARG (Analytical reagent use); ANST (Analytical study); USES (Uses)
(cholesterol-binding domain identification in nicotinic acetylcholine receptor with [125I]azido-cholesterol)

RN 218288-79-0 HCAPLUS

CN Benzamide, 4-azido-N-[(3 α)-cholest-5-en-3-yl]-2-hydroxy-3-(iodo-125I)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 45 THERE ARE 45 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 7 OF 55 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1998:509179 HCAPLUS Full-text

DOCUMENT NUMBER: 129:148906

TITLE: Preparation of 1-acylamino-2-hydroxy-6-iminoindanes and related compounds having muscarinic receptor activity.

INVENTOR(S): Huff, Bret E.; Staszak, Michael A.; Ward, John S.

PATENT ASSIGNEE(S): Eli Lilly and Co., USA

SOURCE: PCT Int. Appl., 72 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9831660	A1	19980723	WO 1998-US1145	19980121 <--
W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
CA 2278424	AA	19980723	CA 1998-2278424	19980121 <--
AU 9859266	A1	19980807	AU 1998-59266	19980121 <--
EP 971885	A1	20000119	EP 1998-902664	19980121
EP 971885	B1	20031210		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI			

10/653,977

JP 2001510481	T2	20010731	JP 1998-534672	19980121
AT 256104	E	20031215	AT 1998-902664	19980121
ES 2212263	T3	20040716	ES 1998-902664	19980121
US 6211364	B1	20010403	US 1999-319652	19990610
PRIORITY APPLN. INFO.:			US 1997-35428P	P 19970122
			WO 1998-US1145	W 19980121

OTHER SOURCE(S): MARPAT 129:148906

GI



AB Title compds. [I; R1 = OR4, SR5, alkyl, alkenyl, halo, cyano, acyl(oxy); R20 = protecting group; R4, R5 = H, alkyl; R10 = H, carbonyl, halo, alkyl; R11 = H, alkyl; R12, R13 = H, alkyl, aryl; R12R13 = specified (substituted) heterocyclyl; R11R12N = 3-6 membered ring; R14 = H, halo, alkyl, alkoxy, etc.; Q = (CH2)n; n = 0-3], were prepared by reaction of [II; R21, R22 = H, O; R20 = protecting group; R = OR4, SR5, alkyl, alkenyl, halo, cyano, acyl(oxy)] with R13R12NCR11(OMe)2 (variables as above). I stimulated cAMP production in CHO-m4 cells by <20 % to 214% compared to oxotremorine-M.

IT 194027-99-1P 194028-05-2P 194028-08-5P
 194028-09-6P 194028-14-3P 194028-15-4P
 194028-16-5P 194028-18-7P 194028-24-5P
 194028-25-6P 194028-29-0P 194028-31-4P
 194028-32-5P 194028-34-7P 194028-35-8P
 194028-36-9P 194028-37-0P 194028-40-5P
 194028-41-6P 194028-43-8P 194028-49-4P
 194028-50-7P 194028-61-0P 194028-62-1P
 194028-64-3P 194028-65-4P 194028-69-8P
 194028-70-1P 194028-73-4P 194028-74-5P
 194028-77-8P 194028-82-5P 194028-83-6P
 194028-84-7P 194028-87-0P 210832-07-8P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); IMF (Industrial manufacture); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of 1-acylamino-2-hydroxy-6-iminoindanes and related compds. having muscarinic receptor activity)

RN 194027-99-1 HCAPLUS

CN Benzamide, 3,5-dichloro-N-[(1R,2R)-2,3-dihydro-2-hydroxy-6-[(1-pyrrolidinylmethylene)amino]-1H-inden-1-yl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.


Double bond geometry unknown.



RN 194028-05-2 HCAPLUS

CN Benzamide, 2-chloro-N-[(1R,2R)-2,3-dihydro-2-hydroxy-6-[(1-pyrrolidinylmethylene)amino]-1H-inden-1-yl]-4-nitro-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry unknown.



RN 194028-08-5 HCAPLUS

CN Benzamide, N-[(1R,2R)-2,3-dihydro-2-hydroxy-6-[(1-pyrrolidinylmethylene)amino]-1H-inden-1-yl]-3,5-difluoro-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry unknown.



RN 194028-09-6 HCAPLUS


CN Benzamide, N-[(1R,2R)-2,3-dihydro-2-hydroxy-6-[(1-pyrrolidinylmethylene)amino]-1H-inden-1-yl]-2,3-difluoro-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.




RN 194028-14-3 HCAPLUS
CN Benzamide, N-[(1R,2R)-2,3-dihydro-2-hydroxy-6-[(1-pyrrolidinylmethylene)amino]-1H-inden-1-yl]-2,3,6-trifluoro-, rel- (9CI)
(CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.



RN 194028-15-4 HCAPLUS
CN Benzamide, N-[(1R,2R)-2,3-dihydro-2-hydroxy-6-[(1-pyrrolidinylmethylene)amino]-1H-inden-1-yl]-3-fluoro-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.




RN 194028-16-5 HCAPLUS
CN Benzamide, 2,3-dichloro-N-[(1R,2R)-2,3-dihydro-2-hydroxy-6-[(1-

10/653,977

pyrrolidinylmethylene)amino]-1H-inden-1-yl]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry unknown.



RN 194028-18-7 HCAPLUS

CN Benzamide, N-[(1R,2R)-2,3-dihydro-2-hydroxy-6-[(1-pyrrolidinylmethylene)amino]-1H-inden-1-yl]-2,3,4-trifluoro-, rel- (9CI)
(CA INDEX NAME)


Relative stereochemistry.
Double bond geometry unknown.



RN 194028-24-5 HCAPLUS

CN Benzamide, N-[(1R,2R)-2,3-dihydro-2-hydroxy-6-[(1-pyrrolidinylmethylene)amino]-1H-inden-1-yl]-3,4,5-trifluoro-, rel- (9CI)
(CA INDEX NAME)


Relative stereochemistry.
Double bond geometry unknown.



RN 194028-25-6 HCAPLUS

CN Benzamide, N-[(1R,2R)-2,3-dihydro-2-hydroxy-6-[(1-pyrrolidinylmethylene)amino]-1H-inden-1-yl]-2,3,4,5-tetrafluoro-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry unknown.



RN 194028-29-0 HCAPLUS

CN Benzamide, 2-chloro-N-[(1R,2R)-2,3-dihydro-2-hydroxy-6-[(1-pyrrolidinylmethylene)amino]-1H-inden-1-yl]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry unknown.



RN 194028-31-4 HCAPLUS


CN Benzamide, 2,6-dichloro-N-[(1R,2R)-2,3-dihydro-2-hydroxy-6-[(1-pyrrolidinylmethylene)amino]-1H-inden-1-yl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.




RN 194028-32-5 HCAPLUS
CN Benzamide, 2,4,6-trichloro-N-[(1R,2R)-2,3-dihydro-2-hydroxy-6-[(1-pyrrolidinylmethylene)amino]-1H-inden-1-yl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.




RN 194028-34-7 HCAPLUS
CN Benzamide, N-[(1R,2R)-2,3-dihydro-2-hydroxy-6-[(1-pyrrolidinylmethylene)amino]-1H-inden-1-yl]-2,4,5-trifluoro-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.




RN 194028-35-8 HCAPLUS

CN Benzamide, N-[(1R,2R)-2,3-dihydro-2-hydroxy-6-[(1-pyrrolidinylmethylene)amino]-1H-inden-1-yl]-2,6-difluoro-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.

RN 194028-36-9 HCAPLUS


CN Benzamide, N-[(1R,2R)-2,3-dihydro-2-hydroxy-6-[(1-pyrrolidinylmethylene)amino]-1H-inden-1-yl]-2-iodo-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.

RN 194028-37-0 HCAPLUS

CN Benzamide, N-[(1R,2R)-2,3-dihydro-2-hydroxy-6-[(1-pyrrolidinylmethylene)amino]-1H-inden-1-yl]-2,4-difluoro-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry unknown.



RN 194028-40-5 HCAPLUS

CN Benzamide, N-[(1R,2R)-2,3-dihydro-2-hydroxy-6-[(1-pyrrolidinylmethylene)amino]-1H-inden-1-yl]-3-fluoro-4-(trifluoromethyl)-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry unknown.



RN 194028-41-6 HCAPLUS

CN Benzamide, N-[(1R,2R)-2,3-dihydro-2-hydroxy-6-[(1-pyrrolidinylmethylene)amino]-1H-inden-1-yl]-2-fluoro-6-(trifluoromethyl)-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.



RN 194028-43-8 HCAPLUS


CN Benzamide, 3,5-dichloro-N-[(1R,2R)-6-[[(dimethylamino)methylene]amino]-2,3-

10/653,977

dihydro-2-hydroxy-1H-inden-1-yl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry unknown.




RN 194028-49-4 HCAPLUS

CN Benzamide, N-[(1R,2R)-6-[[[(dimethylamino)methylene]amino]-2,3-dihydro-2-hydroxy-1H-inden-1-yl]-3-fluoro-5-(trifluoromethyl)-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry unknown.




RN 194028-50-7 HCAPLUS

CN Benzamide, N-[(1R,2R)-6-[[[(dimethylamino)methylene]amino]-2,3-dihydro-2-hydroxy-1H-inden-1-yl]-3,4,5-trifluoro-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry unknown.




RN 194028-61-0 HCAPLUS

CN Benzamide, 3,4-dichloro-N-[(1R,2R)-6-[[[1-(dimethylamino)ethylidene]amino]-2,3-dihydro-2-hydroxy-1H-inden-1-yl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.


Double bond geometry unknown.



RN 194028-62-1 HCAPLUS

CN Benzamide, 3,4-dichloro-N-[(1R,2R)-2,3-dihydro-2-hydroxy-6-[(1-piperidinylmethylene)amino]-1H-inden-1-yl]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry unknown.



RN 194028-64-3 HCAPLUS

CN Benzamide, N-[(1R,2R)-2,3-dihydro-2-hydroxy-6-[(1-piperidinylmethylene)amino]-1H-inden-1-yl]-3-fluoro-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry unknown.



RN 194028-65-4 HCAPLUS

CN Benzamide, 3-chloro-N-[(1R,2R)-2,3-dihydro-2-hydroxy-6-[(1-piperidinylmethylene)amino]-1H-inden-1-yl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.




10/653,977

RN 194028-69-8 HCAPLUS

CN Benzamide, 2,4-dichloro-N-[(1R,2R)-2,3-dihydro-2-hydroxy-6-[(1-piperidinylmethylene)amino]-1H-inden-1-yl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry unknown.




RN 194028-70-1 HCAPLUS

CN Benzamide, 2-chloro-N-[(1R,2R)-2,3-dihydro-2-hydroxy-6-[(1-piperidinylmethylene)amino]-1H-inden-1-yl]-4-nitro-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry unknown.




RN 194028-73-4 HCAPLUS

CN Benzamide, 2,3-dichloro-N-[(1R,2R)-2,3-dihydro-2-hydroxy-6-[(1-piperidinylmethylene)amino]-1H-inden-1-yl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry unknown.




RN 194028-74-5 HCAPLUS

CN Benzamide, N-[(1R,2R)-2,3-dihydro-2-hydroxy-6-[(1-piperidinylmethylene)amino]-1H-inden-1-yl]-3,4,5-trifluoro-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry unknown.


10/653,977



RN 194028-77-8 HCAPLUS

CN Benzamide, N-[(1R,2R)-2,3-dihydro-2-hydroxy-6-[(1-piperidinylmethylene)amino]-1H-inden-1-yl]-3,4-difluoro-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry unknown.



RN 194028-82-5 HCAPLUS

CN Benzamide, 3,5-dichloro-N-[(1R,2R)-2,3-dihydro-2-hydroxy-6-[(1-piperidinylmethylene)amino]-1H-inden-1-yl]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry unknown.



RN 194028-83-6 HCAPLUS

CN Benzamide, N-[(1R,2R)-2,3-dihydro-2-hydroxy-6-[(1-piperidinylmethylene)amino]-1H-inden-1-yl]-3,5-difluoro-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry unknown.



RN 194028-84-7 HCAPLUS

CN Benzamide, 3-bromo-N-[(1R,2R)-2,3-dihydro-2-hydroxy-6-[(1-piperidinylmethylene)amino]-1H-inden-1-yl]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry unknown.



RN 194028-87-0 HCAPLUS

CN Benzamide, N-[(1R,2R)-2,3-dihydro-2-hydroxy-6-[(1-piperidinylmethylene)amino]-1H-inden-1-yl]-2-iodo-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry unknown.



RN 210832-07-8 HCAPLUS

CN Benzamide, N-[(1R,2R)-2,3-dihydro-2-hydroxy-6-[(1-pyrrolidinylmethylene)amino]-1H-inden-1-yl]-2,5-difluoro-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.




IT 194028-92-7P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 1-acylamino-2-hydroxy-6-iminoindanes and related compds. having muscarinic receptor activity)

RN 194028-92-7 HCAPLUS

CN Benzamide, 3,4-dichloro-N-[(1R,2R)-1,2,3,4-tetrahydro-2-hydroxy-7-[(1-pyrrolidinylmethylene)amino]-1-naphthalenyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.




IT 194028-98-3P 194028-99-4P 194029-00-0P
194029-01-1P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of 1-acylamino-2-hydroxy-6-iminoindanes and related compds. having muscarinic receptor activity)

RN 194028-98-3 HCAPLUS

CN Benzamide, 3,4-dichloro-N-[(1R,2R)-1,2,3,4-tetrahydro-2-hydroxy-7-nitro-1-naphthalenyl]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 194028-99-4 HCAPLUS

CN Benzamide, N-[(1R,2R)-2-(acetyloxy)-1,2,3,4-tetrahydro-7-nitro-1-naphthalenyl]-3,4-dichloro-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 194029-00-0 HCAPLUS

CN Benzamide, N-[(1R,2R)-2-(acetyloxy)-1,2,3,4-tetrahydro-7-[(1-pyrrolidinylmethylene)amino]-1-naphthalenyl]-3,4-dichloro-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry unknown.




RN 194029-01-1 HCAPLUS

CN Benzamide, N-[(1R,2R)-2-(acetyloxy)-7-amino-1,2,3,4-tetrahydro-1-

naphthalenyl]-3,4-dichloro-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 8 OF 55 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1998:270002 HCAPLUS Full-text

DOCUMENT NUMBER: 128:278756

TITLE: Antitumor Agents. 185. Synthesis and Biological Evaluation of Tridemethylthiocolchicine Analogs as Novel Topoisomerase II Inhibitors

AUTHOR(S): Guan, Jian; Zhu, Xiao K.; Tachibana, Yoko; Bastow, Kenneth F.; Brossi, Arnold; Hamel, Ernest; Lee, Kuo-Hsiung

CORPORATE SOURCE: Natural Products Laboratory Division of Medicinal Chemistry and Natural Products School of Pharmacy, University of North Carolina, Chapel Hill, NC, 27599, USA

SOURCE: Journal of Medicinal Chemistry (1998), 41(11), 1956-1961

CODEN: JMCMAR; ISSN: 0022-2623

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Several 1,2,3-tridemethyldeacetylthiocolchicine derivs. have been synthesized and evaluated for cytotoxic activity against various human tumor cell lines and for their inhibitory effects on DNA topoisomerases in vitro. Exhaustive demethylation of thiocolchicine analogs completely changes their biol. profiles. Instead of displaying antitubulin activity, most target compds. inhibited topoisomerase II activity. Only compds. with a larger side chain, such as 15a, 23a, and 24a, did not interfere with topoisomerase II enzymic functions. The cytotoxicity of target compds. was reduced by 3 orders of magnitude compared to that of colchicine in most cell lines. The hydrophilicity of phenolic compds. might prevent drug passage through the cell plasma membrane and, thus, be responsible for the relatively weak cytotoxicity. To test this hypothesis, 27-30 were prepared from 16a by protecting all hydroxy groups with esters with an aim to facilitate drug transportation. In vitro cytotoxicity assays indicated that 27 was more potent than its parent compound in all tested tumor cell lines and showed tissue selective cytotoxicity with a significant inhibitory effect against KB cells (IC₅₀ = 2.7 µg/mL). Therefore, we propose that 27 acts as a prodrug, liberating 16a to exert its antitopoisomerase activity and, finally, to cause cell death.

IT 205805-01-2P 205805-02-3P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(preparation and biol. evaluation of tridemethylthiocolchicine analogs as topoisomerase II inhibitors)

RN 205805-01-2 HCAPLUS

CN Benzamide, 4-fluoro-N-[5,6,7,9-tetrahydro-1,2,3-trihydroxy-10-(methylthio)-9-oxobenzo[a]heptalen-7-yl]-, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 205805-02-3 HCAPLUS

CN Benzamide, 4-chloro-N-[5,6,7,9-tetrahydro-1,2,3-trihydroxy-10-(methylthio)-9-oxobenzo[a]heptalen-7-yl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



IT 147950-67-2 147950-73-0


RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation and biol. evaluation of tridemethylthiocolchicine analogs as topoisomerase II inhibitors)

RN 147950-67-2 HCAPLUS

CN Benzamide, 4-fluoro-N-[5,6,7,9-tetrahydro-1,2,3-trimethoxy-10-(methylthio)-9-oxobenzo[a]heptalen-7-yl]-, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 147950-73-0 HCAPLUS

CN Benzamide, 4-chloro-N-[(7S)-5,6,7,9-tetrahydro-1,2,3-trimethoxy-10-(methylthio)-9-oxobenzo[a]heptalen-7-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 9 OF 55 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1998:214962 HCAPLUS Full-text

DOCUMENT NUMBER: 128:282758

TITLE: Synthesis of certain N-{9-exo-[(dimethylamino- and pyrrolidino)methyl]tricyclo[5.2.1.0^{2,6}]decan-8-endo-yl}arylamides and -3,4-dichlorophenylacetamides with potential analgesic and local anesthetic activities

AUTHOR(S): Aboul Enein, M. Nabil; El-Azzouny, Aida A.; Abdallah, Neveine A.; Maklad, Yousreya A.

CORPORATE SOURCE: Department Pharmaceutical Sciences, Pharmaceutical Chemistry Group, National Research Center, Cairo, Egypt

SOURCE: Scientia Pharmaceutica (1998), 66(1), 59-76
CODEN: SCPHA4; ISSN: 0036-8709

PUBLISHER: Oesterreichische Apotheker-Verlagsgesellschaft

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The synthesis as well as the analgesic and local anesthetic activities of various 8-endo-acylamino-9-exo-[(dimethylamino- and

10/653,977

pyrrolidino)methyl]tricyclo[5.2.1.0^{2,6}]decanes are described. The compound with the highest analgesic activity (ED₅₀ 76.7 mg/kg, s.c) in the current series is much less active than morphine.HCl in hot-plate tests. All tested compds. exhibited noticeable local anesthetic potency compared with procaine.HCl (ED₅₀ 0.3 mg/kg, s.c) in twitch-response tests in guinea-pig skin.

IT 205875-53-2P 205875-54-3P 205875-55-4P
205875-56-5P 205875-57-6P 205875-59-8P
205875-61-2P 205875-63-4P 205875-64-5P
205875-65-6P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(preparation and analgesic and local anesthetic activity of
(acylamino)(aminomethyl)tricyclodecanes)

RN 205875-53-2 HCAPLUS

CN Benzamide, 3-chloro-N-[6-[(dimethylamino)methyl]octahydro-4,7-methano-1H-inden-5-yl]-, (4R,5S,6R,7S)-rel-[partial]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 205875-54-3 HCAPLUS

CN Benzamide, 2-bromo-N-[6-[(dimethylamino)methyl]octahydro-4,7-methano-1H-inden-5-yl]-, (4R,5S,6R,7S)-rel-[partial]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 205875-55-4 HCAPLUS

CN Benzamide, 4-bromo-N-[6-[(dimethylamino)methyl]octahydro-4,7-methano-1H-inden-5-yl]-, (4R,5S,6R,7S)-rel-[partial]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 205875-56-5 HCAPLUS

CN Benzamide, 5-chloro-N-[6-[(dimethylamino)methyl]octahydro-4,7-methano-1H-inden-5-yl]-2-methoxy-, (4R,5S,6R,7S)-rel-[partial]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 205875-57-6 HCAPLUS

CN Benzamide, 3,4-dichloro-N-[6-[(dimethylamino)methyl]octahydro-4,7-methano-1H-inden-5-yl]-, (4R,5S,6R,7S)-rel-[partial]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 205875-59-8 HCAPLUS

CN Benzamide, 3-chloro-N-[octahydro-6-(1-pyrrolidinylmethyl)-4,7-methano-1H-inden-5-yl]-, (4R,5S,6R,7S)-rel-[partial]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 205875-61-2 HCAPLUS

CN Benzamide, 2-bromo-N-[octahydro-6-(1-pyrrolidinylmethyl)-4,7-methano-1H-inden-5-yl]-, (4R,5S,6R,7S)-rel-[partial]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 205875-63-4 HCAPLUS

CN Benzamide, 4-bromo-N-[octahydro-6-(1-pyrrolidinylmethyl)-4,7-methano-1H-inden-5-yl]-, (4R,5S,6R,7S)-rel-[partial]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 205875-64-5 HCAPLUS

CN Benzamide, 5-chloro-2-methoxy-N-[octahydro-6-(1-pyrrolidinylmethyl)-4,7-methano-1H-inden-5-yl]-, (4R,5S,6R,7S)-rel-[partial]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 205875-65-6 HCAPLUS

CN Benzamide, 3,4-dichloro-N-[octahydro-6-(1-pyrrolidinylmethyl)-4,7-methano-1H-inden-5-yl]-, (4R,5S,6R,7S)-rel-[partial]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L17 ANSWER 10 OF 55 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1997:640655 HCAPLUS Full-text

DOCUMENT NUMBER: 127:307398

TITLE: New piperidinyl- and piperazinyl-substituted
1,2,3,4-tetrahydronaphthalene derivatives useful as
5-HT antagonistsINVENTOR(S): Berg, Stefan; Florvall, Lennart; Ross, Svante;
Thorberg, Seth-Olov

PATENT ASSIGNEE(S): Astra AB, Swed.

SOURCE: PCT Int. Appl., 137 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9734883	A1	19970925	WO 1997-SE469	19970320 <--
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN,				

ML, MR, NE, SN, TD, TG

ZA 9702056	A	19970922	ZA 1997-2056	19970310 <--
CA 2247940	AA	19970925	CA 1997-2247940	19970320 <--
AU 9721865	A1	19971010	AU 1997-21865	19970320 <--
AU 709856	B2	19990909		
EP 888319	A1	19990107	EP 1997-914727	19970320 <--
EP 888319	B1	20030129		

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO



CN 1219170	A	19990609	CN 1997-194726	19970320
CN 1073101	B	20011017		
BR 9708093	A	19990727	BR 1997-8093	19970320
NZ 331613	A	20000327	NZ 1997-331613	19970320
JP 2000506883	T2	20000606	JP 1997-533410	19970320
SK 282359	B6	20020107	SK 1998-1188	19970320
AT 231847	E	20030215	AT 1997-914727	19970320
US 6124283	A	20000926	US 1997-836004	19970425
NO 9804385	A	19981123	NO 1998-4385	19980921 <--
NO 311803	B1	20020128		
US 6410530	B1	20020625	US 2000-653427	20000831

PRIORITY APPLN. INFO.:

SE 1996-1110	A	19960322
WO 1997-SE469	W	19970320
US 1997-836004	A3	19970425

OTHER SOURCE(S): MARPAT 127:307398

GI



AB New piperidinyl- and piperazinyl-substituted 1,2,3,4-tetrahydronaphthalene derivs. I [X = N or CH; Y = NR₂CH₂, CH₂NR₂, NR₂CO, CONR₂, or NR₂SO₂; R₁ = H, C1-6 alkyl, or C3-6 cycloalkyl; R₂ = H or C1-6 alkyl; R₃ = C1-6 alkyl, C3-6 cycloalkyl, or (CH₂)_n-aryl where aryl = Ph or heteroarom. ring containing 1 or 2 N/O/S atoms and which may be mono- or di-substituted; n = 0-4], as enantiomers, racemates, free bases, or pharmaceutically acceptable salts or hydrates, are disclosed. Also disclosed are pharmaceutical formulations containing I, use of I in the treatment of disorders mediated by 5-hydroxytryptamine (5-HT), and processes and intermediates for the preparation of I. The compds. are primarily selective antagonists of the 5-HT_{1D} receptor

(no data). A variety of preferred compds., mostly (R)-isomers, are specifically claimed. Synthetic examples (138) include preparation of both I and their intermediates. For instance, (R)-8-methoxy-2-amino-1,2,3,4-tetrahydronaphthalene-HCl was converted in 8 steps to (R)-2-amino-8-(4-methylpiperazin-1-yl)-1,2,3,4-tetrahydronaphthalene, which was condensed with 4-morpholinobenzoic acid using 1,1'-carbonyldiimidazole in DMF to give title compound II.


IT 197445-77-5P 197445-78-6P 197445-79-7P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of piperidiny- and piperazinyl-substituted tetrahydronaphthalenes as 5-HT1D antagonists)

RN 197445-77-5 HCAPLUS

CN Benzamide, 4-fluoro-N-[1,2,3,4-tetrahydro-8-(4-methyl-1-piperazinyl)-2-naphthalenyl]-, (R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 197445-78-6 HCAPLUS

CN Benzamide, 4-bromo-N-[1,2,3,4-tetrahydro-8-(4-methyl-1-piperazinyl)-2-naphthalenyl]-, (R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 197445-79-7 HCAPLUS


CN Benzamide, 4-chloro-N-[1,2,3,4-tetrahydro-8-(4-methyl-1-piperazinyl)-2-naphthalenyl]-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



L17 ANSWER 11 OF 55 HCAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 1997:499097 HCAPLUS Full-text
 DOCUMENT NUMBER: 127:176278
 TITLE: Preparation of indanes as antipsychotics
 INVENTOR(S): Hollinshead, Sean P.; Huff, Bret E.; Hughes, Philip F.; Mendoza, Jose S.; Mitch, Charles H.; Staszak, Michael A.; Ward, John S.; Wilson, Joseph W.; et al.
 PATENT ASSIGNEE(S): Eli Lilly and Co., USA
 SOURCE: PCT Int. Appl., 70 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9725983	A1	19970724	WO 1997-US997	19970122 <--
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2243500	AA	19970724	CA 1997-2243500	19970122 <--
CA 2243717	AA	19970724	CA 1997-2243717	19970122 <--
AU 9718349	A1	19970811	AU 1997-18349	19970122 <--
EP 874625	A1	19981104	EP 1997-903904	19970122 <--
EP 874625	B1	20050316		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
JP 2000504320	T2	20000411	JP 1997-526290	19970122
US 6429317	B1	20020806	US 2000-117089	20000905
PRIORITY APPLN. INFO.:			US 1996-10287P	P 19960122
			WO 1997-US997	W 19970122
OTHER SOURCE(S):			MARPAT 127:176278	
GI				



AB The title compds. [I; R1 = H, C1-3 alkyl, C2-3 alkenyl, etc.; R2 = C1-10 alkyl, C2-10 alkenyl, aryl, etc.; R10 = H, halo, C1-3 alkyl, C(O); R11 = H, C1-3 alkyl; R12 = R13 = H, C1-10 alkyl, aryl; R12R13 = II (wherein X = C, O, S, etc.; m' = 0-2; n' = 0-2; R17 = H, halo, C1-3 alkyl, etc.); R11R12 = 3-6-membered ring; R14 = H, halo, C1-3 alkyl, etc.], useful for treating psychosis and other conditions associated with the modulation of a muscarinic receptor, were prepared and formulated. For example, the title compound III showed 34% maximum stimulation of cAMP production in CHO m4 cells compared to Oxotremorine-M.

IT 194027-99-1P 194028-05-2P 194028-08-5P
 194028-09-6P 194028-14-3P 194028-15-4P
 194028-16-5P 194028-17-6P 194028-18-7P
 194028-24-5P 194028-25-6P 194028-29-0P
 194028-31-4P 194028-32-5P 194028-34-7P
 194028-35-8P 194028-36-9P 194028-37-0P
 194028-40-5P 194028-41-6P 194028-43-8P
 194028-49-4P 194028-50-7P 194028-61-0P
 194028-62-1P 194028-64-3P 194028-65-4P
 194028-69-8P 194028-70-1P 194028-73-4P
 194028-74-5P 194028-77-8P 194028-82-5P
 194028-83-6P 194028-84-7P 194028-87-0P
 194028-92-7P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOI (Biological study); PREP (Preparation); USES (Uses)
 (preparation of indanes as antipsychotics)

RN 194027-99-1 HCAPLUS

CN Benzamide, 3,5-dichloro-N-[(1R,2R)-2,3-dihydro-2-hydroxy-6-[(1-pyrrolidinylmethylene)amino]-1H-inden-1-yl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.


Double bond geometry unknown.



RN 194028-05-2 HCAPLUS

CN Benzamide, 2-chloro-N-[(1R,2R)-2,3-dihydro-2-hydroxy-6-[(1-pyrrolidinylmethylene)amino]-1H-inden-1-yl]-4-nitro-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry unknown.



RN 194028-08-5 HCAPLUS

CN Benzamide, N-[(1R,2R)-2,3-dihydro-2-hydroxy-6-[(1-pyrrolidinylmethylene)amino]-1H-inden-1-yl]-3,5-difluoro-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry unknown.



RN 194028-09-6 HCAPLUS


CN Benzamide, N-[(1R,2R)-2,3-dihydro-2-hydroxy-6-[(1-pyrrolidinylmethylene)amino]-1H-inden-1-yl]-2,3-difluoro-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.




RN 194028-14-3 HCAPLUS
CN Benzamide, N-[(1R,2R)-2,3-dihydro-2-hydroxy-6-[(1-pyrrolidinylmethylene)amino]-1H-inden-1-yl]-2,3,6-trifluoro-, rel- (9CI)
(CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.



RN 194028-15-4 HCAPLUS
CN Benzamide, N-[(1R,2R)-2,3-dihydro-2-hydroxy-6-[(1-pyrrolidinylmethylene)amino]-1H-inden-1-yl]-3-fluoro-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.




RN 194028-16-5 HCAPLUS
CN Benzamide, 2,3-dichloro-N-[(1R,2R)-2,3-dihydro-2-hydroxy-6-[(1-

10/653,977

pyrrolidinylmethylene)amino]-1H-inden-1-yl]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry unknown.



RN 194028-17-6 HCAPLUS

CN Benzamide, 2,5-dichloro-N-[2,3-dihydro-2-hydroxy-6-[(1-pyrrolidinylmethylene)amino]-1H-inden-1-yl]-, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry unknown.



RN 194028-18-7 HCAPLUS


CN Benzamide, N-[(1R,2R)-2,3-dihydro-2-hydroxy-6-[(1-pyrrolidinylmethylene)amino]-1H-inden-1-yl]-2,3,4-trifluoro-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.




RN 194028-24-5 HCAPLUS
 CN Benzamide, N-[(1R,2R)-2,3-dihydro-2-hydroxy-6-[(1-pyrrolidinylmethylene)amino]-1H-inden-1-yl]-3,4,5-trifluoro-, rel- (9CI)
 (CA INDEX NAME)

Relative stereochemistry.
 Double bond geometry unknown.




RN 194028-25-6 HCAPLUS
 CN Benzamide, N-[(1R,2R)-2,3-dihydro-2-hydroxy-6-[(1-pyrrolidinylmethylene)amino]-1H-inden-1-yl]-2,3,4,5-tetrafluoro-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
 Double bond geometry unknown.



RN 194028-29-0 HCAPLUS
 CN Benzamide, 2-chloro-N-[(1R,2R)-2,3-dihydro-2-hydroxy-6-[(1-pyrrolidinylmethylene)amino]-1H-inden-1-yl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
 Double bond geometry unknown.




RN 194028-31-4 HCAPLUS

CN Benzamide, 2,6-dichloro-N-[(1R,2R)-2,3-dihydro-2-hydroxy-6-[(1-pyrrolidinylmethylene)amino]-1H-inden-1-yl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry unknown.




RN 194028-32-5 HCAPLUS

CN Benzamide, 2,4,6-trichloro-N-[(1R,2R)-2,3-dihydro-2-hydroxy-6-[(1-pyrrolidinylmethylene)amino]-1H-inden-1-yl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry unknown.




RN 194028-34-7 HCAPLUS

CN Benzamide, N-[(1R,2R)-2,3-dihydro-2-hydroxy-6-[(1-pyrrolidinylmethylene)amino]-1H-inden-1-yl]-2,4,5-trifluoro-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry unknown.




RN 194028-35-8 HCAPLUS

CN Benzamide, N-[(1R,2R)-2,3-dihydro-2-hydroxy-6-[(1-pyrrolidinylmethylene)amino]-1H-inden-1-yl]-2,6-difluoro-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry unknown.




RN 194028-36-9 HCAPLUS

CN Benzamide, N-[(1R,2R)-2,3-dihydro-2-hydroxy-6-[(1-pyrrolidinylmethylene)amino]-1H-inden-1-yl]-2-iodo-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry unknown.




RN 194028-37-0 HCAPLUS

CN Benzamide, N-[(1R,2R)-2,3-dihydro-2-hydroxy-6-[(1-

10/653,977

pyrrolidinylmethylene)amino]-1H-inden-1-yl]-2,4-difluoro-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry unknown.



RN 194028-40-5 HCAPLUS

CN Benzamide, N-[(1R,2R)-2,3-dihydro-2-hydroxy-6-[(1-pyrrolidinylmethylene)amino]-1H-inden-1-yl]-3-fluoro-4-(trifluoromethyl)-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry unknown.



RN 194028-41-6 HCAPLUS

CN Benzamide, N-[(1R,2R)-2,3-dihydro-2-hydroxy-6-[(1-pyrrolidinylmethylene)amino]-1H-inden-1-yl]-2-fluoro-6-(trifluoromethyl)-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry unknown.



RN 194028-43-8 HCAPLUS

CN Benzamide, 3,5-dichloro-N-[(1R,2R)-6-[[(dimethylamino)methylene]amino]-2,3-dihydro-2-hydroxy-1H-inden-1-yl]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry unknown.



RN 194028-49-4 HCAPLUS

CN Benzamide, N-[(1R,2R)-6-[[(dimethylamino)methylene]amino]-2,3-dihydro-2-hydroxy-1H-inden-1-yl]-3-fluoro-5-(trifluoromethyl)-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry unknown.



RN 194028-50-7 HCAPLUS

CN Benzamide, N-[(1R,2R)-6-[[(dimethylamino)methylene]amino]-2,3-dihydro-2-hydroxy-1H-inden-1-yl]-3,4,5-trifluoro-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry unknown.



RN 194028-61-0 HCAPLUS

CN Benzamide, 3,4-dichloro-N-[(1R,2R)-6-[[1-(dimethylamino)ethyldene]amino]-2,3-dihydro-2-hydroxy-1H-inden-1-yl]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry unknown.



RN 194028-62-1 HCAPLUS

CN Benzamide, 3,4-dichloro-N-[(1R,2R)-2,3-dihydro-2-hydroxy-6-[(1-piperidinylmethylene)amino]-1H-inden-1-yl]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry unknown.



RN 194028-64-3 HCAPLUS

CN Benzamide, N-[(1R,2R)-2,3-dihydro-2-hydroxy-6-[(1-piperidinylmethylene)amino]-1H-inden-1-yl]-3-fluoro-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.




RN 194028-65-4 HCAPLUS

CN Benzamide, 3-chloro-N-[(1R,2R)-2,3-dihydro-2-hydroxy-6-[(1-piperidinylmethylene)amino]-1H-inden-1-yl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry unknown.




RN 194028-69-8 HCAPLUS

CN Benzamide, 2,4-dichloro-N-[(1R,2R)-2,3-dihydro-2-hydroxy-6-[(1-piperidinylmethylene)amino]-1H-inden-1-yl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry unknown.




RN 194028-70-1 HCAPLUS

CN Benzamide, 2-chloro-N-[(1R,2R)-2,3-dihydro-2-hydroxy-6-[(1-piperidinylmethylene)amino]-1H-inden-1-yl]-4-nitro-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry unknown.




RN 194028-73-4 HCAPLUS

CN Benzamide, 2,3-dichloro-N-[(1R,2R)-2,3-dihydro-2-hydroxy-6-[(1-piperidinylmethylene)amino]-1H-inden-1-yl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry unknown.


10/653,977



RN 194028-74-5 HCAPLUS

CN Benzamide, N-[(1R,2R)-2,3-dihydro-2-hydroxy-6-[(1-piperidin-1-ylmethylene)amino]-1H-inden-1-yl]-3,4,5-trifluoro-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry unknown.



RN 194028-77-8 HCAPLUS

CN Benzamide, N-[(1R,2R)-2,3-dihydro-2-hydroxy-6-[(1-piperidin-1-ylmethylene)amino]-1H-inden-1-yl]-3,4-difluoro-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry unknown.



RN 194028-82-5 HCAPLUS

CN Benzamide, 3,5-dichloro-N-[(1R,2R)-2,3-dihydro-2-hydroxy-6-[(1-piperidin-1-ylmethylene)amino]-1H-inden-1-yl]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry unknown.



RN 194028-83-6 HCAPLUS

CN Benzamide, N-[(1R,2R)-2,3-dihydro-2-hydroxy-6-[(1-piperidin-1-ylmethylene)amino]-1H-inden-1-yl]-3,5-difluoro-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry unknown.



RN 194028-84-7 HCAPLUS

CN Benzamide, 3-bromo-N-[(1R,2R)-2,3-dihydro-2-hydroxy-6-[(1-piperidin-1-ylmethylene)amino]-1H-inden-1-yl]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry unknown.



RN 194028-87-0 HCAPLUS

CN Benzamide, N-[(1R,2R)-2,3-dihydro-2-hydroxy-6-[(1-piperidin-1-ylmethylene)amino]-1H-inden-1-yl]-2-iodo-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.




RN 194028-92-7 HCAPLUS

CN Benzamide, 3,4-dichloro-N-[(1R,2R)-1,2,3,4-tetrahydro-2-hydroxy-7-[(1-pyrrolidinylmethylene)amino]-1-naphthalenyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry unknown.



IT 194028-98-3P 194028-99-4P 194029-00-0P

194029-01-1P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of indanes as antipsychotics)

RN 194028-98-3 HCAPLUS

CN Benzamide, 3,4-dichloro-N-[(1R,2R)-1,2,3,4-tetrahydro-2-hydroxy-7-nitro-1-naphthalenyl]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 194028-99-4 HCAPLUS

CN Benzamide, N-[(1R,2R)-2-(acetyloxy)-1,2,3,4-tetrahydro-7-nitro-1-naphthalenyl]-3,4-dichloro-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 194029-00-0 HCAPLUS

CN Benzamide, N-[(1R,2R)-2-(acetyloxy)-1,2,3,4-tetrahydro-7-[(1-pyrrolidinylmethylene)amino]-1-naphthalenyl]-3,4-dichloro-, rel- (9CI)
(CA INDEX NAME)


Relative stereochemistry.
Double bond geometry unknown.




RN 194029-01-1 HCAPLUS

CN Benzamide, N-[(1R,2R)-2-(acetyloxy)-7-amino-1,2,3,4-tetrahydro-1-naphthalenyl]-3,4-dichloro-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




ACCESSION NUMBER: 1997:373472 HCAPLUS Full-text
 DOCUMENT NUMBER: 127:81660
 TITLE: An efficient stereoselective synthesis of
 6- α -aminoestradiol: preparation of estradiol
 fluorescent probes
 AUTHOR(S): Adamczyk, Maciej; mattingly, Phillip G.; Reddy,
 Rajarathnam E.
 CORPORATE SOURCE: Division Organic Chemistry Research, Diagnostic
 Division, Abbott Laboratories, Abbott Park, IL,
 60064-3500, USA
 SOURCE: Steroids (1997), 62(6), 462-467
 CODEN: STEDAM; ISSN: 0039-128X
 PUBLISHER: Elsevier
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 GI



AB Stereoselective syntheses of 6- α -aminoestradiol fluorescent probes I [X =
 bond, (CH₂)₅NHCO] starting from 6-oxoestradiol were described.
 IT 191675-22-6P
 RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
 (stereoselective synthesis of 6- α -aminoestradiol fluorescent
 probes)
 RN 191675-22-6 HCAPLUS
 CN Benzamide, 4-bromo-N-[(6 α ,17 β)-3,17-dihydroxyestra-1,3,5(10)-
 trien-6-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 13 OF 55 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1997:281064 HCAPLUS Full-text

DOCUMENT NUMBER: 127:5099

TITLE: Preparation of pyridazine derivatives for the treatment of endotoxin shock and kidney diseases

INVENTOR(S): Ishida, Akihiko; Honma, Koichi; Tanifuji, Michihisa; Nishama, Nobusuke; Okumura, Fumikazu

PATENT ASSIGNEE(S): Tanabe Seiyaku Co., Ltd., Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 28 pp.

CODEN: JKXXAF


DOCUMENT TYPE: Patent

LANGUAGE: Japanese


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 09071534	A2	19970318	JP 1996-164798	19960625 <--
PRIORITY APPLN. INFO.:			JP 1995-159261	A 19950626
OTHER SOURCE(S):	MARPAT 127:5099			
GI				



I



II

AB The title compds. I [R1 = alkyl, etc.; R2 = H, alkyl; X = CO, etc.; Alk = bond, alkylene; dotted line indicates optional double bond] are prepared When treated with the title compound II at 100 mg/kg orally, mice with endotoxin shock showed 90% survival.


IT 166979-49-3P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyridazine derivs. for the treatment of endotoxin shock and kidney diseases)


RN 166979-49-3 HCAPLUS

CN Benzamide, 4-chloro-N-[2,3-dihydro-5-(1,4,5,6-tetrahydro-6-oxo-3-pyridazinyl)-1H-inden-2-yl]- (9CI) (CA INDEX NAME)




L17 ANSWER 14 OF 55 HCAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 1997:251109 HCAPLUS Full-text
 DOCUMENT NUMBER: 126:238314
 TITLE: Preparation of bicyclic amidine derivatives as nitric oxide synthetase inhibitors
 INVENTOR(S): MacDonald, James Edwin; Shakespeare, William Calvin; Murray, Robert John; Matz, James Russell
 PATENT ASSIGNEE(S): Astra Ab, Swed.; Astra Pharmaceuticals Limited
 SOURCE: PCT Int. Appl., 54 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9706158	A1	19970220	WO 1995-GB1896	19950810 <--
W: AM, AT, BB, BG, BR, BY, CH, CN, CZ, DE, DK, EE, ES, GB, GE, HU, IS, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TT, UA, UG, UZ, VN				
RW: KE, MW, SD, SZ, UG, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
BR 9509297	A	19980707	BR 1995-9297	19950810 <--
RU 2155761	C2	20000910	RU 1997-107473	19950810
SK 281442	B6	20010312	SK 1997-390	19950810
CZ 287969	B6	20010314	CZ 1997-1086	19950810
IL 115482	A1	20010808	IL 1995-115482	19951002
CN 1162310	A	19971015	CN 1995-195570	19960810 <--
PRIORITY APPLN. INFO.: OTHER SOURCE(S):			WO 1995-GB1896	A 19950810
GI			MARPAT 126:238314	




I



II



III




IV

AB The title compds. [I; D = (un)substituted 5-membered heterocyclic aromatic ring containing 1-4 heteroatoms (O, N, S); A = N(X), CH[(CH₂)_mNXY] (wherein X, Y = H, C1-6 alkyl, etc.; NXY = piperidinyl, morpholinyl, etc.); U = NH, O, CH₂; V = (CH₂)_a; W = (CH₂)_b (wherein a, b = 0-3)] and their salts, useful for the treatment or prophylaxis of neurodegenerative disorders, of migraine or for prevention and reversal of tolerance to opiates and diazepam or for the treatment of drug addiction, were prepared. Thus, reaction of 5-aminoindane II with carboximide III.HI in iPrOH/DMF for 14 h followed by treatment of the reaction mixture with 2N NaOH afforded 30% IV.dioxalate which showed IC₅₀ < 10 μ M against the neuronal isoform of nitric oxide synthetase.

IT **181634-18-4P**
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of bicyclic amidine derivs. as nitric oxide synthetase inhibitors)

RN 181634-18-4 HCAPLUS

CN Benzamide, 3-chloro-N-(2,3-dihydro-5-nitro-1H-inden-2-yl)- (9CI) (CA INDEX NAME)



L17 ANSWER 15 OF 55 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1997:145245 HCAPLUS Full-text

DOCUMENT NUMBER: 126:157408

TITLE: Preparation of N-(arylcabonyl or heterocyclylcarbonyl)amino(carboxyalkenyl)bicycloheptane derivatives or analogs thereof and prostaglandin D₂ (PGD₂) antagonists containing the same

INVENTOR(S): Ohtani, Mitsuaki; Arimura, Akinori; Tsuru, Tatsuo; Kishino, Junji; Honma, Tsunetoshi

PATENT ASSIGNEE(S): Shionogi and Co., Ltd., Japan

SOURCE: PCT Int. Appl., 242 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9700853	A1	19970109	WO 1996-JP1685	19960619 <--
W: AL, AU, BB, BG, BR, CA, CN, CZ, EE, GE, HU, IL, IS, JP, KR, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, TR, TT, UA, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2225250	AA	19970109	CA 1996-2225250	19960619 <--
AU 9661370	A1	19970122	AU 1996-61370	19960619 <--
AU 714312	B2	19991223		
EP 837052	A1	19980422	EP 1996-918841	19960619 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				

IE, SI, LT, LV, FI

CN 1193315	A	19980916	CN 1996-196326	19960619 <--
CN 1134410	B	20040114		
BR 9608498	A	19990706	BR 1996-8498	19960619
CZ 285870	B6	19991117	CZ 1997-4013	19960619
JP 3195361	B2	20010806	JP 1997-503724	19960619
JP 2001288160	A2	20011016	JP 2001-73708	19960619
TW 513422	B	20021211	TW 1996-85107425	19960619
PL 185107	B1	20030228	PL 1996-324115	19960619
NO 9705994	A	19980223	NO 1997-5994	19971219 <--
US 6172113	B1	20010109	US 1998-973983	19980422
US 6384075	B1	20020507	US 2000-506608	20000218
US 6498190	B1	20021224	US 2000-506606	20000218

PRIORITY APPLN. INFO.:

JP 1995-154575	A	19950621
JP 1997-503724	A3	19960619
WO 1996-JP1685	W	19960619
US 1998-973983	A3	19980422

OTHER SOURCE(S): MARPAT 126:157408

GI For diagram(s), see printed CA Issue.

AB Compds. of general formula [I; ring Y = Q - Q3; A = alkylene optionally interrupted with phenylene or hetero atoms and optionally containing oxo and/or unsatd. bonds; B = H, alkyl, aralkyl, acyl; R = CO2R1, CH2OR2, CONR3R4; R1, R2 = H, alkyl; R3, R4 = H, alkyl, OH, alkylsulfonyl; X1 = single bond, phenylene, naphthylene, thiophenediyl, indolediyl, oxazolediyl; X2 = single bond, N:N, N:CH, CH:N, CH:NN, CH:NO, C:NNHCSNH, C:NNHCONH, CH:CH, CH(OH), CCl:CCl, (CH2)n, C.tplbond.C, NR5, NR5CO, NR5SO2, NR5CONR5, CONR5, SO2NR5, O, S, SO, SO2, CO, oxadiazolediyl, thiadiazolediyl, tetrazolediyl; wherein R5 = H, alkyl; X3 = alkyl, alkenyl, alkynyl, aryl, aralkyl, heterocyclyl, cycloalkyl, cycloalkenyl, thiazolylidene, etc.; Z = SO2, CO; m = 0,1; wherein if the substituents are in the form of rings, they may be optionally substituted] or salts thereof or hydrates thereof are prepared These compds. are useful as a PGD2 antagonists and thus usable in, for example, a remedy for systemic mastocytosis or systemic mast cell activation disorders, a drug for bronchoconstriction, an antiasthmatic, a drug for allergic rhinitis agent, a drug for allergic conjunctivitis, a drug for urticaria, a remedy for ischemia reperfusion disorders or an antiinflammatory agent. They are particularly useful in the treatment of nasal occlusion. Thus, a bicyclo[2.2.1]heptane derivative (II; R = Me, R7 = H) was condensed with 2-chlorosulfonyldibenzofuran in the presence of Et3N in CH2Cl2 to give, after saponification, II .Na (R = H, R7 = Q3). I in vitro inhibited the binding of [3H]PGD2 to PGD2 receptor preparation from human blood platelet fraction with IC50 of 0.003-8.6 μ M. A tablet and granule formulation containing the title compound (III.1/2Ca) were described.

IT 186532-89-8P 186532-90-1P 186533-04-0P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of amino(carboxyalkenyl)bicycloheptane derivs. as prostaglandin


D2 antagonists for disease therapy)

RN 186532-89-8 HCAPLUS

CN 5-Heptenoic acid, 7-[2-[(4-chlorobenzoyl)amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, methyl ester, [1R-[1 α ,2 β ,3 α (Z),5 α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry as shown.



RN 186532-90-1 HCAPLUS

CN 5-Heptenoic acid, 7-[2-[(4-chlorobenzoyl)amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, [1R-[1 α ,2 β ,3 α (Z),5.alp ha.]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 186533-04-0 HCAPLUS

CN 5-Heptenoic acid, 7-[2-[(4-bromobenzoyl)amino]-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-, [1R-[1 α ,2 β ,3 α (Z),5.alp ha.]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




L17 ANSWER 16 OF 55 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1997:78140 HCAPLUS Full-text

DOCUMENT NUMBER: 126:128258

TITLE: Synthesis and physiological activity of amides and ureas with pinane skeleton

AUTHOR(S): Nomura, Masato; Sakakiyama, Toshiaki; Takishita, Masayoshi; Fujihara, Yoshihito



AB (+)- α -Pinene (I), (-)- β -pinene, and (-)-l-verbenone (II) were converted to primary and/or secondary amines by hydroboration, Swern oxidation, oximation (N,N-dimethylhydrazonation, methylation and elimination reaction), or reduction with LiAlH_4 . These amine derivs. were condensed with six kinds of chloride to obtain urea compds. and amide compds. The 18 terpene derivs. obtained were tested for growth-regulating activity toward plants and insecticidal activity toward *Tyrophagus putrescentiae* and *Dermatophagoides farinae*. On filter paper, urea compds. and amides from I and II, at 1.0 g/m², showed insecticidal activity of 69-100% against *D. farinae*, higher than the activity of N,N-diethyl-m-toluamide (DEET). *D. farinae* was almost eradicated by III, IV, V, and VI at 0.5 g/m².


RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation and properties and insecticidal and plant growth-regulating activity of)

RN 186366-38-1 HCAPLUS

CN Benzamide, 2-chloro-N-(2,6,6-trimethylbicyclo[3.1.1]hept-3-yl)-,
 (1R,5S)-[partial]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 186366-50-7 HCAPLUS

CN Benzamide, 2-chloro-N-(4,6,6-trimethylbicyclo[3.1.1]hept-2-yl)-,
{1S,5S}-[partial]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L17 ANSWER 17 OF 55 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1997:53616 HCAPLUS Full-text

DOCUMENT NUMBER: 126:70138

TITLE: 2-(p-Bromobenzoyl) or 2-(p-chlorobenzoyl)-
aminoadamantanes increasing organism resistance to
environmental stress and showing immunostimulating
activity

INVENTOR(S): Morozov, I. S.; Artsimovich, N. G.; Klimova, N. V.;
Fadeeva, T. A.; Zajtseva, N. M.; Galushina, T. S.;
Bykov, N. P.; Pyatin, B. M.; Avdyunina, N. I.; et al.
PATENT ASSIGNEE(S): Nauchno-Issledovatel'skij Institut Farmakologii Amn

SOURCE: U.S.S.R. From: Izobreteniya 1996, (16), 282.
CODEN: URXXAF

DOCUMENT TYPE: Patent

LANGUAGE: Russian

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
SU 1646256	A1	19960610	SU 1989-4735457	19890713 <--
			SU 1989-4735457	19890713

PRIORITY APPLN. INFO.:


AB Title only translated.

IT 185384-78-5 185384-80-9

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)


(2-(p-halobenzoyl)-aminoadamantanes increasing organism resistance to
environmental stress and showing immunostimulating activity)

RN 185384-78-5 HCAPLUS

CN Benzamide, 4-bromo-N-tricyclo[3.3.1.1^{3,7}]dec-2-yl- (9CI) (CA INDEX NAME)

RN 185384-80-9 HCAPLUS

CN Benzamide, 4-chloro-N-tricyclo[3.3.1.1^{3,7}]dec-2-yl- (9CI) (CA INDEX NAME)



L17 ANSWER 18 OF 55 HCAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 1996:596164 HCAPLUS Full-text
 DOCUMENT NUMBER: 125:221608
 TITLE: Preparation of isoquinolinyl- and
 indanylcabamimidothioic acid esters as nitric oxide
 synthase inhibitors
 INVENTOR(S): Macdonald, James Edwin
 PATENT ASSIGNEE(S): Astra Aktiebolag, Swed.
 SOURCE: PCT Int. Appl., 26 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9624588	A1	19960815	WO 1996-SE162	19960209 <--
W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE				
TW 397812	B	20000711	TW 1996-85100971	19960126
IL 116966	A1	20000217	IL 1996-116966	19960130
ZA 9600972	A	19960812	ZA 1996-972	19960207 <--
CA 2211299	AA	19960815	CA 1996-2211299	19960209 <--
AU 9647347	A1	19960827	AU 1996-47347	19960209 <--
AU 699546	B2	19981203		
EP 808307	A1	19971126	EP 1996-903295	19960209 <--
EP 808307	B1	20000112		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, LT, LV				
BR 9607264	A	19971230	BR 1996-7264	19960209 <--
CN 1181070	A	19980506	CN 1996-193123	19960209 <--
JP 10513194	T2	19981215	JP 1996-524210	19960209 <--
AT 188689	E	20000115	AT 1996-903295	19960209
ES 2143181	T3	20000501	ES 1996-903295	19960209
RU 2157802	C2	20001020	RU 1997-115107	19960209
SK 281205	B6	20010118	SK 1997-1040	19960209
EE 3439	B1	20010615	EE 1997-168	19960209
US 5786364	A	19980728	US 1996-615254	19960308 <--
NO 9703614	A	19970929	NO 1997-3614	19970805 <--
NO 309036	B1	20001204		
FI 9703273	A	19970808	FI 1997-3273	19970808 <--
US 6040314	A	20000321	US 1998-73726	19980507
GR 3033135	T3	20000831	GR 2000-400828	20000404
PRIORITY APPLN. INFO.:			GB 1995-2669	A 19950211
			GB 1995-2670	A 19950211

10/653,977

WO 1996-SE162

W 19960209

OTHER SOURCE(S):

CASREACT 125:221608; MARPAT 125:221608

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The title compds. [I; D = C1-6 alkyl; T = C3-5 (substituted) (un)saturated alkylene; (substituted) O(CH₂)₂NH, etc.], particularly useful in the treatment or prophylaxis of neurodegenerative disorders or of migraine, were prepared. Thus, reaction of 2-amino-5-nitroindane.HCl with 3-ClC₆H₄COCl followed by reduction of indane II with BH₃.THF, N-methylation of the intermediate III with HCHO, NO₂-reduction of 5-nitroindane IV with Zn/AcOH, reaction of 5-nitroindane V with C₆H₅CONCS, removal of benzoyl group of the intermediate VI and treatment of the corresponding thiourea with MeSO₃H and then with MeSO₃Et afforded I [D = Et; T = CH₂(3- ClC₆H₄CH₂)CHCH₂] which showed IC₅₀ of < 10 μM against nitric oxide synthase.


IT 181634-18-4P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of isoquinolinyl- and indanylcaramimidothioic acid esters as nitric oxide synthase inhibitors)

RN 181634-18-4 HCAPLUS

CN Benzamide, 3-chloro-N-(2,3-dihydro-5-nitro-1H-inden-2-yl)- (9CI) (CA INDEX NAME)



L17 ANSWER 19 OF 55 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1996:551343 HCAPLUS Full-text

DOCUMENT NUMBER: 125:221372

TITLE: Preparation of optically active aminoindans useful in the treatment of Parkinson's disease

INVENTOR(S): Lidor, Ramy; Bahar, Eliezer

PATENT ASSIGNEE(S): Teva Pharmaceuticals Industries, Ltd., Israel; Lemmon Company

SOURCE: PCT Int. Appl., 137 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9621640	A1	19960718	WO 1996-US169	19960116 <--
W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TT				

10/653,977


RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR,
NE, SN, TD, TG

US 5877218	A	19990302	US 1995-478204	19950607
US 5914349	A	19990622	US 1995-485688	19950607
ZA 9600211	A	19960726	ZA 1996-211	19960111 <--
IL 116748	A1	20021201	IL 1996-116748	19960112
IL 134349	A1	20031210	IL 1996-134349	19960112
AU 9648960	A1	19960731	AU 1996-48960	19960116 <--
US 5639913	A	19970617	US 1996-712580	19960913 <--
US 5880159	A	19990309	US 1997-948212	19971009
US 5994408	A	19991130	US 1997-951272	19971016
US 5877221	A	19990302	US 1997-953097	19971017
US 6271263	B1	20010807	US 1999-260755	19990302
US 2002068839	A1	20020606	US 1999-420126	19991019
US 6528685	B2	20030304		

PRIORITY APPLN. INFO.:

US 1995-372064	A1	19950112
US 1994-179539	B2	19940110
US 1994-179607	B2	19940110
US 1995-475398	B1	19950607
US 1995-477163	B1	19950607
US 1995-478204	A1	19950607
US 1995-482941	B1	19950607
IL 1996-116748	A3	19960112
WO 1996-US169	W	19960116
US 1999-260755	A1	19990302

OTHER SOURCE(S): CASREACT 125:221372; MARPAT 125:221372
GI




AB The title compds. [I; R1, R2 = H, OH, (substituted) C1-4 alkyl, etc.; R3 = H, C1-4 alkyl; n = 0-2], their N-substituted derivs. and salts, useful in the treatment of Parkinson's disease, dementia, epilepsy, convulsions, or seizures, were prepared by reacting racemic N-benzyl analog of the desired compound with an enantiomer of mandelic acid followed by crystallization of the mandelate salt and its conversion to its corresponding optically active base. Thus, reaction of 1-chloroindane with PhCH2NH2 in PhMe followed by treatment of N-benzyl-1-aminoindane with L-(+)-mandelic acid as resolving agent in absolute EtOH, separation of (R)-(+)-N-benzyl-1-aminoindane L-mandelate ethanolate (II) by crystallization, converting II into (R)-(+)-N-benzyl-1-aminoindane and deprotection afforded (R)-(-)-1-aminoindane [(R)-I; R1-R3 = H; n = 1] which showed ED50 of 184 mg/kg when tested using maximal electroshock (MES) model.

IT 168902-59-8P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of optically active aminoindans useful in the treatment of Parkinson's disease)

RN 168902-59-8 HCAPLUS

CN Benzamide, N-(2,3-dihydro-1H-inden-1-yl)-4-fluoro- (9CI) (CA INDEX NAME)



L17 ANSWER 20 OF 55 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1996:259457 HCAPLUS Full-text

DOCUMENT NUMBER: 124:289248

TITLE: Preparation of N-arylthiopheneimidamides and analogs as nitric oxide synthetase inhibitors

INVENTOR(S): MacDonald, James Edwin; Shakespeare, William Calvin; Murray, Robert John; Matz, James Russell

PATENT ASSIGNEE(S): Astra Aktiebolag, Swed.

SOURCE: PCT Int. Appl., 54 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English



FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9601817	A1	19960125	WO 1995-GB1041	19950509 <--
W: AU, CA, FI, JP, MX, NO, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA 2188680	AA	19960125	CA 1995-2188680	19950509 <--
AU 9524139	A1	19960209	AU 1995-24139	19950509 <--
AU 682768	B2	19971016		
EP 759027	A1	19970226	EP 1995-918069	19950509 <--
EP 759027	B1	19990804		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
JP 10500138	T2	19980106	JP 1995-501368	19950509 <--
AT 182889	E	19990815	AT 1995-918069	19950509
ES 2137512	T3	19991216	ES 1995-918069	19950509
ZA 9508088	A	19960508	ZA 1995-8088	19950926 <--
US 5807886	A	19980915	US 1996-737286	19961105 <--
FI 9604463	A	19961106	FI 1996-4463	19961106 <--
NO 9604698	A	19961106	NO 1996-4698	19961106 <--
HK 1009043	A1	20000420	HK 1998-109759	19980807
US 6117898	A	20000912	US 1999-358427	19990722
GR 3031693	T3	20000229	GR 1999-402784	19991029
PRIORITY APPLN. INFO.:			GB 1994-9201	A 19940507
			GB 1994-9462	A 19940512
			WO 1995-GB1041	W 19950509
			US 1998-111483	B1 19980708

OTHER SOURCE(S): MARPAT 124:289248

GI




AB Title compds. [I; R = C-attached 5-membered heteroaryl; R1R2 = UVAW; A = NX, CH[(CH2)mNXY]; U = NH, O, CH2; V,W = (CH2)0-3; X,Y = H, alkyl, phenyl(alkyl), etc.; NXY = pyrrolidino, piperidino, etc.; m = 0-5] were prepared. Thus, 5-nitro-2-indanone was reductively aminated and the protected product, after reduction, N-acylated with RC(:NH)SMe (R = 2-thienyl) to give, after deprotection, title compound II which was isolated as the dioxalate. The latter had IC50 of <10µM against neuronal nitric oxide synthetase activity in vitro.

IT **175871-14-4P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of N-arylthiopheneimidamides and analogs as nitric oxide synthetase inhibitors)

RN 175871-14-4 HCAPLUS

CN Benzamide, 3-chloro-N-(2,3-dihydro-6-nitro-1H-inden-1-yl)- (9CI) (CA INDEX NAME)



L17 ANSWER 21 OF 55 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1996:202755 HCAPLUS Full-text

DOCUMENT NUMBER: 124:260842

TITLE: Benzopyrans and their use as CNS therapeutic agents

INVENTOR(S): Chan, Wai Ngor; Thompson, Mervyn; Evans, John Morris

PATENT ASSIGNEE(S): SmithKline Beecham P.L.C., UK

SOURCE: PCT Int. Appl., 32 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9534546	A1	19951221	WO 1995-EP2246	19950608 <--
W: JP, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
EP 764158	A1	19970326	EP 1995-923294	19950608 <--
EP 764158	B1	20020918		
R: BE, CH, DE, FR, GB, IT, LI, NL				
JP 10501255	T2	19980203	JP 1995-501603	19950608 <--

10/653,977

US 6211211
PRIORITY APPLN. INFO.:


B1 20010403

US 1998-56554
GB 1994-11635
WO 1995-EP2246
US 1996-750613

19980407
A 19940610
W 19950608
B1 19961210

OTHER SOURCE(S):
GI

MARPAT 124:260842



AB The invention relates to substituted benzopyran amides and analogs, having various substituents in the aryl or heteroaryl moiety contained in an amide linkage at position C-4. The compds. are useful for treatment of a wide variety of CNS conditions and disorders. Four compds. were prepared For example, amidation of 4-carboxybenz-2,1,3-oxadiazole with (3R,4S)-trans-6-acetyl-4-amino-3,4-dihydro-2,2-dimethyl-2H-1-benzopyran-3-ol [as D-(-)-mandelic acid salt] using EDC, Et3N, and HOBT in DMF, gave title compound I. In the maximal electroshock seizure test in mice, I at 10 mg/kg orally increased seizure threshold by 49%.


IT 174960-51-1P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of benzopyrans as CNS agents)

RN 174960-51-1 HCAPLUS

CN Benzamide, N-(6-acetyl-2,3-dihydro-2-hydroxy-3,3-dimethyl-1H-inden-1-yl)-4-fluoro-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L17 ANSWER 22 OF 55 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1995:851833 HCAPLUS Full-text

DOCUMENT NUMBER: 123:246859

TITLE: Aminoindan derivatives for the treatment of neurological disorders

INVENTOR(S): Cohen, Sasson; Herzig, Yaacov; Levy, Ruth; Speiser, Tzipora; Shirvan, Mitchell; Sterling, Jeff; Veinberg, Alex; Youdim, Moussa B. H.; Finberg, John P. M.; et

al.
 PATENT ASSIGNEE(S): Teva Pharmaceutical Industries Ltd., Israel; Technion Research and Development Foundation Ltd.
 SOURCE: PCT Int. Appl., 143 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9518617	A1	19950713	WO 1995-US245	19950109 <--
W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, US				
RW: KE, MW, SD, SZ, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2180841	AA	19950713	CA 1995-2180841	19950109 <--
AU 9518670	A1	19950801	AU 1995-18670	19950109 <--
EP 738149	A1	19961023	EP 1995-910862	19950109 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
HU 75067	A2	19970328	HU 1996-1888	19950109 <--
JP 09510188	T2	19971014	JP 1995-518644	19950109 <--
ZA 9500144	A	19950908	ZA 1995-144	19950110 <--
IL 112292	A1	20000726	IL 1995-112292	19950110
US 5877218	A	19990302	US 1995-478204	19950607
US 5914349	A	19990622	US 1995-485688	19950607
NO 9602842	A	19960828	NO 1996-2842	19960705 <--
NO 315594	B1	20030929		
US 5639913	A	19970617	US 1996-712580	19960913 <--
US 5880159	A	19990309	US 1997-948212	19971009
US 5994408	A	19991130	US 1997-951272	19971016
US 5877221	A	19990302	US 1997-953097	19971017
US 6271263	B1	20010807	US 1999-260755	19990302
US 2002068839	A1	20020606	US 1999-420126	19991019
US 6528685	B2	20030304		
PRIORITY APPLN. INFO.:			US 1994-179539	A 19940110
			US 1994-179607	A 19940110
			WO 1995-US245	W 19950109
			US 1995-372064	B3 19950112
			US 1995-475398	B1 19950607
			US 1995-477163	B1 19950607
			US 1995-478204	A1 19950607
			US 1995-482941	B1 19950607
			US 1999-260755	A1 19990302

OTHER SOURCE(S): MARPAT 123:246859

AB Novel derivs. of 1-aminoindan and their salts are described. Parkinson's disease, dementia, epilepsy, convulsions, seizures, acute neurol. traumatic disorder, and neurotrauma are treated by administering the compds. Seventy-five synthetic examples are provided. Effects of 1-aminoindans in an exptl. model of dopaminergic hypofunction were tested with α -methyl-p-tyrosine-induced hypokinesia in hypoxic rats; (R)-1-aminoindan·HCl was effective in treating hypokinetic syndrome, bringing the level of activity almost to that seen in the control hypoxia-unlesioned group.

IT 168902-59-8


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES

(Uses)

(aminoindan derivs. for treatment of neurol. disorders)

RN 168902-59-8 HCAPLUS

CN Benzamide, N-(2,3-dihydro-1H-inden-1-yl)-4-fluoro- (9CI) (CA INDEX NAME)



L17 ANSWER 23 OF 55 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1995:758807 HCAPLUS Full-text

DOCUMENT NUMBER: 123:169643

TITLE: Preparation of pyridazinonylindanes useful for the treatment of endotoxic shock and/or nephritis

INVENTOR(S): Ishida, Akihiko; Homma, Koichi; Yato, Michihisa; Nishiyama, Shinsuke; Okumura, Fumikazu

PATENT ASSIGNEE(S): Tanabe Seiyaku Co., Ltd., Japan

SOURCE: Eur. Pat. Appl., 38 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 661274	A1	19950705	EP 1994-120822	19941228 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
CA 2139088	AA	19950629	CA 1994-2139088	19941223 <--
JP 07233151	A2	19950905	JP 1994-321978	19941226 <--
JP 2757352	B2	19980525		
CN 1107843	A	19950906	CN 1994-113329	19941228 <--
US 5605901	A	19970225	US 1994-365289	19941228 <--
US 5543409	A	19960806	US 1995-445202	19950523 <--
PRIORITY APPLN. INFO.:			JP 1993-333967	A 19931228
			US 1994-365289	A3 19941228

OTHER SOURCE(S): MARPAT 123:169643

GI



I

AB The title compds. [I; A = direct bond, lower alkylene; R1 = (un)substituted aryl, cycloalkyl, alkenyl, (un)substituted mono- or bicyclic aromatic heterocyclyl, etc.; R2 = H, lower alkyl; X = CO, CS; the dotted line represents an optional double bond], useful for treating endotoxic shock


and/or nephritis, are prepared Thus, 2-amino-5-[4,5-dihydropyridazin-3(2H)-on-6-yl]indane was amidated with butyryl chloride, producing 2-butyrylamino-5-[4,5-dihydropyridazin-3(2H)-on-6-yl]indane (II), m.p. 214-215°. Mice which were administered 100 mg/kg II (p.o.) and subsequently injected (i.p.) with E. coli endotoxin, had a 100% survival rate, vs. 20% for control mice.

IT 166979-49-3P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyridazinonylindanes useful for endotoxic shock and/or nephritis)

RN 166979-49-3 HCAPLUS

CN Benzamide, 4-chloro-N-[2,3-dihydro-5-(1,4,5,6-tetrahydro-6-oxo-3-pyridazinyl)-1H-inden-2-yl]- (9CI) (CA INDEX NAME)



L17 ANSWER 24 OF 55 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1995:408385 HCAPLUS Full-text

DOCUMENT NUMBER: 122:187124

TITLE: Carboxylic acid derivatives as inhibitors of human steroid 5 α -reductase

INVENTOR(S): Ueno, Hiroaki; Morioka, Masahiko; Hatanaka, Fumiko

PATENT ASSIGNEE(S): USA

SOURCE: Can. Pat. Appl., 162 pp.

CODEN: CPXXEB

DOCUMENT TYPE: Patent


LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CA 2100642	AA	19940118	CA 1993-2100642	19930715 <--
PRIORITY APPLN. INFO.:			JP 1992-140991	A 19920717
OTHER SOURCE(S):	MARPAT	122:187124		

GI



AB Carboxylic acid derivs. of the formula I [R1-R4 each independently represents H, halo, adamantyl, etc.; R5 = H, C1-5 alkyl; X = CONR13 or SO2NR13 (R13 = H,

C1-6 alkyl); Y = single bond, OCH₂, CH:CH; A = benzene, cyclohexene, or cyclohexadiene ring; dotted line = single bond or double bond; n = 1 or 2, with the proviso that when the C atom to which R₅ is attached has a double bond, R₅ is not present] are provided, which are useful for treatment of androgen dependent diseases such as benign prostatic hyperplasia, acne, seborrhea, female hirsutism, and male alopecia. IC₅₀ values (μM) for human steroid 5α-reductase inhibiting activity of as low as 0.065 were reported.


IT 158860-59-4 161480-06-4

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation as human steroid 5α-reductase inhibitor)

RN 158860-59-4 HCAPLUS


CN 2-Naphthalenecarboxylic acid, 5-[[3-bromo-5-[4-(1-methylethyl)phenoxy]benzoyl]amino]-3,4,4a,5,6,7-hexahydro-4a-methyl- (9CI)
(CA INDEX NAME)



RN 161480-06-4 HCAPLUS

CN 2-Naphthalenecarboxylic acid, 5-[[3-bromo-5-[2-methyl-1-(1-methylethyl)propoxy]benzoyl]amino]-3,4,4a,5,6,7-hexahydro-4a-methyl-, (4aS-cis)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L17 ANSWER 25 OF 55 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1994:680398 HCAPLUS Full-text

DOCUMENT NUMBER: 121:280398

TITLE: Preparation of hydronaphthalenecarboxylates as 5α-reductase inhibitors

INVENTOR(S): Ueno, Hiroaki; Morioka, Masahiko; Hatanaka, Fumiko

PATENT ASSIGNEE(S): Mitsubishi Kasei Corp., Japan

SOURCE: Eur. Pat. Appl., 100 pp.



CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 579223	A1	19940119	EP 1993-111367	19930715 <--
EP 579223	B1	19961009		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
JP 06041038	A2	19940215	JP 1992-190991	19920717 <--
AT 143942	E	19961015	AT 1993-111367	19930715 <--
ES 2095529	T3	19970216	ES 1993-111367	19930715 <--
US 5385917	A	19950131	US 1993-92055	19930716 <--
PRIORITY APPLN. INFO.:			JP 1992-190991	A 19920717
OTHER SOURCE(S):	MARPAT 121:280398			
GI				




AB Title compds. [I; R = (substituted)Ph; R5 = H, alkyl; X = CONR13, SO2NR13; R13 = H, alkyl; Y = bond, OCH2, CH:CH; A ring may be a benzene, cyclohexadiene, or cyclohexene ring; dashed line = optional bond] were prepared. Thus, hexahydronaphthalenecarboxylate II (R = H, R1 = Me) was amidated by 3-(cyclohexylmethyl)benzoic acid and the product saponified to give II [R = 3-(cyclohexylmethyl)benzoyl, R1 = H] which had IC50 of 0.16μM against steroid 5α-reductase in vitro.

IT 158860-59-4P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of, as testosterone 5α-reductase inhibitor)

RN 158860-59-4 HCAPLUS

CN 2-Naphthalenecarboxylic acid, 5-[[3-bromo-5-[4-(1-methylethyl)phenoxy]benzoyl]amino]-3,4,4a,5,6,7-hexahydro-4a-methyl- (9CI)
(CA INDEX NAME)



ACCESSION NUMBER: 1994:549100 HCAPLUS Full-text
 DOCUMENT NUMBER: 121:149100
 TITLE: Potassium channel activators for use in therapy for
 brain disorders and effects associated with withdrawal
 from abused substances
 INVENTOR(S): Vong, Kuok Keong; Evans, John Morris; Nadler, Guy
 Marguerite Marie Gerard; Willette, Robert Nicholas
 PATENT ASSIGNEE(S): SmithKline Beecham PLC, UK; SmithKline Beecham
 Corporation
 SOURCE: PCT Int. Appl., 33 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9413292	A1	19940623	WO 1993-GB2514	19931208 <--
W: JP, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
EP 673248	A1	19950927	EP 1994-902046	19931208 <--
R: BE, CH, DE, ES, FR, GB, IT, LI, NL				
JP 08504432	T2	19960514	JP 1993-513936	19931208 <--
PRIORITY APPLN. INFO.:			GB 1992-25860	A 19921211
			WO 1993-GB2514	W 19931208

OTHER SOURCE(S): MARPAT 121:149100

AB A method of treatment and/or prophylaxis of anxiety, mania, depression, the effects associated with withdrawal from substances of abuse such as cocaine, nicotine, alc. and benzodiazepines; disorders treatable and/or preventable with anticonvulsive agents, such as epilepsy; and in the treatment or prevention of cerebral ischemia, disorders resulting from sub-arachnoid hemorrhage, Parkinson's disease, migraine, and/or psychosis, comprises administering to the sufferer in need thereof an effective or prophylactic amount of a potassium channel activator (Markush included). Trans-3-cyano-5-(4-fluorobenzamido)-6,7,8,9-tetrahydro-5H-benzocycloheptan-6-ol and trans-7-cyano-5-(4-fluorobenzamino)-4-hydroxy-2,2-dimethyl-2,3,4,5-tetrahydro-1-benzoxepine are specifically claimed. Preparation of selected compds. of the invention are included. Trans-7-(4-fluorobenzamido)-5,6-dihydro-6-hydroxy-2-nitro-5,5-dimethyl-7H-thieno[3,2-b]pyran enhanced the threshold of shock by 95% at 30 mg/kg p.o. in a rodent maximal electroshock seizure threshold test.

IT 157403-54-8


RL: BIOL (Biological study)

(for treatment of brain disorders and effects associated with withdrawal from abused substances)


RN 157403-54-8 HCAPLUS

CN Benzamide, N-(3-cyano-6,7,8,9-tetrahydro-6-hydroxy-5H-benzocyclohepten-5-yl)-4-fluoro-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L17 ANSWER 27. OF 55 HCAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 1994:408589 HCAPLUS Full-text
 DOCUMENT NUMBER: 121:8589
 TITLE: Isomerization reactions of dicyclopentadiene derivatives. Preparation of amides and carboxylic acids
 AUTHOR(S): Bakke, Jan M.; Knudsen, Boore
 CORPORATE SOURCE: Norwegian Inst. Technol., Univ. Trondheim, Trondheim, N-7034, Norway
 SOURCE: Acta Chemica Scandinavica (1994), 48(3), 234-9
 CODEN: ACHSE7; ISSN: 0904-213X
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 121:8589
 GI



AB The dicyclopentadiene (DPD) derivs. 8,9-endo-dihydro-DPD (I), 8-exo-hydroxy-exo-tetrahydro-DPD (II), and 2-hydroxy-endo-tetrahydro-DPD (III) have been reacted with acetonitrile in sulfuric acid. Reaction for 6 h at 30°C gave an 82% yield of N-(2-exo-tetrahydro-DPD-yl)acetamide. Reaction of III for 1 min at 20°C gave N-(2-endo-tetrahydro-DPD-yl)acetamide (95% yield) and reaction of II with acetonitrile and boron trifluoride in sulfur dioxide gave a 95% yield of N-(exo-8-exo-tetrahydro-DPD-yl)acetamide. The reactions of III with benzonitrile and substituted benzonitriles were monitored by ¹H NMR spectroscopy. The observed rate consts. could be correlated by the Hammett σ -consts. with a ρ constant of 1.00 ($R^2 = 0.987$). These results were in accordance with a reaction scheme in which the isomerizations proceed via carbocations in equilibrium with nitrile adducts. Reaction of 8-exo-chloro-exo-tetrahydro-DPD with carbon monoxide and antimony pentafluoride in sulfur dioxide gave 2-carboxy-endo-tetrahydro-DPD at -78°C and 2-carboxy-exo-2-tetrahydro-DPD at 20°C.

IT 155507-28-1P


RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)

RN 155507-28-1 HCAPLUS


CN Benzamide, 4-chloro-N-(octahydro-4,7-methano-1H-inden-5-yl)-,

(3 α , 4 β , 5 β , 7 β , 7 α)- (9CI) (CA INDEX NAME)

Relative stereochemistry.




L17 ANSWER 28 OF 55 HCAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 1993:560066 HCAPLUS Full-text
 DOCUMENT NUMBER: 119:160066
 TITLE: 2,2-Dialkylnaphthalen-1-ones as new potassium channel activators
 AUTHOR(S): Almansa, Carmen; Gomez, Luis A.; Cavalcanti, Fernando L.; Rodriguez, Ricardo; Carceller, Elena; Bartroli, Javier; Garcia-Rafanell, Julian; Forn, Javier
 CORPORATE SOURCE: Res. Cent., J. Uriach y Cia.S.A., Barcelona, 08026, Spain
 SOURCE: Journal of Medicinal Chemistry (1993), 36(15), 2121-33
 CODEN: JMCMAR; ISSN: 0022-2623
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 GI



AB A new series of 2,2-dialkylnaphthalen-1-one potassium channel activators has been prepared, and their in vitro relaxant activities in isolated rat portal vein and guinea pig tracheal spirals as well as their oral antihypertensive effect in spontaneously hypertensive rats have been evaluated. The group of 1,2-dihydro-4-(1,2-dihydro-2-oxo-1-pyridyl)-2,2-dimethylnaphthalen-1-ones with an electron-withdrawing substituent at the 6-position contain the most active compds. and 1,2-dihydro-4-(1,2-dihydro-2-oxo-1-pyridyl)-2,2-dimethyl-1-oxonaphthalene-6-carbonitrile, (UR-8225) (I), has been selected for further pharmacol. development.

IT 149915-59-3P 149915-60-6P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation and potassium channel activator activity of)
 RN 149915-59-3 HCAPLUS
 CN Benzamide, 2,4-dichloro-N-(7-cyano-1,2,3,4-tetrahydro-2-hydroxy-3,3-dimethyl-4-oxo-1-naphthalenyl)-, trans- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 149915-60-6 HCAPLUS

CN Benzamide, 3,4-dichloro-N-(7-cyano-1,2,3,4-tetrahydro-2-hydroxy-3,3-dimethyl-4-oxo-1-naphthalenyl)-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L17 ANSWER 29 OF 55 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1993:409007 HCAPLUS Full-text

DOCUMENT NUMBER: 119:9007

TITLE: Antitumor agents. 141. Synthesis and biological evaluation of novel thiocolchicine analogs: N-acyl, N-aroyl-, and N-(substituted benzyl)deacetylthiocolchicines as potent cytotoxic and antimitotic compounds

AUTHOR(S): Sun, Li; Hamel, Ernest; Lin, Chii M.; Hastie, Susan B.; Pyluck, Amy; Lee, Kuo Hsiung

CORPORATE SOURCE: Sch. Pharm., Univ. North Carolina, Chapel Hill, NC, 27599, USA


SOURCE: Journal of Medicinal Chemistry (1993), 36(10), 1474-9

CODEN: JMCMAR; ISSN: 0022-2623

DOCUMENT TYPE: Journal

LANGUAGE: English

GI



AB Three series of novel thiocolchicine analogs, N-acyl-, N-aroyl-, and N-(substituted benzyl)-deacetylthiocolchicinoids I (R = 4-O₂NC₆H₄CH₂, 4-FC₆H₄CO, 4-FC₆H₄CO, nonyl, etc.), were synthesized and evaluated for their cytotoxicity against various tumor cell lines, especially solid tumor cell lines, and for their inhibitory effects on tubulin polymerization in vitro. Most of these compds. showed strong inhibitory effects on tubulin polymerization comparable to that obtained with thiocolchicine and greater than that obtained with colchicine. Only compds. with a long side chain at the C(7) position, such as I (R = nonyl), did not inhibit tubulin polymerization. Several of the active N-aroyldeacetylthiocolchicine analogs had pos. optical rotations, in contrast to the neg. optical rotation observed with most colchicinoids. This property might be attributed to a reversal of biaryl configuration from the normal aS to aR. Therefore, the N-aroyl analogs were further evaluated by CD, which readily distinguishes between the aS and aR biaryl configurations. This latter technique demonstrated that the active N-aroyl analogs do have an aS configuration despite their pos. optical rotations. However, comparison of ¹H NMR and UV spectral data of N-(substituted benzyl)-deacetylthiocolchicines with those of corresponding N-aroyldeacetylthiocolchicines suggested a different biaryl dihedral angle [even though these compds. have the same aS biaryl configuration]. The similar tubulin binding properties of these compds. suggest that a biaryl dihedral angle of 53° is not essential for colchicinoid-tubulin interaction. The increased cytotoxicity of N-(substituted benzyl)deacetylthiocolchicines compared to the N-aroyldeacetylthiocolchicines may be attributed to different lipophilicity, drug uptake, or drug metabolism in the tumor cells. The side chain at the C(7) position affects inhibition of tubulin polymerization and the cytotoxic activity of colchicinoids as a function of its size and its contribution to lipophilicity.

IT **147950-67-2P**


RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation and cytotoxicity and inhibition of tubulin polymerization by)

RN 147950-67-2 HCAPLUS

CN Benzamide, 4-fluoro-N-[5,6,7,9-tetrahydro-1,2,3-trimethoxy-10-(methylthio)-9-oxobenzo[a]heptalen-7-yl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 147950-73-0P

RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
(preparation and cytotoxicity of)

RN 147950-73-0 HCAPLUS

CN Benzamide, 4-chloro-N-[(7S)-5,6,7,9-tetrahydro-1,2,3-trimethoxy-10-(methylthio)-9-oxobenzo[a]heptalen-7-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L17 ANSWER 30 OF 55 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1992:651262 HCAPLUS Full-text

DOCUMENT NUMBER: 117:251262

TITLE: Antirhinoviral activity of heterocyclic analogs of Win 54954

AUTHOR(S): Bailey, Thomas R.; Diana, Guy D.; Kowalczyk, Paul J.;
Akullian, Vahan; Eissenstat, Michael A.; Cutcliffe,
David; Mallamo, John P.; Carabateas, Philip M.;
Pevear, Daniel C.

CORPORATE SOURCE: Sterling Winthrop Pharm. Res. Group, Rensselaer, NY,
12144, USA


SOURCE: Journal of Medicinal Chemistry (1992),
35(24), 4628-33

CODEN: JMCMAR; ISSN: 0022-2623

DOCUMENT TYPE: Journal

LANGUAGE: English.

GI



AB A variety of heterocyclic analogs of Win 54954 have been synthesized and tested in vitro against human rhinovirus type 14 (HRV-14) in a plaque reduction assay. Thus, 2,6-dichloro-4-iodophenol was alkylated with 5-(5-bromopentyl)-3-methylisoxazole to give (isoxazolylpentyloxy)benzene I (R = iodo). The latter compound was reacted with 2- (trimethylstannyl)thiophene to give I (R = 2-thienyl). Other analogs, I (R = 3-thienyl, 5-methyl-2-thienyl, 2-, 3-furyl, 2-pyridyl, 1-methyl-2-pyrrolyl, etc.), were also prepared. The more active compds. were tested against 14 addnl. serotypes, and the concentration which inhibited 80% of the serotypes tested (MIC80) was measured. One compound, I (R = 2-methyl-5-(2H)tetrazolyl), exhibited activity comparable to Win 54954. Physicochem. as well as electrostatic parameters were calculated and the results subjected to a QSAR anal. in an effort to explain differences in activity observed between these compds.; however, no meaningful correlation with biol. activity was found with any of these parameters.

IT **144413-12-7P**


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation and retro-Diels-Alder reaction of)

RN 144413-12-7 HCAPLUS

CN Benzamide, 3,5-dichloro-N-(3-hydroxybicyclo[2.2.1]hept-2-yl)-4-[[5-(3-methyl-5-isoxazolyl)pentyl]oxy]-, (endo,endo)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L17 ANSWER 31 OF 55 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1990:55876 HCAPLUS Full-text

DOCUMENT NUMBER: 112:55876

TITLE: Preparation and formulation of imidazoles for gastrointestinal disorder treatment

INVENTOR(S): Yokomori, Sadakazu; Hayashi, Masatoshi; Hatsutori, Keiko; Hatayama, Katsuo; Soda, Kaoru

PATENT ASSIGNEE(S): Taisho Pharmaceutical Co., Ltd., Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 7 pp.

CODEN: JKXXAF


DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 01193253	A2	19890803	JP 1988-18978	19880129 <--
PRIORITY APPLN. INFO.:			JP 1988-18978	19880129
OTHER SOURCE(S):	MARPAT 112:55876			
GI				



AB Title compds. I [R = halo, CF₃, lower alkyl, lower alkoxy, lower alkylthio, Ph (mono-, di-, or trisubstituted with cyano and/or NO₂), naphthyl; X = CH₂, S; Y = H, Ph; Z = CH₂, vinylene, none; when R = Ph, then Z = CH₂ or vinylene] or their salts were prepared Treatment of 3.00 g 2-amino-1-tetralone.HCl with 1.8 mL 4-fluorobenzoyl chloride and Et₃N in CH₂Cl₂ at room temperature for 30 min gave 3.37 g 2-(4-fluorobenzamido)-1-tetralone, which (3.3 g) was treated with AcONH₄ at 130° for 3 h to afford 2.96 g I (ZR = 4-fluorophenyl, X = CH₂, Y = H).HCl (II). II at 50 mg/kg i.p. showed 96.7% inhibition against stress-induced ulcer in rats. A formulation containing II is given. LD₅₀ value of II was >300 mg/kg p.o. in mice.


IT 124655-18-1P, 2-(4-Fluorobenzamido)-1-tetralone
 124655-19-2P, 2-(2-Chlorobenzamido)-1-tetralone
 124655-20-5P, 2-(3-Chlorobenzamido)-1-tetralone
 124655-21-6P, 2-(4-Chlorobenzamido)-1-tetralone
 124655-22-7P, 2-(3,4-Dichlorobenzamido)-1-tetralone

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation and cyclocondensation of, with ammonium acetate)


RN 124655-18-1 HCAPLUS

CN Benzamide, 4-fluoro-N-(1,2,3,4-tetrahydro-1-oxo-2-naphthalenyl)- (9CI)
 (CA INDEX NAME)




RN 124655-19-2 HCAPLUS


CN Benzamide, 2-chloro-N-(1,2,3,4-tetrahydro-1-oxo-2-naphthalenyl)- (9CI)
 (CA INDEX NAME)




RN 124655-20-5 HCAPLUS
 CN Benzamide, 3-chloro-N-(1,2,3,4-tetrahydro-1-oxo-2-naphthalenyl)- (9CI)
 (CA INDEX NAME)



RN 124655-21-6 HCAPLUS
 CN Benzamide, 4-chloro-N-(1,2,3,4-tetrahydro-1-oxo-2-naphthalenyl)- (9CI)
 (CA INDEX NAME)



RN 124655-22-7 HCAPLUS
 CN Benzamide, 3,4-dichloro-N-(1,2,3,4-tetrahydro-1-oxo-2-naphthalenyl)- (9CI)
 (CA INDEX NAME)




L17 ANSWER 32 OF 55 HCAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 1990:20896 HCAPLUS Full-text
 DOCUMENT NUMBER: 112:20896
 TITLE: Heterocyclylindanes as bronchodilators and
 antihypertensives and their preparation
 INVENTOR(S): Tedder, John Martin; Pinto, Ivan Leo; Edge, Colin
 Michael
 PATENT ASSIGNEE(S): Beecham Group PLC, UK
 SOURCE: Eur. Pat. Appl., 62 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 321175	A1	19890621	EP 1988-311762	19881213 <--
R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
DK 8806914	A	19890615	DK 1988-6914	19881212 <--

10/653,977

AU 8826780	A1	19890622	AU 1988-26780	19881212 <--
AU 609232	B2	19910426		
ZA 8809271	A	19891227	ZA 1988-9271	19881212 <--
JP 02000141	A2	19900105	JP 1988-313080	19881213 <--
PRIORITY APPLN. INFO.:			GB 1987-29141	A 19871214
			GB 1988-18877	A 19880809
			GB 1988-18878	A 19880809

GI



AB The title compds. I [A = C:X; X = O, S, or A = bond; Y = N, NO, or CR8; R1, R2 = H, alkyl; or R1R2 = C2-7 polymethylene moiety; R3 = H, OH, alkoxy, acyloxy; R4 = H; or R3R4 = bond; when A = C:X, then R5 = H, (substituted) alkyl, etc.; R6 = H, alkyl; or R5R6 = linking chain A1A2, A1 being attached to the N atom of the moiety NA and A2 being attached to the group A on said moiety, and wherein A1 = (substituted) methylene, A2 = 2 or 3 linking members; when A = bond, then NR5R6 forms an unsatd. heterocyclic ring having 5 to 7 ring atoms; R7, R8 = H, (substituted) alkyl, alkoxy, C3-8 cycloalkyl, OH, NO2, cyano, halo, etc.; when Y = CR8, at least one of R7 and R8 is not H; p = 0 or 1], useful as bronchodilators and antihypertensives, were prepared. A mixture of 1,1-dimethyl-2,3-epoxy-5-nitroindane, 2-pyrrolidinone, and tert-BuOK was stirred for 3.5 h to give trans-1,1-dimethyl-5-nitro-3-(2-oxopyrrolidin-1-yl)indan-2-ol (II) and the corresponding cis isomer. II at 10 mg/kg orally decreased blood pressure in spontaneously hypertensive rats by 48%.


IT 124369-15-9P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as bronchodilator and antihypertensive)

RN 124369-15-9 HCAPLUS

CN Benzamide, N-(2,3-dihydro-2-hydroxy-6-nitro-1H-inden-1-yl)-4-fluoro-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.




L17 ANSWER 33 OF 55 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1985:6924 HCAPLUS Full-text

DOCUMENT NUMBER: 102:6924

TITLE: Synthesis of an antiarrhythmic agent auluton and its derivatives

AUTHOR(S): Fang, Chenglin; Liao, Qingjiang; Xu, Fang
 CORPORATE SOURCE: Nanjing Coll. Pharm., Nanjing, Peop. Rep. China
 SOURCE: Yiyao Gongye (1984), (9), 15-19
 CODEN: YIGODN; ISSN: 0255-7223
 DOCUMENT TYPE: Journal
 LANGUAGE: Chinese
 GI



AB Auluton (I) and 11 derivs. were prepared, e.g., by O-acylation of azido hydroxy derivs. II with m-ClC₆H₄COCl, nicotinoyl chloride, 3,4-(MeO)₂C₆H₃COCl. Among five of the derivs. tested 3 had antiarrhythmic activity.


IT 93517-81-8P

RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)

RN 93517-81-8 HCAPLUS

CN Benzamide, 3-chloro-N-[(2β,3α,5α)-2-[(3,4-dimethoxybenzoyl)oxy]-17-oxoandrostan-3-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L17 ANSWER 34 OF 55 HCAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 1985:6063 HCAPLUS Full-text
 DOCUMENT NUMBER: 102:6063
 TITLE: Antihypercholesterolemic compounds
 INVENTOR(S): Hoffman, William F.; Lee, Ta Jyh; Smith, Robert L.; Willard, Alvin K.
 PATENT ASSIGNEE(S): Merck and Co., Inc., USA
 SOURCE: Eur. Pat. Appl., 44 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent

LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 113881	A1	19840725	EP 1983-112563	19831214 <--
EP 113881	B1	19870812		
R: CH, DE, FR, GB, IT, LI, NL				
US 4472426	A	19840918	US 1982-452176	19821222 <--
JP 59130249	A2	19840726	JP 1983-241099	19831222 <--
JP 04019223	B4	19920330		
US 4503072	A	19850305	US 1984-621393	19840618 <--
PRIORITY APPLN. INFO.:			US 1982-452176	A 19821222
GI				



AB The compactin analogs I (R = OH, R1 = H; RR1 = bond; R2 = H, alkyl, cycloalkyl, alkenyl, haloalkyl, CH2Ph, substituted CH2Ph; R3 = C1-C10 alkyl, alkenyl, haloalkyl, Ph, substituted Ph, phenylalkyl; R4 = H, Me) and their various dehydro derivs. were prepared for use as anticholesteremics and fungicides (no data). Thus, II (R5 = SiMe2CMe3, R6 = H, R7 = OH) was oxidized to II (R6R7 = O) which was converted to II (R6R7 = NOH) and reduced with PtO2 to give II (R6 = H, R7 = NH2). Acylation of the amine with EtCMe2COCl and desilylation gave II (R5 = R6 = H, R7 = NHCOMe2Et).


IT **93412-17-0P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and desilylation of)

RN 93412-17-0 HCAPLUS

CN Benzamide, N-[8-[2-[4-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]tetrahydro-6-oxo-2H-pyran-2-yl]ethyl]decahydro-3,7-dimethyl-1-naphthalenyl]-4-fluoro-, [1S-[1 α , 3 α , 4 α , 7 β , 8 β (2S*, 4S*), 8 α]]]-
 (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 93367-60-3P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 93367-60-3 HCAPLUS

CN Benzamide, N-[decahydro-3,7-dimethyl-8-[2-(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl]-1-naphthalenyl]-4-fluoro-, [1S-[1 α , 3 α , 4 α , 7 β , 8 β (2S*, 4S*), 8a β]]- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.



L17 ANSWER 35 OF 55 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1984:610165 HCAPLUS Full-text

DOCUMENT NUMBER: 101:210165


TITLE: Saturated heterocycles. 66. Stereochemical studies -
79. Synthesis and kinetic study on the retrodiene
decomposition of norbornene-condensed
1,3-oxazin-4-onesAUTHOR(S): Stajer, Geza; Mod, Laszlo; Szabo, Angela E.; Fulop,
Ferenc; Bernath, Gabor; Sohar, PalCORPORATE SOURCE: Inst. Pharm. Chem., Univ. Med. Sch. Szeged, Szeged,
H-6701, Hung.SOURCE: Tetrahedron (1984), 40(12), 2385-93
CODEN: TETRAB; ISSN: 0040-4020

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 101:210165

GI



AB The cis-exo amino acid (I) was converted into 2-aryl-cis-exo-1,3-oxazin-4-ones (II; R = Ph, p-MeC₆H₄, p-ClC₆H₄, 3,4-Cl₂C₆H₃). II undergo retrodiene decomposition under mild conditions to give 2-aryl-6H-1,3-oxazin-6-ones (III; R as above) in 50-60% yield. The ratio of the decomposition rate consts. of the tricyclic diendo and diexo 1,3-oxazin-4-ones, measured in toluene solution, is .apprx. 2.


IT 92511-30-3P 92511-31-4P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 92511-30-3 HCAPLUS

CN Bicyclo[2.2.1]hept-5-ene-2-carboxylic acid, 3-[(4-chlorobenzoyl)amino]-, (exo,exo)- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 92511-31-4 HCAPLUS

CN Bicyclo[2.2.1]hept-5-ene-2-carboxylic acid, 3-[(3,4-dichlorobenzoyl)amino]-, (exo,exo)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L17 ANSWER 36 OF 55 HCAPLUS COPYRIGHT 2005 ACS on STN


ACCESSION NUMBER: 1984:510843 HCAPLUS Full-text

DOCUMENT NUMBER: 101:110843

TITLE: Stereochemical studies. Part 64. Saturated heterocycles. 49. Novel preparation of

10/653,977

AUTHOR(S): 6H-1,3-oxazin-6-ones by retrodiene reaction
Stajer, Geza; Szabo, Angela E.; Fulop, Ferenc;
Bernath, Gabor
CORPORATE SOURCE: Inst. Pharm. Chem., Univ. Med. Sch., Szeged, 6720,
Hung.
SOURCE: Synthesis (1984), (4), 345-6
CODEN: SYNTBF; ISSN: 0039-7881
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 101:110843
GI



AB 3,1-Benzoxazin-4-ones I (R = Ph, tolyl, ClC₆H₄, Cl₂C₆H₃) underwent a retro-Diels-Alder reaction to yield oxazinones II. Thus, norbornene derivative III was N-acylated by BzCl, the product was treated with SOCl₂ and Et₃N to give I (R = Ph), and the latter was heated at 150° to give II (R = Ph).

IT 91813-48-8P 91813-49-9P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation and cyclocondensation of, in preparation of oxazinone derivative)

RN 91813-48-8 HCAPLUS

CN Bicyclo[2.2.1]hept-5-ene-2-carboxylic acid, 3-[(4-chlorobenzoyl)amino]-, (endo,endo)- (9CI) (CA INDEX NAME)


Relative stereochemistry.




RN 91813-49-9 HCAPLUS

CN Bicyclo[2.2.1]hept-5-ene-2-carboxylic acid, 3-[(3,4-dichlorobenzoyl)amino]-, (endo,endo)- (9CI) (CA INDEX NAME)

Relative stereochemistry.




L17 ANSWER 37 OF 55 HCAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 1980:446980 HCAPLUS Full-text
 DOCUMENT NUMBER: 93:46980
 TITLE: Remote oxidation of a steroidal amide, ether, and sulfonate
 AUTHOR(S): Wolner, Daniel
 CORPORATE SOURCE: Chem. Dep., Columbia Univ., New York, NY, 10027, USA
 SOURCE: Tetrahedron Letters (1979), (48), 4613-14
 CODEN: TELEAY; ISSN: 0040-4039
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 GI



AB The cholestenes I (R_2 = bond, Z = CH_2O , $CONH$, SO_3) were prepared by regiospecific photochem. chlorination ($PhICl_2$) of the cholestanes I ($R = H$) at C-9, and subsequent dehydrochlorination.
 IT **74214-01-0P**
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and dehydrochlorination of)
 RN 74214-01-0 HCAPLUS
 CN Benzamide, N-[(3 α ,5 α)-9-chlorocholestan-3-yl]-3-iodo- (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.




IT 74214-02-1P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 74214-02-1 HCAPLUS

CN Benzamide, N-[(3 α ,5 α)-cholest-9(11)-en-3-yl]-3-iodo- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.




IT 74214-00-9

RL: RCT (Reactant); RACT (Reactant or reagent)
(regiospecific photochem. chlorination of, template-directed)

RN 74214-00-9 HCAPLUS

CN Benzamide, N-[(3 α ,5 α)-cholestan-3-yl]-3-iodo- (9CI) (CA INDEX
NAME)

Absolute stereochemistry.



L17 ANSWER 38 OF 55 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1980:198423 HCAPLUS Full-text

DOCUMENT NUMBER: 92:198423

TITLE: Antidiabetic active sulfonamide.

INVENTOR(S): Heerdt, Ruth; Huebner, Manfred; Schmidt, Felix Helmut;
Stach, Kurt; Muth, Karl

PATENT ASSIGNEE(S): Boehringer Mannheim G.m.b.H., Fed. Rep. Ger.

SOURCE: Ger., 4 pp. Addn. and Division of Ger. 1,670,282.

CODEN: GWXXAW


DOCUMENT TYPE: Patent

LANGUAGE: German


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 1795842	B1	19800110	DE 1967-1795842	19680518 <--
DE 1795842	C2	19800918		
PRIORITY APPLN. INFO.:			DE 1967-1795842	A 19680518
GI				



I



II

AB The sulfonamides I (R = cyclohexyl, MeOCH₂, EtOCH₂) were prepared for use as antidiabetics. Thus, II reacted with 2-amino-5-cyclohexylpyrimidine in pyridine solution to give I (R = cyclohexyl), which at 0.025 mg/kg i.v. gave 15% lowering of blood sugar in rabbits.

IT 24445-66-7P 24445-67-8P 24445-69-0P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

10/653,977

(preparation and antidiabetic activity of)


RN 24445-66-7 HCAPLUS

CN Benzamide, 5-chloro-N-[2,3-dihydro-5-[[[5-(methoxymethyl)-2-pyrimidinyl]amino]sulfonyl]-1H-inden-2-yl]-2-methoxy- (9CI) (CA INDEX NAME)




RN 24445-67-8 HCAPLUS

CN Benzamide, 5-chloro-N-[5-[[[5-(ethoxymethyl)-2-pyrimidinyl]amino]sulfonyl]-2,3-dihydro-1H-inden-2-yl]-2-methoxy- (9CI) (CA INDEX NAME)



RN 24445-69-0 HCAPLUS

CN Benzamide, 5-chloro-N-[5-[[[5-(cyclohexyl)-2-pyrimidinyl]amino]sulfonyl]-2,3-dihydro-1H-inden-2-yl]-2-methoxy- (9CI) (CA INDEX NAME)




IT 24446-19-3

RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, with aminopyrimidine)

RN 24446-19-3 HCAPLUS

CN 1H-Indene-5-sulfonyl chloride, 2-[(5-chloro-2-methoxybenzoyl)amino]-2,3-dihydro- (9CI) (CA INDEX NAME)



10/653,977

L17 ANSWER 39 OF 55 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1973:442214 HCAPLUS Full-text

DOCUMENT NUMBER: 79:42214

TITLE: Hypoglycemic N-sulfonyl-N'-(cyclopentylalkyl)ureas

INVENTOR(S): Weber, Helmut; Aumuellner, Walter; Weyer, Rudi; Muth, Karl; Hitzel, Volker

PATENT ASSIGNEE(S): Farbwerke Hoechst A.-G.

SOURCE: Ger. Offen., 16 pp.

CODEN: GWXXBX

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2157607	A1	19730524	DE 1971-2157607	19711120 <--
DE 2157607	B2	19790719		
NL 7215460	A	19730522	NL 1972-15460	19721115 <--
AU 7248931	A1	19740124	AU 1972-48931	19721116 <--
CH 589616	A	19770715	CH 1972-16674	19721116 <--
CH 599930	A	19780615	CH 1972-352177	19721116 <--
CH 599931	A	19780615	CH 1972-352277	19721116 <--
CH 599932	A	19780615	CH 1972-352377	19721116 <--
CH 599933	A	19780615	CH 1972-352477	19721116 <--
CH 599934	A	19780615	CH 1972-352577	19721116 <--
CH 601212	A	19780630	CH 1972-352077	19721116 <--
ZA 7208159	A	19730725	ZA 1972-8159	19721117 <--
AT 7209813	A	19760215	AT 1972-9813	19721117 <--
AT 332880	B	19761025		
CA 991188	A1	19760615	CA 1972-156783	19721117 <--
BE 791638	A1	19730521	BE 1972-124379	19721120 <--
FR 2160669	A1	19730629	FR 1972-41131	19721120 <--
JP 48061455	A2	19730828	JP 1972-116509	19721120 <--
JP 54038093	B4	19791119		
GB 1414514	A	19751119	GB 1972-53512	19721120 <--
US 3927088	A	19751216	US 1972-308002	19721120 <--
US 3984416	A	19761005	US 1975-581764	19750529 <--
AT 7504365	A	19760915	AT 1975-4365	19750609 <--
AT 336632	B	19770510		
AT 7504366	A	19770715	AT 1975-4366	19750609 <--

PRIORITY APPLN. INFO.:

DE 1971-2157607	A	19711120
AT 1972-9813	A	19721117
US 1972-308002	A3	19721120

GI For diagram(s), see printed CA Issue.


AB Twenty-six title compds., XCONHQSO₂NHCONH(CH₂)_nZ [I; X = aryl, e.g. 5,2-Me(MeO)C₆H₃, 3-alkoxy-2-thienyl, or 6-chloro-8-quinolyl; Q = Q₁ (with R₁ = R₂ = H or R₁ ≠ R₂ = H or Me), Q₂, or Q₃; R = H, 2-Et, or 3-Me; n = 1 or 2] were prepared either by reaction of XCONHQSO₂NHCO₂Me with H₂N(CH₂)_nZ, or of XCONHQ₃SO₂NH₂ with Z(CH₂)_nNCO, or of H₂NQ₂SO₂NHCONH(CH₂)_nZ with XCOCl. Some I lowered blood sugar levels by >50%.

IT 42079-28-7P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 42079-28-7 HCAPLUS

CN Benzamide, 5-chloro-N-[5-[[[(cyclopentylmethyl)amino]carbonyl]amino]sulfonyl]-2,3-dihydro-1H-inden-2-yl]-2-methoxy- (9CI) (CA INDEX NAME)



L17 ANSWER 40 OF 55 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1973:111008 HCAPLUS Full-text

DOCUMENT NUMBER: 78:111008

TITLE: [2-(Acylamino)-1,2,3,4-tetrahydro-7-naphthylsulfonyl]ureas

INVENTOR(S): Heerdt, Ruth; Huebner, Manfred; Schmidt, Felix Helmut; Thiel, Max; Aumuellner, Walter

PATENT ASSIGNEE(S): Boehringer, Mannheim G.m.b.H.

SOURCE: Ger. Offen., 17 pp.

CODEN: GWXXBX

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2135805	A1	19730208	DE 1971-2135805	19710717 <--
GB 1336983	A	19731114	GB 1972-32364	19720711 <--
FR 2146260	A1	19730302	FR 1972-25217	19720712 <--
SE 382632	B	19760209	SE 1972-9167	19720712 <--
CH 577468	A	19760715	CH 1975-16011	19720712 <--
CH 583187	A	19761231	CH 1972-10482	19720712 <--
AT 320661	B	19750225	AT 1972-6093	19720714 <--
AT 324350	B	19750825	AT 1973-9454	19720714 <--
			DE 1971-2135805	A 19710717

PRIORITY APPLN. INFO.:

GI For diagram(s), see printed CA Issue.


AB Nineteen title compds. [I, e.g. R = 2,5-MeOMeC₆H₃, 2,5-MeOFC₆H₃, 2,5-(MeO)2C₆H₃, 2,5-EtOC₆H₃, 3-(β-methoxyethoxy)-2-thienyl, fluoren-9-ylmethyl, 5-methyl-3-isoxazolyl; R₁ = Bu, cyclopentyl, 4-methylcyclohexyl, 3-cyclohexenyl, 1-adamantyl, or 4-methylpiperidino], useful as hypoglycemics, were prepared by reaction of II with OCNR₁ or of III with H₂NR₁. I (R = 5-methyl-3-isoxazolyl, R₁ = cyclohexyl) was prepared by adding 5-methylisoxazole-3-carbonyl chloride to N-(2-amino-1,2,3,4-tetrahydro-7-naphthylsulfonyl)-N'-cyclohexylurea.

IT 40153-55-7P 40153-61-5P 40153-65-9P
 40153-67-1P 40153-76-2P 40153-78-4P
 40153-79-5P 40153-80-8P 40153-82-0P
 40323-15-7P 40488-90-2P

RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)


RN 40153-55-7 HCAPLUS

CN Benzamide, N-[7-[[[(cyclopentylamino)carbonyl]amino]sulfonyl]-1,2,3,4-tetrahydro-2-naphthalenyl]-5-fluoro-2-methoxy- (9CI) (CA INDEX NAME)




RN 40153-61-5 HCAPLUS

CN Benzamide, 5-chloro-N-[7-[[[(3-cyclohexen-1-ylamino)carbonyl]amino]sulfonyl]-1,2,3,4-tetrahydro-2-naphthalenyl]-2-ethoxy- (9CI) (CA INDEX NAME)




RN 40153-65-9 HCAPLUS

CN Benzamide, 5-chloro-N-[7-[[[(cyclohexylamino)carbonyl]amino]sulfonyl]-1,2,3,4-tetrahydro-2-naphthalenyl]-2-methoxy- (9CI) (CA INDEX NAME)




RN 40153-67-1 HCAPLUS

CN Benzamide, 5-chloro-2-methoxy-N-[1,2,3,4-tetrahydro-7-[[[(tricyclo[3.3.1.1^{3,7}]dec-1-ylamino)carbonyl]amino]sulfonyl]-2-naphthalenyl]- (9CI) (CA INDEX NAME)




RN 40153-76-2 HCAPLUS

CN Benzamide, 5-chloro-N-[7-[[[(4,4-dimethyl-1-piperidinyl)amino]carbonyl]amino]sulfonyl]-1,2,3,4-tetrahydro-2-naphthalenyl]-2-methoxy- (9CI) (CA INDEX NAME)




RN 40153-78-4 HCAPLUS

CN Benzamide, N-[7-[[[(bicyclo[2.2.1]hept-2-ylamino)carbonyl]amino]sulfonyl]-1,2,3,4-tetrahydro-2-naphthalenyl]-5-chloro-2-methoxy- (9CI) (CA INDEX NAME)




RN 40153-79-5 HCAPLUS

CN Benzamide, 5-bromo-N-[7-[[[(3,4-dimethylcyclohexylamino)carbonyl]amino]sulfonyl]-1,2,3,4-tetrahydro-2-naphthalenyl]-2-methoxy- (9CI) (CA INDEX NAME)




RN 40153-80-8 HCAPLUS

CN Carbamic acid, [[7-[(5-bromo-2-methoxybenzoyl)amino]-5,6,7,8-tetrahydro-2-naphthalenyl]sulfonyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 40153-82-0 HCAPLUS

CN Benzamide, N-[7-[[[(3-azaspiro[5.5]undec-3-ylamino)carbonyl]amino]sulfonyl]-1,2,3,4-tetrahydro-2-naphthalenyl]-5-chloro-2-methoxy- (9CI) (CA INDEX NAME)




RN 40323-15-7 HCAPLUS

CN Benzamide, N-[7-[[[(8-azabicyclo[3.2.1]oct-8-ylamino)carbonyl]amino]sulfonyl]-1,2,3,4-tetrahydro-2-naphthalenyl]-5-chloro-2-methoxy- (9CI) (CA INDEX NAME)



RN 40488-90-2 HCAPLUS

CN Benzamide, 5-chloro-N-[7-[[[(hexahydro-1H-azepin-1-yl)amino]carbonyl]amino]sulfonyl]-1,2,3,4-tetrahydro-2-naphthalenyl]-2-methoxy- (9CI) (CA INDEX NAME)




IT 40153-81-9

RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, with Et chloroformate)

RN 40153-81-9 HCAPLUS

CN Benzamide, N-[7-(aminosulfonyl)-1,2,3,4-tetrahydro-2-naphthalenyl]-5-bromo-2-methoxy- (9CI) (CA INDEX NAME)




IT 40153-77-3

RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, with dimethylpiperidine)

RN 40153-77-3 HCAPLUS

CN Carbamic acid, [[7-[(5-chloro-2-methoxybenzoyl)amino]-5,6,7,8-tetrahydro-2-naphthalenyl]sulfonyl]-, ethyl ester (9CI) (CA INDEX NAME)




IT 35265-99-7 40153-56-8 40153-62-6

RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, with isocyanates)


RN 35265-99-7 HCAPLUS

CN Benzamide, N-[7-(aminosulfonyl)-1,2,3,4-tetrahydro-2-naphthalenyl]-5-chloro-2-methoxy- (9CI) (CA INDEX NAME)




RN 40153-56-8 HCAPLUS

CN Benzamide, N-[7-(aminosulfonyl)-1,2,3,4-tetrahydro-2-naphthalenyl]-5-fluoro-2-methoxy- (9CI) (CA INDEX NAME)



RN 40153-62-6 HCAPLUS

CN Benzamide, N-[7-(aminosulfonyl)-1,2,3,4-tetrahydro-2-naphthalenyl]-5-chloro-2-ethoxy- (9CI) (CA INDEX NAME)



L17 ANSWER 41 OF 55 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1972:488739 HCAPLUS Full-text
DOCUMENT NUMBER: 77:88739

TITLE: Stereospecific approach to diterpene alkaloids with a bridge across ring B

AUTHOR(S): Wiesner, K.; Ho, Pak-Tsun; Chang, D.; Blount, J. F.

CORPORATE SOURCE: Nat. Prod. Res. Cent., Univ. New Brunswick, Fredericton, NB, Can.

SOURCE: Experientia (1972), 28(7), 766-7
CODEN: EXPEAM; ISSN: 0014-4754

DOCUMENT TYPE: Journal


LANGUAGE: English

AB Pentacyclic keto lactam (I), an intermediate for the synthesis of songorine, was prepared from the tricyclic ester (II) in 25 steps via the diketone (III) and the ester (IV).

IT **38689-71-3P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 38689-71-3 HCAPLUS

CN 2H-4a,9-Methanophenanthrene-1-carboxylic acid, 4-(acetyloxy)-11-[(3-bromobenzoyl)amino]-1,3,4,9,10,10a-hexahydro-6-methoxy-1-methyl-10-oxo-, methyl ester (9CI) (CA INDEX NAME)



L17 ANSWER 42 OF 55 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1972:434561 HCAPLUS Full-text

DOCUMENT NUMBER: 77:34561

TITLE: N-[5-[(Alkylthio)alkyl]-2-pyrimidinyl]-4-[2-(acylamino)ethyl]benzenesulfonamides

INVENTOR(S): Huebner, Manfred; Heerdt, Ruth; Schmitd, Felix Helmut; Stach, Kurt; Weyer, Rudi

PATENT ASSIGNEE(S): Boehringer Mannheim G.m.b.H.

SOURCE: Ger. Offen., 19 pp.
CODEN: GWXXBX

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2048906	A	19720413	DE 1970-2048906	19701006 <--
GB 1310198	A	19730314	GB 1971-46098	19711004 <--
CH 567000	A	19750930	CH 1971-14424	19711004 <--
CH 568984	A	19751114	CH 1975-8757	19711004 <--

CH 568985	A	19751114	CH 1975-8758	19711004 <--
CH 568986	A	19751114	CH 1975-8759	19711004 <--
AT 311361	B	19731112	AT 1971-8601	19711005 <--
AT 311367	B	19731112	AT 1972-10136	19711005 <--
AT 311368	B	19731112	AT 1972-10138	19711005 <--
AT 313908	B	19740311	AT 1972-10137	19711005 <--
FR 2110250	A5	19720602	FR 1971-35933	19711006 <--
FR 2110250	B1	19750606		

PRIORITY APPLN. INFO.:

DE 1970-2048906

A 19701006

GI For diagram(s), see printed CA Issue.


AB Thirteen title compds. I (R = e.g. 5-methyl-3-isoxazolyl, 9-fluorenylmethyl, and substituted phenyl; R1 = Me, Et, Pr, or iso-Pr; n = 1 or 2), 2-(5-chloro-2-ethoxybenzamido)-N-[5-[(ethylthio)methyl]-2-pyrimidinyl]-5-indansulfonamide, and 2-(5-chloro-2-methoxybenzamido)-N-[5-[(methylthio)methyl]-2-pyrimidinyl]-1,2,3,4-tetrahydro-7-naphthalenesulfonamide, useful as antidiabetics, were prepared by reaction of acyl chlorides with the 4-(aminoethyl)benzenesulfonamides, of benzenesulfonyl chlorides with 2-aminopyrimidines, of (phenylsulfonyl)guanidines with COCl₂, DMF, and EtSCH₂CH₂CH(OEt)₂ (II), or of benzenesulfonamides with 2-(trimethylammonio)pyrimidine chlorides. Thus, refluxing 5-methyl-3-isoxazolecarboxylic acid with SOCl₂ and DMF 1 hr in C₆H₆ gave the chloride, which on reaction with 4-(2-aminoethyl)-N-[5-[(ethylthio)methyl]-2-pyrimidinyl]benzenesulfonamide in aqueous NaOH gave 56% I (R = 5-methyl-3-isoxazolyl, R1 = Et, n = 1). Reaction of EtSCH₂CH₂CHO, prepared by addition of EtSH to acrolein, with HC(OEt)₃ gave II which was treated with p-[5,2-Cl(MeO)C₆H₃CONHCH₂CH₂-C₆H₄SO₂NHC(:NH)NH₂, COCl₂, and DMF to give I (R = 5,2-Cl(MeO)C₆H₃, R1 = Et, n = 1).

IT 37795-62-3P 37795-65-6P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)


RN 37795-62-3 HCAPLUS

CN Benzamide, 5-chloro-2-ethoxy-N-[5-[[[5-[(ethylthio)methyl]-2-pyrimidinyl]amino]sulfonyl]-2,3-dihydro-1H-inden-2-yl]- (9CI) (CA INDEX NAME)



RN 37795-65-6 HCAPLUS

CN Benzamide, 5-chloro-2-methoxy-N-[1,2,3,4-tetrahydro-7-[[[5-[(methylthio)methyl]-2-pyrimidinyl]amino]sulfonyl]-2-naphthalenyl]- (9CI) (CA INDEX NAME)



L17 ANSWER 43 OF 55 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1972:99694 HCAPLUS Full-text

DOCUMENT NUMBER: 76:99694

TITLE: Blood sugar-lowering sulfonylamino pyrimidines

INVENTOR(S): Hagedorn, Adolf; Huebner, Manfred; Heerdt, Ruth;
Schmidt, Felix Helmut; Aumuehler, Walter

PATENT ASSIGNEE(S): Boehringer Mannheim G.m.b.H.

SOURCE: Ger. Offen., 18 pp.

CODEN: GWXXBX

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2022746	A	19711202	DE 1970-2022746	19700509 <--
CH 563992	A	19750715	CH 1971-6640	19710505 <--
CH 563993	A	19750715	CH 1975-3593	19710505 <--
CH 563994	A	19750715	CH 1975-3594	19710505 <--
CH 572913	A	19760227	CH 1975-3595	19710505 <--
GB 1291661	A	19721004	GB 1971-1291661	19710506 <--
FR 2100641	A5	19720324	FR 1971-16514	19710507 <--
FR 2100641	B1	19750418		
AT 306728	B	19730425	AT 1971-3996	19710507 <--
AT 306737	B	19730425	AT 1972-4102	19710507 <--
AT 306738	B	19730425	AT 1972-4104	19710507 <--
AT 307428	B	19730525	AT 1972-4103	19710507 <--

PRIORITY APPLN. INFO.: DE 1970-2022746 A 19700509

GI For diagram(s), see printed CA Issue.


AB Approx. 20 title compds. [I, R = 5,2-Me(MeO)C₆H₃, 5,2-Cl(MeO)C₆H₃, 5,2-Cl(EtO)C₆H₃, 5,2-F(MeO)C₆H₃, 5,2-Br(MeO)C₆H₃, 9-fluorenylmethyl, 2-MeOC₆H₄, 3-ethoxy-2-thienyl, 3-(2-methoxyethoxy)-2-thienyl; R₁ = Me₂CHO, Pr, MeOCH₂, Me₂CHS, Me₂CHCH₂, PhCH₂, MeOCH₂CH₂, cyclohexyl, cyclohexylmethyl, cyclohexyloxy, Ph; R₂ = H, Me; R₁R₂ = (CH₂)₄] were prepared -(2-Methoxy-5-methylbenzamido)-1,2,3,4-tetrahydronaphthalene-7- sulfonyl chloride was treated with 2-amino-5-isopropoxypyrimidine in absolute pyridine to give I [R = 5,2-Me(MeO)C₆H₃, R₁ = Me₂CHO, R₂ = H]. -Fluorenylacetyl chloride was treated with 2-amino-N-(5-isobutyl-2- pyrimidinyl)-1,2,3,4-tetrahydronaphthalene-7-sulfonamide to give 2-(9-fluorenylacetyl)-N-(5-isobutyl-2-pyrimidinyl)-1,2,3,4- tetrahydronaphthalene-7-sulfonamide. -(5-Chloro-2-methoxybenzamido)-1,2,3,4-tetrahydronaphthalene-7-sulfonamide Na salt and 5-isobutyl-2-trimethylammonio-pyrimidine chloride gave I [R = 5,2-Cl(MeO)C₆H₃, R₁ = Me₂CHCH₂, R₂ = H].

IT 35204-69-4P 35204-70-7P 35204-71-8P
35204-72-9P 35204-73-0P 35204-74-1P
35204-75-2P 35204-76-3P 35204-77-4P
35204-78-5P 35204-79-6P 35265-98-6P
35265-99-7P 35266-01-4P 35266-02-5P
35277-69-1P 35277-70-4P 35293-71-1P
35322-11-3P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)


RN 35204-69-4 HCAPLUS

CN Benzamide, 5-chloro-2-methoxy-N-[1,2,3,4-tetrahydro-7-[[[5-(2-methylpropyl)-2-pyrimidinyl]amino]sulfonyl]-2-naphthalenyl]- (9CI) (CA INDEX NAME)




RN 35204-70-7 HCAPLUS

CN 2-Naphthalenesulfonyl chloride, 7-[(5-chloro-2-methoxybenzoyl)amino]-5,6,7,8-tetrahydro- (9CI) (CA INDEX NAME)




RN 35204-71-8 HCAPLUS

CN Benzamide, 5-chloro-2-methoxy-N-(1,2,3,4-tetrahydro-2-naphthalenyl)- (9CI) (CA INDEX NAME)




RN 35204-72-9 HCAPLUS

CN Benzamide, 5-chloro-2-methoxy-N-[1,2,3,4-tetrahydro-7-[[[5-(phenylmethyl)-2-pyrimidinyl]amino]sulfonyl]-2-naphthalenyl]- (9CI) (CA INDEX NAME)




RN 35204-73-0 HCAPLUS

CN Benzamide, 5-chloro-2-ethoxy-N-[1,2,3,4-tetrahydro-7-[[[5-(2-methoxyethoxy)-2-pyrimidinyl]amino]sulfonyl]-2-naphthalenyl]- (9CI) (CA INDEX NAME)




RN 35204-74-1 HCAPLUS

CN Benzamide, 5-chloro-2-ethoxy-N-(1,2,3,4-tetrahydro-2-naphthalenyl)- (9CI)
(CA INDEX NAME)




RN 35204-75-2 HCAPLUS

CN Benzamide, 5-chloro-2-ethoxy-N-[1,2,3,4-tetrahydro-7-[[(5,6,7,8-tetrahydro-2-quinazolinyl) amino] sulfonyl]-2-naphthalenyl]- (9CI) (CA INDEX NAME)



RN 35204-76-3 HCAPLUS


CN 2-Naphthalenesulfonyl chloride, 7-[(5-fluoro-2-methoxybenzoyl) amino]-5,6,7,8-tetrahydro- (9CI) (CA INDEX NAME)



RN 35204-77-4 HCAPLUS


CN Benzamide, 5-bromo-N-[7-[[[5-(cyclohexylmethyl)-2-pyrimidinyl] amino] sulfonyl]-1,2,3,4-tetrahydro-2-naphthalenyl]-2-methoxy- (9CI) (CA INDEX NAME)

10/653,977




RN 35204-78-5 HCAPLUS

CN 2-Naphthalenesulfonyl chloride, 7-[(5-bromo-2-methoxybenzoyl)amino]-5,6,7,8-tetrahydro- (9CI) (CA INDEX NAME)




RN 35204-79-6 HCAPLUS

CN Benzamide, 5-bromo-2-methoxy-N-(1,2,3,4-tetrahydro-2-naphthalenyl)- (9CI) (CA INDEX NAME)



RN 35265-98-6 HCAPLUS


CN Benzamide, 5-chloro-N-[5-[[[5-(cyclohexyloxy)-2-pyrimidinyl]amino]sulfonyl]-1,2,3,4-tetrahydro-2-naphthalenyl]-2-ethoxy- (9CI) (CA INDEX NAME)



RN 35265-99-7 HCAPLUS


10/653,977

CN Benzamide, N-[7-(aminosulfonyl)-1,2,3,4-tetrahydro-2-naphthalenyl]-5-chloro-2-methoxy- (9CI) (CA INDEX NAME)




RN 35266-01-4 HCAPLUS

CN Benzamide, N-[7-[[[aminoiminomethyl]amino]sulfonyl]-1,2,3,4-tetrahydro-2-naphthalenyl]-5-chloro-2-methoxy- (9CI) (CA INDEX NAME)




RN 35266-02-5 HCAPLUS

CN Benzamide, 5-chloro-2-methoxy-N-[1,2,3,4-tetrahydro-7-[[[5-phenyl-2-pyrimidinyl]amino]sulfonyl]-2-naphthalenyl]- (9CI) (CA INDEX NAME)




RN 35277-69-1 HCAPLUS

CN Benzamide, 5-chloro-N-[7-[[[5-(cyclohexyloxy)-2-pyrimidinyl]amino]sulfonyl]-1,2,3,4-tetrahydro-2-naphthalenyl]-2-ethoxy- (9CI) (CA INDEX NAME)




RN 35277-70-4 HCAPLUS

CN Benzamide, 5-chloro-N-[8-[[[5-(cyclohexyloxy)-2-pyrimidinyl]amino]sulfonyl]-1,2,3,4-tetrahydro-2-naphthalenyl]-2-ethoxy- (9CI) (CA INDEX NAME)




RN 35293-71-1 HCAPLUS

CN Benzamide, 5-fluoro-2-methoxy-N-(1,2,3,4-tetrahydro-2-naphthalenyl)- (9CI)
(CA INDEX NAME)



RN 35322-11-3 HCAPLUS

CN Benzamide, N-[7-[[[(5-cyclohexyl-2-pyrimidinyl)amino]sulfonyl]-1,2,3,4-tetrahydro-2-naphthalenyl]-5-fluoro-2-methoxy- (9CI) (CA INDEX NAME)



L17 ANSWER 44 OF 55 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1970:509969 HCAPLUS Full-text

DOCUMENT NUMBER: 73:109969

TITLE: Metal chelate steroid analog. [7-Amino-3-(1,5-dimethylhexyl)dodecahydro-3a,6-dimethyl-1H-benz[e]indene-6-methylamine]bis(ethylenediamine)cobalt (3 +) trichloride

AUTHOR(S): Donaruma, Lorraine G.; Flath, Patricia U.

CORPORATE SOURCE: Dep. of Chem., Clarkson Coll. of Technol., Potsdam, NY, USA


SOURCE: Journal of Medicinal Chemistry (1970), 13(5), 966-7

CODEN: JMCMAR; ISSN: 0022-2623

DOCUMENT TYPE: Journal

LANGUAGE: English

GI For diagram(s), see printed CA Issue.
 AB The title compound (I) is prepared by the treatment of II with cis-[Co(en)2Cl2]Cl. I has hepatic cholesterogenesis inhibitor activity. III is treated with NaN3 and H2SO4 to give II.
 IT **28936-17-6P**
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 28936-17-6 HCAPLUS
 CN Benzamide, N,N'-1,5-seco-A-trinorcholestan-1,5-ylenebis[4-chloro- (8CI)
 (CA INDEX NAME)



L17 ANSWER 45 OF 55 HCAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 1970:24598 HCAPLUS Full-text
 DOCUMENT NUMBER: 72:24598
 TITLE: Steroid amides tert-amino salts
 PATENT ASSIGNEE(S): Omnium Chimique S. A.
 SOURCE: Fr., 8 pp.
 CODEN: FRXXAK
 DOCUMENT TYPE: Patent
 LANGUAGE: French
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FR 1539352		19680913		
GB 1208301			GB	
PRIORITY APPLN. INFO.:			BE	19660929

GI For diagram(s), see printed CA Issue.
 AB The title compds. (I) are prepared Thus, p-ClC6H4CO2H and 3β-dimethylamino-17β-(p-chlorobenzamido)androst-5-ene give 70% Ia (R = R' = p-ClC6H4), m. 273°. The following I are also prepared (compound, R', R and m.p. given): Ia, p-FC6H4, p-FC6H4, 185°; Ia, p-FC6H4, p-ClC6H4, 275°; Ia, 2,4-Cl2C6H3, 2,4-Cl2C6H3, >300°; Ib, p-FC6H4, p-FC6H4, 192°; Ia, 3-pyridyl, Ph, 165°; Ia, 2-thienyl, 2-thienyl, 212°; Ia, 5-chloro-2-thienyl (A), A, 236°; Ic, Ph, p-ClC6H4, 249-80°. I are antiinflammatory.
 IT **26194-40-1P 26194-41-2P 26195-04-0P 26250-42-0P**
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 26194-40-1 HCAPLUS
 CN Benzoic acid, p-fluoro-, compd. with p-chloro-N-[3β-

10/653,977


(dimethylamino)androst-5-en-17 β -yl]benzamide (1:1) (8CI) (CA INDEX NAME)

CM 1

CRN 47698-74-8

CMF C28 H39 Cl N2 O


Absolute stereochemistry.



CM 2

CRN 456-22-4

CMF C7 H5 F O2



RN 26194-41-2 HCAPLUS


CN Benzoic acid, 2,4-dichloro-, compd. with 2,4-dichloro-N-[3 β -(dimethylamino)androst-5-en-17 β -yl]benzamide (1:1) (8CI) (CA INDEX NAME)

CM 1

CRN 47723-53-5

CMF C28 H38 Cl2 N2 O


Absolute stereochemistry.



CM 2

CRN 50-84-0

CMF C7 H4 Cl2 O2



RN 26195-04-0 HCAPLUS


CN Benzoic acid, p-fluoro-, compd. with N-[3β-(dimethylamino)androst-5-en-17β-yl]-p-fluorobenzamide (1:1) (8CI) (CA INDEX NAME)

CM 1

CRN 47698-77-1

CMF C28 H39 F N2 O


Absolute stereochemistry.



CM 2

CRN 456-22-4

CMF C7 H5 F O2




RN 26250-42-0 HCAPLUS

CN Benzoic acid, p-chloro-, compd. with p-chloro-N-[3β-(dimethylamino)androst-5-en-17β-yl]benzamide (1:1) (8CI) (CA INDEX NAME)

CM 1


CRN 47698-74-8
CMF C28 H39 Cl N2 O

Absolute stereochemistry.



CM 2

CRN 74-11-3
CMF C7 H5 Cl O2



L17 ANSWER 46 OF 55 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1970:12763 HCAPLUS Full-text
DOCUMENT NUMBER: 72:12763
TITLE: Anti-diabetically effective 2-substituted-N-(5-substituted-2-pyrimidinyl)hydrindene-5-sulfonamides
INVENTOR(S): Heerdt, Ruth; Huebner, Manfred; Schmidt, Felix Helmut; Stach, Kurt; Muth, Karl
PATENT ASSIGNEE(S): Boehringer Mannheim G.m.b.H.
SOURCE: S. African, 26 pp.
CODEN: SFXXAB
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
ZA 6806875		19690326		<--
CA 950913			CA	
DE 1670282			DE	
FR 1592146			FR	
FR 8133			FR	
GB 1171070			GB	
US 3565897		19710000	US	<--
PRIORITY APPLN. INFO.:			DE	19671024
GI	For diagram(s), see printed CA Issue.			
AB	The title compds. (I, R = Et, Pr, PrO, iso-Pr, MeOCH2, EtOCH2, PhCH2, PrS, EtO, cyclohexylmethyl, cyclohexyl, cyclohexyloxy, or 5,6,7,8-			


tetrahydroquinazolinyll; R1 = H or Me; R2 = 2,5-(MeO)ClC6H3, 2,5-(MeO)BrC6H3, cyclohexyl, m-MeC6H4, m-ClC6H4, PhSCH2, 3-methoxy-2-thienyl, 2-furyl, PhOCH2, Me(o-MeC6H4)N, o-MeOC6H4, 3-chloro-2-thienyl, PhCH2CH2, m-F3CC6H4, m-FC6H4, 2,5-(MeO)ClC6H3CH2CH2, or PhCH2O) are prepared by reacting II (X = COR2, Y = Cl; X = H, Y = 2-pyrimidinylamino; X = R2CO, Y = H2N) with the appropriate 2-aminopyrimidine, R2COCl, and 2-chloropyrimidine, resp. For example, sulfochlorination of 2-(5-chloro-2-methoxybenzamido)hydrindene gave II (X = 2,5-(MeO)ClC6H3CO, Y = Cl) (III), m. 133°. III (3.2 g) was added to 1.23 g 2-amino-5-propoxypyrimidine in 5 ml anhydrous pyridine, and the mixture kept overnight and heated 2 hr on a steam bath to give 75% I (R = PrO, R1 = H, R2 = 5,2-(MeO)C6H3), m. 122-4°. Alkaline hydrolysis of I (R = iso-Bu, R1 = H, R2 = OEt) gave 5-(5-isobutyl-2-pyrimidinylaminosulfonyl)-2-aminohydrindene (IV), 235-40°. A solution of 2 g IV in 3.4 ml 2N NaOH and 5 ml water was treated with 1.2 g 1-indolinecarbonyl chloride in 10 ml CH2Cl2 to give 59.8% I (R = iso-Bu, R1 = H, R3 = 1-indolinyll), m. 247-9°. A mixture of 2.3 g II (X = PhCH2CH2CO, Y = NH2), 1.15 g 2-chloro-5-isobutylpyrimidine and 0.9 g K2CO3 was heated to 190° to give I (R = iso-Bu, R1 = H, R2 = PhCH2CH2), m. 202-4°.

IT 24445-39-4P 24445-40-7P 24445-41-8P
 24445-49-6P 24445-61-2P 24445-65-6P
 24445-66-7P 24445-67-8P 24445-68-9P
 24445-69-0P 24445-70-3P 24446-19-3P
 24446-20-6P 24446-21-7P 24446-22-8P
 24446-23-9P 24446-24-0P 24446-29-5P
 24446-30-8P 24446-31-9P 24446-32-0P
 24506-08-9P 24506-09-0P

RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)


RN 24445-39-4 HCAPLUS

CN 5-Indansulfonyl chloride, 2-(5-bromo-o-anisamido)- (8CI) (CA INDEX NAME)




RN 24445-40-7 HCAPLUS

CN o-Anisamide, 5-bromo-N-2-indanyl- (8CI) (CA INDEX NAME)




RN 24445-41-8 HCAPLUS

CN o-Anisamide, 5-bromo-N-[5-[[5-(propylthio)-2-pyrimidinyl]sulfamoyl]-2-indanyl]- (8CI) (CA INDEX NAME)




RN 24445-49-6 HCAPLUS

CN Benzamide, m-chloro-N-[5-[(5-isobutyl-2-pyrimidinyl)sulfamoyl]-2-indanyl]- (8CI) (CA INDEX NAME)




RN 24445-61-2 HCAPLUS

CN Benzamide, m-fluoro-N-[5-[(5-isobutyl-2-pyrimidinyl)sulfamoyl]-2-indanyl]- (8CI) (CA INDEX NAME)




RN 24445-65-6 HCAPLUS

CN o-Anisamide, 5-chloro-N-[5-[[5-(cyclohexyloxy)-2-pyrimidinyl]sulfamoyl]-2-indanyl]- (8CI) (CA INDEX NAME)




RN 24445-66-7 HCAPLUS

CN Benzamide, 5-chloro-N-[2,3-dihydro-5-[[[5-(methoxymethyl)-2-pyrimidinyl]amino]sulfonyl]-1H-inden-2-yl]-2-methoxy- (9CI) (CA INDEX NAME)




RN 24445-67-8 HCAPLUS

CN Benzamide, 5-chloro-N-[5-[[5-(ethoxymethyl)-2-pyrimidinyl]amino]sulfonyl]-2,3-dihydro-1H-inden-2-yl]-2-methoxy- (9CI) (CA INDEX NAME)




RN 24445-68-9 HCAPLUS

CN o-Anisamide, N-[5-[(5-benzyl-2-pyrimidinyl)sulfamoyl]-2-indanyl]-5-chloro- (8CI) (CA INDEX NAME)




RN 24445-69-0 HCAPLUS

CN Benzamide, 5-chloro-N-[5-[[5-(cyclohexyl)-2-pyrimidinyl]amino]sulfonyl]-2,3-dihydro-1H-inden-2-yl]-2-methoxy- (9CI) (CA INDEX NAME)




RN 24445-70-3 HCAPLUS

CN o-Anisamide, 5-chloro-N-[5-[[5-(ethylthio)-4-methyl-2-pyrimidinyl]sulfamoyl]-2-indanyl]- (8CI) (CA INDEX NAME)




RN 24446-19-3 HCAPLUS

CN 1H-Indene-5-sulfonyl chloride, 2-[(5-chloro-2-methoxybenzoyl)amino]-2,3-dihydro- (9CI) (CA INDEX NAME)




RN 24446-20-6 HCAPLUS

CN o-Anisamide, 5-chloro-N-2-indanyl- (8CI) (CA INDEX NAME)




RN 24446-21-7 HCAPLUS

CN o-Anisamide, 5-chloro-N-[5-[(5-propyl-2-pyrimidinyl)sulfamoyl]-2-indanyl]- (8CI) (CA INDEX NAME)



RN 24446-22-8 HCAPLUS


CN o-Anisamide, 5-chloro-N-[5-[[5-(cyclohexylmethyl)-2-pyrimidinyl]sulfamoyl]-2-indanyl]- (8CI) (CA INDEX NAME)



RN 24446-23-9 HCAPLUS


CN o-Anisamide, 5-chloro-N-[5-[(5,6,7,8-tetrahydro-2-quinazolinyl)sulfamoyl]-2-indanyl]- (8CI) (CA INDEX NAME)

10/653,977




RN 24446-24-0 HCAPLUS

CN o-Anisamide, 5-chloro-N-[5-[[5-(2-methoxyethoxy)-2-pyrimidinyl]sulfamoyl]-2-indanyl]- (8CI) (CA INDEX NAME)




RN 24446-29-5 HCAPLUS

CN Benzamide, 5-chloro-2-ethoxy-N-[5-[(5-isobutyl-4-methyl-2-pyrimidinyl)sulfamoyl]-2-indanyl]- (8CI) (CA INDEX NAME)




RN 24446-30-8 HCAPLUS

CN 5-Indansulfonyl chloride, 2-(5-chloro-2-ethoxybenzamido)- (8CI) (CA INDEX NAME)




RN 24446-31-9 HCAPLUS

CN Benzamide, 5-chloro-2-ethoxy-N-2-indanyl- (8CI) (CA INDEX NAME)




RN 24446-32-0 HCAPLUS

CN o-Anisamide, 5-bromo-N-[5-[(5-propoxy-2-pyrimidinyl)sulfamoyl]-2-indanyl]-
(8CI) (CA INDEX NAME)




RN 24506-08-9 HCAPLUS

CN o-Anisamide, 5-chloro-N-[5-[(5-propoxy-2-pyrimidinyl)sulfamoyl]-2-indanyl]-
(8CI) (CA INDEX NAME)



RN 24506-09-0 HCAPLUS

CN o-Anisamide, 5-chloro-N-[5-[(5-isobutyl-2-pyrimidinyl)sulfamoyl]-2-indanyl]-
(8CI) (CA INDEX NAME)



L17 ANSWER 47 OF 55 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1969:470352 HCAPLUS Full-text

DOCUMENT NUMBER: 71:70352

TITLE: Experimental study and prospects of using phenanthrene
in organic synthesis

AUTHOR(S): Novikov, A. N.

CORPORATE SOURCE: Tomsk. Politekh. Inst. im. Kirova, Tomsk, USSR

SOURCE: Itogi Issled. Khim. 50 let, 1917-1967, Tr. Mezhvuz.

Nauch. Konf. (1968), Meeting Date 1967,

54-67. Editor(s): Serebrennikov, V. V. Izd. Tomsk.

Univ.: Tomsk, USSR.

CODEN: 21DQAY

DOCUMENT TYPE: Conference; General Review

LANGUAGE: Russian


AB The ozonolysis and methanolysis of tech. grade phenanthrene to 5,8-dihydro-5,8-dimethoxydibenzo[d,f][1,2]dioxocin, its conversion to diphenic anhydride and diphenic acid (I), and the preparation of various monoesters, diesters, amido esters, monoamides, diamides, imides of I, and amides of nitrodiphenic acid, Schiff bases of the diphenic aldehyde acid suitable for use as plasticizers, pesticides, herbicides, insecticides and new monomers for preparation of polyamide and polyester resins and other high-mol.-weight compds. are reviewed. Starting from the resp. derivs. of I, various derivs. of fluorene-4-carboxylic acid (II) and of fluorene-9-one-4-carboxylic acid (III) were prepared and their insecticidal activity was tested. The phys. consts. of over 150 derivs. of I-III are tabulated. 51 references.

IT 2841-48-7 2841-49-8 2841-50-1
2841-51-2 2841-52-3 2841-53-4
2841-54-5 2841-55-6 24025-70-5

RL: RCT (Reactant); RACT (Reactant or reagent))


RN 2841-48-7 HCAPLUS

CN Fluorene-4-carboxylic acid, 9-(p-chlorobenzamido)- (7CI, 8CI) (CA INDEX NAME)




RN 2841-49-8 HCAPLUS

CN Fluorene-4-carboxylic acid, 9-(o-chlorobenzamido)- (7CI, 8CI) (CA INDEX NAME)




RN 2841-50-1 HCAPLUS

CN Fluorene-4-carboxylic acid, 9-(2,4-dichlorobenzamido)- (7CI, 8CI) (CA INDEX NAME)




RN 2841-51-2 HCAPLUS

CN Fluorene-4-carboxylic acid, 9-(p-bromobenzamido)- (7CI, 8CI) (CA INDEX NAME)




RN 2841-52-3 HCAPLUS

CN Fluorene-4-carboxylic acid, 9-(o-bromobenzamido)- (7CI, 8CI) (CA INDEX NAME)




RN 2841-53-4 HCAPLUS

CN Fluorene-4-carboxylic acid, 9-(o-iodobenzamido)- (7CI, 8CI) (CA INDEX NAME)




RN 2841-54-5 HCAPLUS

CN Fluorene-4-carboxylic acid, 9-(p-iodobenzamido)- (7CI, 8CI) (CA INDEX NAME)




RN 2841-55-6 HCAPLUS

CN Fluorene-4-carboxylic acid, 9-(m-iodobenzamido)- (7CI, 8CI) (CA INDEX NAME)



RN 24025-70-5 HCAPLUS

CN Fluorene-4-carboxylic acid, 9-(p-bromobenzamido)-, ethyl ester (7CI, 8CI) (CA INDEX NAME)



L17 ANSWER 48 OF 55 HCAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 1968:506324 HCAPLUS Full-text
 DOCUMENT NUMBER: 69:106324
 TITLE: N-(Hydrindene-5-sulfonyl)-N-substituted-ureas
 PATENT ASSIGNEE(S): Boehringer, C. F., und Soehne G.m.b.H.
 SOURCE: Brit., 7 pp.
 CODEN: BRXXAA
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
GB 1123036		19680807		<--
DE 1294957			DE	
FR 1530037			FR	
US 3549645		19700000	US	<--
PRIORITY APPLN. INFO.:			DE	19660702

GI For diagram(s), see printed CA Issue.

AB I and II, where R₁ is an acyl, thioacyl, or carbamoyl group, are prepared A mixture of 3.6 g. 2-(m-chlorobenzamido)hydrindene-5-sulfonamide, 4.4 g. K₂CO₃, and 40 ml. Me₂CO is boiled 0.5 hr., 1.4 g. cyclohexyl isocyanate is added, and the mixture is refluxed 8 hrs. to give 73% N-[2-(m-chlorobenzamido)hydrindene-5-sulfonyl]-N'-cyclohexylurea, m. 195-6°. Similarly prepared are the following I (R, R₁, R₂, m.p., and % yield given): cyclohexyl (A), MeO, MeO, 118-20°, 80; Bu, MeO, Br, 97° (decomposition), 65; 4-methylcyclohexyl (B), MeO, Me, 126-8°, -; cyclohex-3-enyl, MeO, Br, 191-2°, 53. II prepared are (R, R₁, m.p., and % yield given): B, MePhNCO, 110° (decomposition), 60; A, PhCH₂CS, 144-6°, 70; B, PhCH₂CH₂CO, 128-30° (decomposition), 65; B, cyclohexylcarbonyl, 193-5°, 80. II (R = A, R₁ = H) is treated with 5,2-Cl(MeO)C₆H₃COCl to give 53% I (R = A, R₁ = MeO, R₂ = Cl), m. 124-6°. N-[2-(2-methoxy-5-chlorobenzamido)hydrindene-5-sulfonyl]carbamate is treated with N-amino-4,4-dimethylpiperidine (III) to give I [R = 4,4-dimethylpiperidino (C), R₁ = MeO, R₂ = Cl] (IV), m. 195-7°. Similarly prepared are the following I (R = Me) (R, R₂, m.p., and % yield given): B, Me, 120° (decomposition), 50; C, Me, 130° (decomposition), 53; B, Cl, 187-8°, 58; 4,4-dimethylcyclohexyl, Cl, 130-2° (decomposition), 60. IV (m. 195-7°) is also prepared from the sulfonamide and III in the presence of NaH and EtO₂COCO₂Ph. Similarly prepared is I (R = 4-methylpiperidino, R₁ = MeO, R₂ = Br), m. 180-3°.

IT 20338-67-4P 20338-68-5P 20338-69-6P

10/653,977


20343-34-4P 20343-36-6P 20343-41-3P

20343-42-4P 20343-43-5P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)


RN 20338-67-4 HCAPLUS

CN Urea, 1-[[2-(5-chloro-o-anisamido)-5-indanyl]sulfonyl]-3-(4-methylcyclohexyl)- (8CI) (CA INDEX NAME)




RN 20338-68-5 HCAPLUS

CN Urea, 1-[[2-(5-chloro-o-anisamido)-5-indanyl]sulfonyl]-3-(4,4-dimethylcyclohexyl)- (8CI) (CA INDEX NAME)




RN 20338-69-6 HCAPLUS

CN Urea, 1-[[2-(5-bromo-o-anisamido)-5-indanyl]sulfonyl]-3-(4-methylpiperidino)- (8CI) (CA INDEX NAME)




RN 20343-34-4 HCAPLUS

CN Urea, 1-[[2-(m-chlorobenzamido)-5-indanyl]sulfonyl]-3-cyclohexyl- (8CI)
(CA INDEX NAME)




RN 20343-36-6 HCAPLUS

CN Urea, 1-[[2-(5-bromo-o-anisamido)-5-indanyl]sulfonyl]-3-butyl- (8CI) (CA INDEX NAME)




RN 20343-41-3 HCAPLUS

CN Urea, 1-[[2-(5-bromo-o-anisamido)-5-indanyl]sulfonyl]-3-(3-cyclohexen-1-yl)- (8CI) (CA INDEX NAME)




RN 20343-42-4 HCAPLUS

CN Urea, 1-[[2-(5-chloro-o-anisamido)-5-indanyl]sulfonyl]-3-cyclohexyl- (8CI) (CA INDEX NAME)



RN 20343-43-5 HCAPLUS

CN Urea, 1-[[2-(5-chloro-o-anisamido)-5-indanyl]sulfonyl]-3-(4,4-dimethylpiperidino)- (8CI) (CA INDEX NAME)



L17 ANSWER 49 OF 55 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1966:499589 HCAPLUS Full-text

DOCUMENT NUMBER: 65:99589

ORIGINAL REFERENCE NO.: 65:18663f-h,18664a

TITLE: Steroidal amides

INVENTOR(S): Anon.

PATENT ASSIGNEE(S): Omnium Chimique, Societe

SOURCE: 26 pp.

DOCUMENT TYPE: Patent
 LANGUAGE: Unavailable
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	BE 672238		19660301	BE	19651112 <--
AB	<p>3α-Amino-5α-pregnan-20-one (3.28 g.) in 100 ml. 15% KOH treated 2 hrs. with cooling with 3.0 g. 4-ClC₆H₄COCl (I), the mixture filtered, the precipitate suspended 15 min. in 60 ml. H₂O and crystallized from MeOH yielded 2.46 g. 3α-(4-chlorobenzamido)-5α-pregnan-20-one, m. 206-7°. 3α,17β-Diamino-5α-androstane (3.46 g.) in 150 ml. C₆H₆ and 15 ml. C₅H₅N treated dropwise with 6.1 g. I in 50 ml. C₆H₆ in 30 min., the mixture filtered after 1 hr., and the filtrate concentrated yielded 5.4 g. 3α,17β-bis(4-chlorobenzamido)-5α- androstane, m. 170° and 244°. Similarly prepared were: 3α-(4-chlorobenzamido)-17β-hydroxyandrostane, m. 236°; 3α-(4-chlorobenzamido)-17β-(4-chlorobenzoyloxy)androstane, m. 201°; 3α-(4-chlorobenzamido)-α-pregnan-20α-ol, m. 233°; 3α-isonicotinamido-5α-pregnan-20α-ol, m. 192°; 3α-(2-chlorobenzamido)-5α-pregnan-20-one, m. 199-200°; 3α-(2,4-dichlorobenzamido)-5α-pregnan-20-one, m. 197-9°; 3α-(pyridine-4-carboxamido)-5α-pregnan-20-one, m. 184-6°; 3α-(4-chlorobenzamido)pregn-5-en-20-one, m. 186-9°; 3β-(4-chlorobenzamido)pregn-5-en-20-one, m. 178-9°; 3β-(4-chloro-N-methylbenzamido)pregn-5-en-20-one, m. 205-7°; 3β-(4-chloro-N-methylbenzamido)18,20-imino pregn-5-ene, m. 196-8°; 3α-(4-chlorobenzamido)-5α-pregnane-(20α-hydroxy-18-carboxylic acid lactone), m. 247-8°; 3α-(4-chlorobenzamido)-5α-pregnane 18,20-epoxide, m. 237°; 3β-dimethylamino-17β-(4-chlorobenzamido) androst-5-ene-HCl, m. >300°; 3β-dimethylamino-17β-isonicotinamidandrost-5-ene, m. 217-19°; 3β-dimethylamino-20β-(4-chlorobenzamido)pregn-5-ene, m. 250-1°; 3β-dimethylamino-20β-isonicotinamidopregn-5-ene, m. 227°; 3α,17α-bis(4-chlorobenzamido)androst-5-ene, m. 197-8°; 3β,17β-bis(4-chlorobenzamido)androst-5-ene, m. 194-5°; 3α,20α-bis(4-chlorobenzamido)-5α-pregnene, m. 230-1°; 3α,20α-bis(isonicotinamido)-5α-pregnane, m. 204-6°; bis(4-chlorobenzamido)hydroconimine, m. 226°; 3β,20β-bis(4-chlorobenzamido)pregn-5-ene, m. 248-50°; 3β-(4-chloro-N-methylbenzamido)-20α-(4-chlorobenzamido)pregn-5-ene, m. 276-8°, and bis(4-chlorobenzamido)conimine, m. 217-20°.</p>				
IT	<p>10393-68-7, 5α-Androstan-17β-ol, 3α-(p-chlorobenzamido)-, p-chlorobenzoate 10393-69-8, 5α-Pregnan-20α-ol, 3α-(p-chlorobenzamido)- 10393-71-2, 5α-Pregnan-20-one, 3α-(o-chlorobenzamido)- 10393-72-3, 5α-Pregnan-20-one, 3α-(2,4-dichlorobenzamido)- 10393-73-4, Pregn-5-en-20-one, 3α-(p-chlorobenzamido)- 10393-74-5, Pregn-5-en-20-one, 3β-(p-chlorobenzamido)- 10393-78-9, Androst-5-en-3β-amine, 17β-(p-chlorobenzamido)-N,N-dimethyl-, hydrochloride 10401-39-5, 5α-Pregnan-20-one, 3α-(p-chlorobenzamido)- 10401-40-8, 5α-Androstane, 3α,17β-bis(p-chlorobenzamido)- 10401-41-9, 5α-Androstan-17β-ol, 3α-(p-chlorobenzamido)- 10529-60-9, Androst-5-ene, 3β,17β-bis(p-chlorobenzamido)- 10529-61-0, 5α-Pregnane, 3α,20α-bis(p-chlorobenzamido)- 10529-64-3, Pregn-5-ene, 3β,20β-bis(p-chlorobenzamido)- (preparation of)</p>				

10/653,977

RN 10393-68-7 HCAPLUS

CN 5 α -Androstan-17 β -ol, 3 α -(p-chlorobenzamido)-,
p-chlorobenzoate (7CI, 8CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 10393-69-8 HCAPLUS

CN 5 α -Pregnan-20 α -ol, 3 α -(p-chlorobenzamido)- (7CI, 8CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 10393-71-2 HCAPLUS

CN 5 α -Pregnan-20-one, 3 α -(o-chlorobenzamido)- (7CI, 8CI) (CA
INDEX NAME)

Absolute stereochemistry.




10/653,977

RN 10393-72-3 HCAPLUS

CN 5 α -Pregnan-20-one, 3 α -(2,4-dichlorobenzamido)- (7CI, 8CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 10393-73-4 HCAPLUS

CN Pregn-5-en-20-one, 3 α -(p-chlorobenzamido)- (7CI, 8CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 10393-74-5 HCAPLUS

CN Pregn-5-en-20-one, 3 β -(p-chlorobenzamido)- (7CI, 8CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 10393-78-9 HCAPLUS

CN Benzamide, 4-chloro-N-[(3 β ,17 β)-3-(dimethylamino)androst-5-en-17-yl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 10401-39-5 HCAPLUS

CN 5α-Pregnan-20-one, 3α-(p-chlorobenzamido)- (7CI, 8CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 10401-40-8 HCAPLUS

CN 5α-Androstane, 3α,17β-bis(p-chlorobenzamido)- (7CI, 8CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 10401-41-9 HCAPLUS

10/653,977

CN 5 α -Androstan-17 β -ol, 3 α -(p-chlorobenzamido)- (7CI, 8CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 10529-60-9 HCAPLUS

CN Benzamide, N,N'-[(3 β ,17 β)-androst-5-ene-3,17-diyl]bis[4-chloro-
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 10529-61-0 HCAPLUS

CN Benzamide, N,N'-[(3 α ,5 α ,20S)-pregnane-3,20-diyl]bis[4-chloro-
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 10529-64-3 HCAPLUS

CN Benzamide, N,N'-[(3 β ,20R)-pregn-5-ene-3,20-diyl]bis[4-chloro- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.



L17 ANSWER 50 OF 55 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1966:3956 HCAPLUS Full-text

DOCUMENT NUMBER: 64:3956

ORIGINAL REFERENCE NO.: 64:666g-h,667a-b

TITLE: Esters and ester amides of 9-aminofluorene-4-carboxylic acid

AUTHOR(S): Stepnova, G. M.; Kovalenok, A. V.; Belyaeva, A. P.

SOURCE: Zhurnal Obshchei Khimii (1965), 1(8), 1425-6

CODEN: ZOKHA4; ISSN: 0044-460X

DOCUMENT TYPE: Journal

LANGUAGE: Russian


GI For diagram(s), see printed CA Issue.

AB The title acid or its appropriate amide heated with ROH in xylene in the presence of H₂SO₄ 4 hrs. gave the following I (R and R' shown resp.): H, Et (HCl salt) m. 190°; H, Me (HCl salt), m. 185°; H, Bu (HCl salt, m. 140°; H, Am (HCl salt) m. 140°; Ac, Et m. 186°; Bz, Et m. 202°; p-O₂NC₆H₄CO, Et m. 271°; m-O₂NC₆H₄CO, Et m. 216°; o-O₂NC₆H₄CO, Et m. 258°; 2,6-(O₂N)₂C₆H₃CO, Et m. 260°; p-BrC₆H₄CO, Et m. 261°; ClCH₂CO, Et m. 206°; p-O₂NC₆H₄CO, Et, m. 290° (this appears to be a misprint in original; GMK); treatment of appropriate amide of title acid with SOCl₂, followed by a phenol 4 hrs. at 150° gave the following I: p-O₂NC₆H₄CO, p-O₂NC₆H₄ m. 250°; p-O₂NC₆H₄CO, o-O₂NC₆H₄ (II) m. 251°; p-O₂NC₆H₄CO, p-ClC₆H₄ m. 233°; p-O₂NC₆H₄CO, o-ClC₆H₄ m. 191°; p-O₂NC₆H₄CO, 2,4-Cl₂C₆H₃ m. 210°; p-O₂NC₆H₄CO, 3,4,5-Cl₃C₆H₂ m. 259°. II had some insecticidal activity.

IT **24025-70-5**, Fluorene-4-carboxylic acid, 9-(p-bromobenzamido)-, ethyl ester **95812-86-5**, Fluorene-4-carboxylic acid, 9-(p-chlorobenzamido)-, ethyl ester (preparation of)


RN 24025-70-5 HCAPLUS

CN Fluorene-4-carboxylic acid, 9-(p-bromobenzamido)-, ethyl ester (7CI, 8CI)
(CA INDEX NAME)



RN 95812-86-5 HCAPLUS

CN Fluorene-4-carboxylic acid, 9-(p-chlorobenzamido)-, ethyl ester (7CI) (CA INDEX NAME)



L17 ANSWER 51 OF 55 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1965:497409 HCAPLUS Full-text

DOCUMENT NUMBER: 63:97409

ORIGINAL REFERENCE NO.: 63:17823b-c

TITLE: Kinetic studies of the fluorene series. IV.
Acid-catalyzed solvolysis of 4-substituted
9-diazofluorenes

AUTHOR(S): Warren, Keith D.; Yandle, J. R.

CORPORATE SOURCE: Univ. Coll. South Wales, Cardiff

SOURCE: Journal of the Chemical Society, Abstracts (1965), (Aug), 4221-5

CODEN: JCSAAZ; ISSN: 0590-9791


DOCUMENT TYPE: Journal

LANGUAGE: English

AB cf. CA 63, 6810a. The rates of perchloric acid-catalyzed solvolysis of some 4-substituted 9-diazofluorenes in 93.8% ethanol are determined. Solvolysis is hindered by electron-withdrawing groups, and the energies and entropies of activation are linearly related. Treatment of the data by Hammett-type equations shows that transmission of T effects to the 9-position is much less effective than for 2-substituents. This could be due to the displacement of

substituents from the plane of the aromatic ring, by interaction with the 5-hydrogen atom, but is also consistent with the results of simple mol. orbital calcsns.

IT 2841-50-1, Fluorene-4-carboxylic acid, 9-(2,4-dichlorobenzamido)-
(preparation of)
RN 2841-50-1 HCAPLUS
CN Fluorene-4-carboxylic acid, 9-(2,4-dichlorobenzamido)- (7CI, 8CI) (CA
INDEX NAME)



L17 ANSWER 52 OF 55 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1965:497408 HCAPLUS Full-text

DOCUMENT NUMBER: 63:97408

ORIGINAL REFERENCE NO.: 63:17822g-h, 17823a-b

TITLE: Carbonyl derivatives of heterocyclic compounds. II.

Carboxyl derivatives of pyrrole

AUTHOR(S): Khan, M. K. A.; Morgan, K. J.

CORPORATE SOURCE: Univ. Birmingham, UK

SOURCE: Tetrahedron (1965), 21(9), 2197-204

CODEN: TETRAB; ISSN: 0040-4020


DOCUMENT TYPE: Journal

LANGUAGE: English

AB cf. CA 61, 10644g. The dissociation consts. of pyrrole-2-carboxylic acid (I), pyrrole-3-carboxylic acid (II), and the ir spectra and rates of alkaline hydrolysis of I Me ester (III), II Me ester (IV), and the Me and Et esters (V, VI) of pyrrole-1-carboxylic acid were determined. C₄H₄NMgI (from 20 g. pyrrole, 8 g. Mg, and 47 g. MeI) treated with 7.5 g. ClCO₂Et and the product refluxed 3 hrs. in 80 ml. EtOH with 21 g. KOH yielded 23% I, m. 208°; III m. 73-4°. Preparation from 1,3-dicarbethoxypyrrolid-4- one and extraction with Et₂O yielded 60% II, m. 150-50.5°; IV m. 87-8°. C₄H₄NK (from 20 g. pyrrole and 11 g. K) in dry Et₂O treated with 21 g. ClCO₂Et gave 7.4 g. VI, b₁₃ 75°. H₂O (400 ml.) made up to 1 l. with dried (K₂CO₃), distilled Me₂CO and 0.1N solns. of ester and NaOH in aqueous Me₂CO equilibrated sep. at the reaction temperature were mixed in aqueous vols. (50 ml.) at the start of the alkaline hydrolysis reactions. Aliquots (10 ml.) were periodically withdrawn, added to excess of standard HCl, and back-titrated in the presence of cresol red. Rate consts. were calculated from the expression $k = 1/t[x/a(a - x)]$. The acids (0.01M in CO₂ free H₂O) equilibrated at 20° were treated with 0.1N KOH added in 10 equal portions (O-free N atmospheric) and the pH read potentiometrically after each addition using a combined electrode and pH meter. The ionization consts. for I and II were pK_a 4.39 ± 0.01, and 5.00 ± 0.01 at 20°, resp. Rate constant for the alkaline hydrolysis of the pyrrole esters in NaOH in aqueous Me₂CO gave excellent 2nd-order plots [ester, k₂ (l. mole⁻¹ sec.⁻¹) + 103 at 25.3, 35.5, 49.7° given]: III, 0.41, 0.995, 3.39; IV, 0.059, 0.157, 0.56; VI

23.10,-,-. V had an estimated $k = 68.3 + 10^{-3} \text{ l. mole}^{-1} \text{ sec.}^{-1}$ at 25° . The ir spectra of III, IV, and V were measured in a wide variety of solvents (C_6H_{14} , CCl_4 , MeCN , dioxane, MeNO_2 , CH_2Cl_2 , CHCl_3 , Me_2SO , CHBr_3). The C:O-stretching frequencies showed that considerable mesomeric interaction occurs between the CO_2H group and the ring. The anomalously high ionization constant of I and the high rate of hydrolysis of III were ascribed to intramol. H-bonding in the anion and intermediate anion, resp.

IT **2841-50-1**, Fluorene-4-carboxylic acid, 9-(2,4-dichlorobenzamido)-
(preparation of)
RN 2841-50-1 HCAPLUS
CN Fluorene-4-carboxylic acid, 9-(2,4-dichlorobenzamido)- (7CI, 8CI) (CA INDEX NAME)



L17 ANSWER 53 OF 55 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1965:488503 HCAPLUS Full-text

DOCUMENT NUMBER: 63:88503

ORIGINAL REFERENCE NO.: 63:16227e-f

TITLE: Spirans. X. Aminospirans

AUTHOR(S): Rice, Leonard M.; Dobbs, Edward C.; Grogan, Charles H.

CORPORATE SOURCE: Howard Univ., Washington, DC

SOURCE: Journal of Medicinal Chemistry (1965), 8(6), 825-9

CODEN: JMCMAR; ISSN: 0022-2623

DOCUMENT TYPE: Journal


LANGUAGE: English

AB cf. CA 63, 13244b. Aminospirans (I) were prepared and examined for pharmacological activity. Those aminospirans in which the exonitrogen atom was substituted β or γ to the spiro carbon atom displayed potent analgesic, analeptic, and local anesthetic activity. These activities were either absent or greatly reduced when the exo-amino substituent was α to the spiro atom. The aminospirans were obtained by reduction of the oximes of spiro ketones.

IT **3896-80-8**, Benzamide, m-chloro-N-spiro[5.5]undec-3-yl-
(preparation of)

RN 3896-80-8 HCAPLUS

CN Benzamide, m-chloro-N-spiro[5.5]undec-3-yl- (7CI, 8CI) (CA INDEX NAME)



L17 ANSWER 54 OF 55 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1965:462796 HCAPLUS Full-text

DOCUMENT NUMBER: 63:62796

ORIGINAL REFERENCE NO.: 63:11452g-h

TITLE: Acyl derivatives of 9-aminofluorene-4-carboxylic acid

AUTHOR(S): Stepnova, G. M.; Tabinskaya, P. F.; Kovalenok, A. V.

CORPORATE SOURCE: S. M. Kirov Polytech. Inst., Tomsk

SOURCE: Zhurnal Obshchei Khimii (1965), 1(6), 1087-9

CODEN: ZOKHA4; ISSN: 0044-460X

DOCUMENT TYPE: Journal


LANGUAGE: Russian

AB 9-Fluorenone-4-carboxylic acid oxime reduced with Zn dust in aqueous AcOH at 100° 30-40 min. to 9-aminofluorene-4-carboxylic acid, decomposed at 214° (HCl salt decomposed at 215). This heated with acyl chlorides in xylene gave the following N-acyl derivs.: benzoyl, m. 279°; p-nitrobenzoyl, m. 269°; m-isomer, m. 262°; o-isomer, m. 274°; 3,5-dinitrobenzoyl, m. 269°; p-chlorobenzoyl, m. 274°; o-isomer, m. 281°; 2,4-dichlorobenzoyl, m. 276°; p-bromobenzoyl, m. 277°; o-isomer, m. 275°; o-iodobenzoyl, m. 274°; p-isomer, m. 271°; m-fluorobenzoyl, m. 275°; chloroacetyl, m. 275°; trichloroacetyl, m. 242°; phenylacetyl, m. 279°; diphenylacetyl, m. 264°.

IT 2841-48-7, Fluorene-4-carboxylic acid, 9-(p-chlorobenzamido)-
 2841-49-8, Fluorene-4-carboxylic acid, 9-(o-chlorobenzamido)-
 2841-50-1, Fluorene-4-carboxylic acid, 9-(2,4-dichlorobenzamido)-
 2841-51-2, Fluorene-4-carboxylic acid, 9-(p-bromobenzamido)-
 2841-52-3, Fluorene-4-carboxylic acid, 9-(o-bromobenzamido)-
 2841-53-4, Fluorene-4-carboxylic acid, 9-(o-iodobenzamido)-
 2841-54-5, Fluorene-4-carboxylic acid, 9-(p-iodobenzamido)-
 2841-55-6, Fluorene-4-carboxylic acid, 9-(m-fluorobenzamido)-
 (preparation of)


RN 2841-48-7 HCAPLUS

CN Fluorene-4-carboxylic acid, 9-(p-chlorobenzamido)- (7CI, 8CI) (CA INDEX NAME)




RN 2841-49-8 HCAPLUS

CN Fluorene-4-carboxylic acid, 9-(o-chlorobenzamido)- (7CI, 8CI) (CA INDEX NAME)




RN 2841-50-1 HCAPLUS

CN Fluorene-4-carboxylic acid, 9-(2,4-dichlorobenzamido)- (7CI, 8CI) (CA INDEX NAME)




RN 2841-51-2 HCAPLUS

CN Fluorene-4-carboxylic acid, 9-(p-bromobenzamido)- (7CI, 8CI) (CA INDEX NAME)




RN 2841-52-3 HCAPLUS

CN Fluorene-4-carboxylic acid, 9-(o-bromobenzamido)- (7CI, 8CI) (CA INDEX NAME)




RN 2841-53-4 HCAPLUS

CN Fluorene-4-carboxylic acid, 9-(o-iodobenzamido)- (7CI, 8CI) (CA INDEX NAME)




RN 2841-54-5 HCAPLUS

CN Fluorene-4-carboxylic acid, 9-(p-iodobenzamido)- (7CI, 8CI) (CA INDEX NAME)



RN 2841-55-6 HCAPLUS

CN Fluorene-4-carboxylic acid, 9-(m-fluorobenzamido)- (7CI, 8CI) (CA INDEX NAME)



L17 ANSWER 55 OF 55 HCAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 1965:454931 HCAPLUS Full-text
 DOCUMENT NUMBER: 63:54931
 ORIGINAL REFERENCE NO.: 63:10034h,10035a-c
 TITLE: Aminoaroyl aminosteroids
 INVENTOR(S): Grant, Norman H.; Alburn, Harvey E.
 PATENT ASSIGNEE(S): American Home Products Corp.
 SOURCE: 2 pp.
 DOCUMENT TYPE: Patent
 LANGUAGE: Unavailable
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 3196168		19650720	US	19640218 <--

GI For diagram(s), see printed CA Issue.

AB 3 α Amino-5 α -pregnan-20-one or -ol (I and II, resp.) are condensed with isatoic anhydride (III) or a substituted derivative of III to give 3 α -(aminobenzamido)pregnanes (IV). Ten g. crude I was stirred with 150 ml. dioxane and filtered, the filtrate refluxed 4.5 hrs. with 3.8 g. III and evaporated and the residue washed with 2 50 ml. vols. Et₂O to give 3.5 g. 3 α -(o-aminobenzamido)-5 α -pregnan-20-one (EtOAc). Alternately, 1 g. I in 25 ml. dioxane was filtered, 500 mg. 6-chloroisatoic anhydride added, and the solution heated 4 hrs. at 100°, and worked-up to give 0.5 g. 3 α -(2-amino-5-chlorobenzamido)-5 α -pregnan-20-one, m. 180-4° (decomposition) (50% EtOH). Similarly prepared from I and II were: 3 α -(2-ethylamino-3,5-dichlorobenzamido)-, 3 α -(2-amino-3,5-dimethylbenzamido)-, 3 α -(2-phenethylamino-5-propylbenzamido)-, 3 α -(2-methyl-amino-3-methylbenzamido), 3 α -(2-amino-5-sulfobenzamido)-, 3 α -(2-methylamino-5-phenylbenzamido)-, or 3 α -(2-methylamino-3,5-dimethylbenzamido)-5 α -pregnan-20-one; and 3 α -(2-amino-5-nitrobenzamido)-, 3 α -(2-phenylamino-5-bromobenzamido)-, 3 α -(2-amino-5-chlorobenzamido)-, or 3 α -(2-amino-5-methyl-3-chlorobenzamido)-5 α -pregnan-20-ol.


IT **2693-89-2**, 5 α -Pregnan-20-one, 3 α -(2-amino-5-chlorobenzamido)- **4501-91-1**, 5 α -Pregnan-20 α -ol, 3 α -(2-anilino-5-bromobenzamido)- (preparation of)

RN 2693-89-2 HCAPLUS

CN Benzamide, 2-amino-5-chloro-N-(20-oxo-5 α -pregnan-3 α -yl)- (8CI)
 (CA INDEX NAME)

Absolute stereochemistry.


10/653,977



RN 4501-91-1 HCAPLUS

CN 5α-Pregnan-20α-ol, 3α-(2-anilino-5-bromobenzamido)-
(7CI, 8CI) (CA INDEX NAME)

Absolute stereochemistry.



=>